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Stellingen behorende bij het proefschrift 
Preclinical leads for chemoprevention of colorectal cancer: 
novel strategies to regulate apoptosis and proliferation 
1. De combinatie van sulindac en TRAIL is een effectieve manier om apoptose te induceren in 
colorectale adenoomcellen. (dit proefschrift) 
2. De apoptotische effecten van de combinatie van een NSAID en TRAIL worden gemedieerd 
door de transcriptionele activiteit van TCF-4. (dit proefschrift) 
3. Het analyseren van microarray-expressiedata op het niveau van pathways, leidt tot biologisch 
relevante informatie. (o.a. dit proefschrift) 
4. De opname van 18F-fluorodeoxyglucose in het abdomen kan gebruikt worden als maat voor 
het aantal grote (2'.: 2 mm) adenomen in de darm van de ApcMln muis. (dit proefschrift) 
5. De verschillen tussen sporadische en erfelijke darmtumoren met betrekking tot genetische 
achtergrond en biologie vereisen onderzoek in specifieke preklinische modellen. (o.a. dit 
proefschrift) 
6. Geurdetectie in de ontlasting, uitgevoerd door een hond, is een accurate screeningsmethode 
voor het colorectaal carcinoom. (Sonoda et al, Gut 2011; epub ahead of print) 
7. Dagelijks gebruik van een lage dosis aspirine op populatiebrede schaal vermindert de sterfte 
ten gevolge van veel voorkomende vormen van kanker. (Lancet 2011;377:31-41) 
8. Het feit dat er dagelijks 75 publicaties over resultaten van klinische trials verschijnen, 
benadrukt de relevantie van systematische reviews voor de ontwikkeling van de 
geneeskunde. (gebaseerd op Pies Medicine 2010;7:e1000326) 
9. Ook voor de geneeskundeopleiding geldt: zonder theorie is de praktijk slechts een routine die 
door gewoonten geboren wordt. (gebaseerd op Louis Pasteur) 
10. De menselijke geest behandelt een nieuw idee op dezelfde manier als het lichaam een 
vreemd eiwit behandelt: hij verwerpt het. (Peter Brian Medawar) 
11. The man who has no more problems to solve, is out of the game. (Elbert Hubbard) 
12. De wijze overdenkt zijn eigen fouten, niet die van een ander. 
Dianne Heijlnk 
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General introduction and thesis outline 
GENERAL INTRODUCTION 
Colorectal cancer (CRC) is the third most common cancer in men and the second in 
women worldwide.1 Surgical resection is the mainstay of CRC treatment. Additional 
treatment is considered depending on the disease stage. For colon cancer this treatment 
consists of adjuvant chemotherapy while neoadjuvant (chemo)radiotherapy is advised 
for rectal cancer.2'3 Despite these treatments, CRC still accounts for 8% of all cancer 
deaths worldwide.1 The rapidly growing insights into the molecular biology of CRC have 
led to high expectations for the use of targeted treatments.4 The first examples of these 
treatments have found their way to the clinic. The Vascular Endothelial Growth Factor 
(VEGF) inhibitor bevacizumab and the Epidermal Growth Factor Receptor (EGFR) 
inhibitors cetuximab and panitumumab can be added to standard chemotherapy in 
patients with metastasized CRC. Optimal use of patient-tailored targeted therapies, 
possibly combined with conventional treatment regimens may ultimately improve 
survival of CRC patients. 
CRC commonly arises from its precursor lesion, the adenoma. The progression from 
normal colorectal mucosa to adenoma and from adenoma to cancer, cal led the 
adenoma-carcinoma sequence, is driven by the stepwise accumulation of genetic 
mutations. The first hit nearly always involves a mutation in a Wnt pathway gene, in most 
cases the Adenomatous Polyposis Coli {APC) gene. 5 Such a mutation prevents the 
degradation of �-catenin resulting in the accumulation of �-catenin in the cytoplasm and 
subsequent translocation to the nucleus. Here, �-catenin activates the T-Cel l Factor-4 
(TCF-4) transcription factor leading to the transcription of genes associated with 
carcinogenesis.6 
In approximately 5% of al l CRC cases evidence of an inherited CRC syndrome exists, of 
which Lynch syndrome and Familial Adenomatous Polyposis (FAP) are the best studied. 
Lynch syndrome (formerly referred to as Hereditary Non-Polyposis Colorectal Cancer, 
HNPCC) is autosomal dominantly inherited and caused by a mutation in one of the 
mismatch repair (MMR) genes. Loss of function of the second MMR gene allele renders a 
mutator phenotype. Carriers of an MMR gene mutation have a cumulative risk of 30-80% 
of developing CRC and also bear an increased risk of extracolonic tumors. FAP is an 
autosomal dominant condition caused by a germline APC gene mutation. After loss of the 
second al lele, hundreds of colorectal adenomas develop, commonly already during 
childhood. Without surgical intervention, FAP patients almost inevitably develop CRC by 
age 40-50 years.7 
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Individuals with an increased risk of developing CRC are good candidates for 
chemoprevention. To this group belong people with a hereditary predisposition, but also 
those with familial clustering of CRC without the evidence of an inherited syndrome and 
those with a history of colorectal adenomas or cancer. Chemoprevention aims to 
prevent, delay or even reverse the development of colorectal adenomas and subsequent 
cancer.8 Ideally, agents for chemoprevention are suitable for long-term use and benefits 
should outweigh the risk of adverse effects. Chemoprevention research has focused 
much on Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). In clinical trials enrolling 
patients with a history of sporadic adenomas9'10 or patients with a hereditary 
predisposition11'12, NSAIDs reduced the incidence of adenomas and cancer. NSAIDs 
probably exert their chemopreventive effects through inhibition of cyclooxygenases 
(COX) as well as through COX-independent mechanisms such as Wnt pathway 
inhibition.13 However, the chemopreventive effects of NSAIDs are incomplete, indicating 
that better chemopreventive approaches are needed. As with the treatment of CRC, 
optimal chemoprevention might be achieved by the use of targeted therapies. 
Interesting new targeted agents are Tumor Necrosis Factor (TNF)-Related Apoptosis 
Inducing Ligand (TRAIL) receptor agonistic agents. They induce apoptosis after binding to 
the proapoptotic TRAIL death receptors DR4 and DRS on the cell membrane. After 
binding of TRAIL to the death receptors, the Death-Inducing Signaling Complex (DISC) is 
assembled. Formation of the DISC, consisting of the death receptors, the adaptor protein 
FADD, caspase-8 and caspase-10, leads to the activation of caspase-8. Active caspase-8 
can directly trigger the activation of executor caspases resulting in apoptosis, or activate 
the mitochondrial pathway leading to indirect apoptosis induction.14 TRAIL receptor 
agonistic agents induce apoptosis in CRC cell lines as well as in colorectal adenoma cell 
l ines and ex vivo cultured human colorectal adenomas.15 TRAIL receptor agonists 
selectively kill transformed cells while not harming normal cells. Apoptosis induction by 
these agents seems an elegant approach to treat and prevent CRC. 
The aim of this thesis was to explore novel targeted approaches for chemoprevention 
and treatment of CRC, mainly focusing on the combination of NSAIDs and TRAIL. 
OUTLINE OF THE THESIS 
Since apoptosis induction via TRAIL receptor agonistic agents is an appealing strategy for 
chemoprevention and treatment of CRC, information regarding the basal expression of 
important players of the TRAIL pathway is needed in order to assess whether necessary 
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components are present and to identify possible obstacles when targeting this pathway. 
Therefore, in Chapter 2 we describe a study in which the expression of the initiator 
caspase, caspase-8 and the competitive inhibitor of caspase-8, cFLIP was investigated. In 
this study immunohistochemistry was performed on normal colorectal tissue, adenomas 
and carcinomas derived from sporadic and Lynch syndrome-associated neoplasms. 
TRAIL receptor agonistic agents have already been combined with various therapies in 
preclinical tumor models. In most models, combination therapy was more effective than 
monotherapy due to sensitization for apoptosis.14 To this end, the potential of the 
combination of recombinant human (rh)TRAIL and NSAIDs (aspirin and sul indac) was 
investigated in adenoma cell l ines, ex vivo cultured human adenomas and CRC cell lines 
as described in Chapter 3. Involvement of the crucial Wnt pathway in this sensitization 
was studied by switching off TCF-4 activity in a colon cancer cell line. Receptor 
expression, clustering of the death receptors and expression of intracellular proteins 
belonging to different biological pathways were examined in order to investigate the 
mechanism of sensitization. 
The ApcMin mouse model is the most frequently used model to study FAP and sporadic 
colorectal carcinogenesis. It is very suitable for the evaluation of chemopreventive 
strategies since these mice, harboring a truncating mutation in the murine Ape gene, 
develop multiple intestinal adenomas.16 The gold standard for assessing adenoma 
numbers in ApcMin mice is post-mortem microscopic examination. Making use of a non­
invasive method to visualize adenoma formation and growth in living mice could 
potentially allow longitudinal monitoring of chemopreventive effects. Chapter 4 
therefore presents the results from a study investigating the application of 
fluorodeoxyglucose (FDG) PET scanning for the detection of intestinal adenomas in the 
ApcMin mouse model. Ex vivo intestinal 18F-FDG uptake and in vivo abdominal 18F-FDG 
uptake were measured and related to the total number of adenomas and the number of 
large adenomas (� 2 mm). 
Our final goal is to examine the chemopreventive potential of the combination of 
sulindac and TRAIL receptor targeting in vivo using the ApcMin mouse model. In 
preparation for this study we investigated different treatment durations and 
concentrations of sulindac for their effects on the adenoma burden in ApcMin mice as 
12 
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described in Chapter 5. Furthermore, we tested the feasibility of using MDS-1, a mouse­
TRAIL receptor specific agonistic antibody. MDS-1 induced cholangiocyte apoptosis 
leading to liver failure in C57BL/6J mice17• Therefore, we investigated whether repeated 
treatment with a low dose of MDS-1 was tolerated in ApcMin mice (which have a 
C57BL/6J background). 
To (further) improve chemoprevention and treatment of CRC, we did not only focus on 
TRAIL and NSAIDs, but also broadly searched for novel strategies. For this we applied a 
pathway analysis on microarray data and performed a systematic literature search. The 
findings are described in the next two chapters. 
The development of the microarray technique has made it possible to perform whole 
genome expression profiling. Analyzing these results at the level of biological pathways 
instead of the conventional single gene level is a powerful approach to identify novel 
routes that can be potential targets for therapy.18 In Chapter 6 the results from an 
analysis of microarray expression data from normal colorectal mucosa and colorectal 
adenoma samples is described. Biological pathways enriched in adenomas were 
identified with Gene Set Enrichment Analysis (GSEA). The findings were validated in an 
independent data set by RT-PCR. The functional relevance of targeting of two novel 
identified pathways was examined. To this end, two adenoma cell l ines were treated 
with the Rb pathway inhibitors roscovitine and PD-0332991 and with the Src pathway 
inhibitor dasatinib and the effect on cell growth was assessed. 
Research on treatment and chemoprevention of CRC is often performed using models for 
sporadic carcinogenesis. However, results obtained for sporadic CRC cannot 
automatical ly be translated to Lynch syndrome individuals given the difference in genetic 
background, mutational spectrum, biological behavior of the tumor and response to 
therapy. Chapter 7 describes the results from a literature review regarding the current 
state of art for chemoprevention and treatment of CRC in Lynch syndrome individuals. 
Clinical and preclinical evidence for novel strategies are summarized in order to provide 
guidance for future studies. 
In Chapter 8 a summary of al l results is given. This is fol lowed by a discussion on the 
interpretation and implications of the results and an outline of the future perspectives. 
13 
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ABSTRACT 
Background: TNF-Related Apoptosis Inducing Ligand (TRAIL) is a promising agent for the 
induction of apoptosis in neoplastic tissues. Important determinants of TRAIL sensitivity 
are two intracel lular proteins of the TRAIL pathway, caspase-8 and its anti-apoptotic 
competitor cellular Flice-Like Inhibitory Protein (cFLIP). 
Methods: The aim of this study was to investigate basic expression of caspase-8 and 
cFLIP in normal colorectal epithelium (n = 20), colorectal adenomas (n = 66) and 
colorectal carcinomas (n = 44) using immunohistochemistry performed on both sporadic 
and Hereditary Non-Polyposis Colorectal Cancer (HNPCC or Lynch syndrome)-associated 
adenomas and carcinomas. 
Results: Expression of both caspase-8 and cFLIP was similar in cases with sporadic and 
hereditary origin. Expression of caspase-8 in colorectal adenomas and carcinomas was 
increased when compared to normal colorectal tissue (P = .02). Nuclear, paranuclear as 
well as cytoplasmic localizations of caspase-8 were detected. lmmunohistochemistry 
revealed an upregulation of cFLIP in colorectal carcinomas in comparison with normal 
epithelium and colorectal adenomas (P < .001). A large variation in the caspase-8/cFLIP 
ratio was observed between the individual adenomas and carcinomas. 
Conclusion: Caspase-8 and cFLIP are upregulated during colorectal carcinogenesis. 
Upregulation of caspase-8 and/or downregulation of cFLIP may be interesting 
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Colorectal cancer is one of the leading causes of cancer-related deaths in the Western 
world.1 The development of colorectal cancer is a multistep process in which normal 
epithelium progresses through adenoma to carcinoma.2 Sporadic neoplasms arise due to 
accumulating somatic mutations. In hereditary syndromes these somatic mutations occur 
on top of a germline mutation in a specific gene such as a mismatch repair (MMR) gene 
in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) or Lynch syndrome.3 
The mainstay for the treatment of sporadic and hereditary colorectal cancer is surgery. 
Additionally, chemotherapy and radiotherapy are frequently used.4 Resistance to 
chemotherapy often occurs, so there is a need for targeted therapy bypassing this 
resistance. The use of biological agents, especial ly  apoptosis inducers such as Tumor 
Necrosis Factor (TNF)-Related Apoptosis Inducing Ligand {TRAIL) or other TRAIL receptor 
agonists, can be of great value in this respect.5•6 
Recombinant human {rh)TRAIL can induce apoptosis in malignant cel ls without harming 
normal cel ls through binding to its death receptors DR4 and DRS on the cell 
membrane. 7'8 Despite the generally extensive expression of the death receptors in both 
sporadic and hereditary colorectal adenomas and carcinomas9, several studies show a 
range of sensitivities for rhTRAIL-induced apoptosis in different colon carcinoma cell 
l ines.10•11 In ex vivo experiments, colorectal adenomas with high-grade dysplasia were 
sensitive to rhTRAIL while adenomas with low-grade dysplasia were not.12 Little is known 
about the mechanisms behind the varying sensitivity for rhTRAIL.13 
Binding of TRAIL to its death receptors causes trimerization of the receptors and 
recruitment of the adaptor protein FADD and of the initiator caspases, procaspase-8 and 
procaspase-10, which results in the formation of the Death-Inducing Signaling Complex 
{DISC).14•15 Caspase-8 is currently regarded as the most important initiator caspase in the 
extrinsic pathway. Procaspase-8 binding to the DISC then results in autocleavage and 
activation of caspase-8. This caspase-8 activation leads directly to the activation of 
caspase-3 and subsequently apoptosis.7 In addition, active caspase-8 thereby triggers the 
mitochondrial pathway.16 An important modulator of caspase-8 activation is the cellular 
Flice-Like Inhibitory Protein {cFLIP). cFLIP shows great homology to procaspase-8, but 
lacks the enzymatic activity of its C-terminal caspase-like domain. There are several 
splicing variants of cFLIP, cFLIPL and cFLIPs being the most predominant.17 cFLIP is 
upregulated in many cancer types when compared to normal tissue and is thought to be 
involved in resistance to death receptor-induced apoptosis and also in resistance to 
17 
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chemotherapy.18-2° From previous experiments, we and others have shown that 
differences in rhTRAIL sensitivity cannot solely be attributed to differences in TRAIL 
receptor expression.11 Several groups suggested the ratio of caspase-8 and cFLIP to be 
important for rhTRAIL sensitivity.11•21•22 In colorectal adenomas and carcinomas TRAIL 
receptor expression has been studied, however, little is known about the expression of 
cFLIP and caspase-8. 
The aim of the present study was to investigate the expression of caspase-8 and cFLIP in 
normal epithelium, sporadic adenomas and carcinomas, and HNPCC adenomas and 
carcinomas. Final ly, caspase-8 and cFLIP expression were related to parameters 
previously determined in these tissues such as apoptosis and TRAIL receptor expression.9 
METHODS 
Patient and tissue selection 
HNPCC patients had a germline mutation in one of the MMR genes and/or fulfilled the 
Amsterdam II criteria. Al l colorectal adenomas and carcinomas removed from HNPCC 
patients at the University Medical Center Groningen between 1979 and 2002, with 
sufficient material available, were selected. In total, 33 adenomas and 17 carcinomas {20 
from mutation carriers and 30 from patients fulfill ing the Amsterdam II criteria) were 
examined. 
Sporadic colorectal adenomas (n = 33) and carcinomas (n = 27), were selected from 
previously studied material, of which sufficient material was available to al low serial 
sectioning for immunohistochemical staining. 23 Sporadic adenomas were selected after 
matching to HNPCC adenomas for degree of dysplasia. 
Twenty samples of normal mucosa were selected from archival materials, which had 
been obtained in 1999. These are samples from patients with normal macroscopic 
findings at colonoscopy. Randomly taken biopsies which did not show any abnormalities 
at histological examination were included. Biopsies from normal mucosa from patients 
with a history of adenomas or carcinomas were excluded. 
Histopathological classification 
For histopathological evaluation haematoxylin and eosin stained slides were used. 
Classification was performed according to the WHO criteria for gastrointestinal tumors. 24 
For adenomas, circumferential size was measured and the degree of dysplasia was 
determined. Adenomas were classified as tubular, tubulovillous, or villous. For statistical 
18 
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purposes, adenomas with tubulovillous and villous histology were combined. For 
carcinomas, stage and differentiation were determined. 
lmmunohistochemistry for cFLIP and caspase-8 
For immunohistochemical staining, serial 3 µm thick sections were cut from paraffin 
blocks. After deparaffinization in xylene and rehydration in alcohol, antigen retrieval was 
performed by high pressure cooking. Sl ides were immersed in 200 µI blocking reagent 
(Boehringer Mannheim, Germany) and underwent 3 sessions of 5 minutes at 115 °C. 
Endogenous peroxidase was blocked with 3% hydrogen peroxide for 30 minutes. For 
cFLIP staining, a mouse monoclonal primary antibody, detecting both FLIPL and FLIP5, 
(1:25; clone NF6; Alexis, Lausen, Switzerland) was appl ied for 24 hours at 4 °C. Then, a 
highly sensitive horseradish peroxidase system, EnVision, was used according to the 
instructions of the manufacturer (DAKO, Glostrup, Denmark). Caspase-8 (both full length 
and cleaved) was detected with a mouse monoclonal antibody (1:50; clone 1C12; Cell 
Signal ing Technology, Beverly, MA, USA) and incubated for 1 hour at room temperature. 
Slides were incubated with rabbit anti-mouse peroxidase antibody (1:50; DAKO), 
fol lowed by addition of goat anti-rabbit peroxidase antibody (1:50; DAKO). Peroxidase 
activity was visualized with diaminobenzidine for al l sl ides. Sl ides were counterstained 
with haematoxyl in. 
Staining was evaluated by l ight microscopy by two independent investigators, with re­
evaluation under a multi-headed microscope if results did not agree. Results from both 
stainings were assessed as negative (-) when there was no significant or very weak 
cytoplasmic immunostaining. Positivity was scored as +/- (moderate positive staining) or 
+ (strong positive staining). If staining intensity in a sl ide was heterogeneous, the area 
with the highest staining intensity was chosen for scoring if present in more than 10% of 
the sl ide. Additional ly, for caspase-8 the presence or absence of nuclear staining and of 
paranuclear staining were assessed and scored as positive (more than 10% positive cells) 
or negative (less than 10% positive cells). 
lmmunohistochemistry for DR4, DRS, apoptosis and proliferation in adenomas and 
carcinomas 
Staining procedures and controls for DR4, DRS and apoptosis staining were described 
previously.23'25 For DR4, a goat polyclonal lgG (1:100; clone C-20; Santa Cruz, CA, USA) 
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out by microwave treatment and a rabbit polyclonal lgG (1:100; Oncogene Research, 
Cambridge, MA, USA) was used. The percentage of stained cel ls  was estimated semi­
quantitatively. Samples with DR4 or DRS staining in more than 10% of cel ls were 
considered positive. Apoptotic cells were determined by using the monoclonal antibody 
M30 (Boehringer Mannheim, Mannheim, Germany) after antigen retrieval by microwave 
treatment. Apoptosis was assessed in at least 1,000 epithelial cells and expressed as a 
percentage of the total number of cells counted (apoptotic index). 
For proliferation, antigen retrieval was performed by high pressure cooking. The primary 
antibody MIB-1 was applied (against Ki67; 1:400; lmmunotech, Marseilles, France). MIB-1 
positive cells were assessed in at least 1,000 cel ls in full length crypts and expressed as a 
percentage of the total number of epithelial cells  counted. 
Controls 
To verify the specificity of the primary antibodies, several experiments were conducted. 
First, a Ramos 8-cell cell line, stably transfected with a cFLIPL construct (cFLIPL cell line), 
as well as a mock transfected cell line (LZRS cell line) (a generous gift from B.J. Kroesen, 
Department of Tumor Immunology, UMCG, the Netherlands), and the untransfected 
Ramos B-cel l cell line expressing endogenous cFLIP were used. Western blots yielded 
protein expression of expected size, with low expression of cFLIPL in Ramos and LZRS cell 
lines and high expression of cFLIPL in the overexpression cell line. After culturing, the cells 
were embedded in paraffin, and 3 µm thick sections were cut from paraffin blocks to be 
used as controls representing high and low expression in immunohistochemistry. 
lmmunostaining of the cell line controls revealed a clearly higher cFLIP expression level in 
the cFLIPL overexpression cell line as compared to the non-transfected Ramos cell line 
with endogenous cFLIP level, indicating a specific and sensitive staining (Figure 1). 
B C - FLIP-L 
------­ B-actin 
LZRS Ramos FLIP-L 
Figure 1. Control model for cFLIP staining. (A) Strong cFLIP staining in cFLIPL overexpression cell line. (B) Weak cFLIP 
staining in Ramos cell line. (C) Western blot analyses for cFLIP confirming differences in cFLIP expression between 
cFLIPL overexpression cell line and Ramos cell line. 
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For caspase-8, two ovarian cancer cell lines were used with low (CP70 cell line) and high 
(A2780 cell line) expression of caspase-8. Western blotting confirmed the expected levels 
of caspase-8 in these cell l ines. As with the cFLIP cell line model, the cell line with high 
levels of caspase-8 showed higher immunostaining intensity than the cell line with low 
levels of caspase-8. 
Secondly, a number of slides were immunostained using non-immunized mouse lgGl 
antibody (Alexis, Lausen, Switzerland) at the same lgG concentration as for the primary 
antibody. In these cases, no immunostaining was detected. 
Thirdly, several slides were treated with Phosphate-Buffered Saline (PBS) in the absence 
of the primary antibody. In these slides, no immunostaining was seen. 
Statistical analysis 
Appropriate tests were used to assess differences in patient and tumor characteristics (X2 
test for discontinuous variables, Mann-Whitney test for continuous variables) and 
immunohistochemical findings (X2 test for discontinuous variables, Kruskal-Wall is test for 
continuous variables). Relationships between stainings of DR4, DRS, degree of apoptosis, 
degree of proliferation and stainings of cFLIP and caspase-8 were tested using Kruskal­
Wallis testing. SPSS (version 12.0) for Windows software (SPSS Inc., Chicago, IL, USA) was 
used in all statistical analyses. P values < .OS were considered statistical ly significant. 
RESULTS 
Patient and tumor characteristics. 
Patient and tumor characteristics are summarized in Table 1. 
Several differences in patient and tumor characteristics were observed between the two 
patient groups. HNPCC patients were more often women (P = .001). Mean age at time of 
diagnosis of patients with sporadic tumors was higher than in HNPCC patients (P = .007). 
Mean adenoma size was smaller in patients with HNPCC (P = .01) and tumor stage was 
lower in HNPCC-associated cancer cases than in sporadic cancer cases (P < .001). 
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There were no differences in the expression patterns of caspase-8 between sporadic and 
HNPCC adenomas and between sporadic and HNPCC carcinomas. Therefore HNPCC and 
sporadic patients were further analyzed as one group. 
Caspase-8 cytoplasmic staining intensity was higher in adenomas and carcinomas 
compared to normal epithelium (P = .02) (Figure 2 and 3). In addition to the cytoplasmic 
staining, caspase-8 was also detected at other subcellular localizations (Figure 4). It was 
present in the nucleus in 75% of the cases, in normal epithelium as well as in adenomas 
and carcinomas. Paranuclear staining was detected in normal epithelium, adenomas and 
carcinomas in 15, 33 and 27 percent of the cases respectively, and was heterogeneously 
distributed. Cytoplasmic, nuclear and paranuclear staining intensity were independent of 
the histopathological characteristics of the adenomas (size, growth type and degree of 
dysplasia) and carcinomas (stage and differentiation). 
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Caspase-8 and cFLIP expression during carcinogenesis 
Figure 2. Cytoplasmic expression of caspase-8 in normal colorectal tissue (A), colorectal adenomas (B) and colorectal 
carcinomas (C). 
A B C 
Figure 3. Representative examples of expression of caspase-8 in normal colorectal tissue, colorectal adenomas and 
carcinomas. (A) Normal tissue showing negative cytoplasmic staining (-). (B) Adenoma showing strong positive staining 
(+). (C) Carcinoma showing strong positive staining (+). 
A 8 
Figure 4. Different subcellular localization of caspase-8. (A) Paranuclear localization of caspase-8 in an adenoma. (B) 
Nuclear localization of caspase-8 in an adenoma. 
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Expression of cFLIP in normal epithelium, adenomas and carcinomas. 
Since analysis did not reveal differences in the expression patterns of cFLIP between 
sporadic and HNPCC adenomas and between sporadic and HNPCC carcinomas, HNPCC 
and sporadic patients were further analyzed as one group. 
cFLIP staining was moderately positive in one and strongly positive in one of the 20 
normal epithelium samples (10%). Staining was moderately and strongly positive in 
respectively 14 and 1 out of the 66 colorectal adenomas (23%), which is not significantly 
different from the results in the controls. In colorectal carcinomas, 75% of the cases 
showed positive staining, being either moderately positive (19 out of 44 cases) or 
strongly positive (14 out of 44 cases) (P < .001 compared to both normal tissue and 
adenomas, Figure 5 and 6). Staining was heterogeneous and detected in the cytoplasm of 
the cel ls. Staining intensity was independent of the histopathological characteristics of 
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C 
Figure 6. Representative examples of expression of cFLIP in normal colorectal tissue, colorectal adenomas and 
carcinomas. (A) Normal epithelium showing negative cytoplasmic staining (-) .  (B) Adenoma showing negative staining 
(-). (C) Carcinoma showing strong positive staining (+). 
Relation between cFLIP and caspase-8 expression and DR4 and DRS expression, 
apoptosis and proliferation. 
Although both caspase-8 and cFLIP expression were elevated in colorectal carcinomas, 
there was no correlation between expression of caspase-8 and cFLIP. In contrast, al l 
possible ratios were observed, varying from high to low caspase-8/cFLIP ratios. In a 
previous study, we determined TRAIL receptor DR4 and DRS expression, apoptosis and 
proliferation in these adenomas and carcinomas al lowing us to relate caspase-8 and cFLIP 
expression to these parameters (Table 2). There was no association between expression of 
caspase-8 and any one of the four parameters. In carcinomas, the expression of DR4 
increased with increasing expression of cFLIP (P = .03). The caspase-8/cFLIP ratio did not 
show any relationship with one of the parameters studied. 
Tabel 2. Immunohistochemical staining for caspase-8, cFLIP, DR4, DRS, apoptosis and proliferation in sporadic (spar) 
and HNPCC adenomas (ad) and carcinomas (ca). Results are expressed as percentage of moderate or strong positive 
cytoplasmic staining (caspase-8 and cFLIP) or median percentage of positive cells (DR4, DRS, apoptosis, proliferation). 
caspase-8 (% of positive cases) 
cFUP % of ositive cases 71 
DR4 (%) 40 so 100 100 
DRS % 100 100 
Apoptosis (%) 0.4 0.4 1.2 0.8 
36 60 
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DISCUSSION 
The present study shows that caspase-8 expression is increased in colorectal neoplasms 
when compared to normal colorectal epithelium. We detected cytoplasmic as well as 
nuclear and paranuclear localization of caspase-8. cFLIP was upregulated in carcinomas 
compared to normal epithelium and adenomas. There was a large variation in the ratio 
of caspase-8 and cFLIP in the different tumors. Despite the different pathways involved in 
carcinogenesis, levels of cFLIP and caspase-8 were similar in tumors occurring 
sporadically and in HNPCC-associated tumors. 
The upregulation of caspase-8 in colorectal adenomas and carcinomas in comparison 
with normal epithelium is not entirely in line with findings in a previous study from which 
it was concluded that cytoplasmic caspase-8 expression was unchanged or only slightly 
upregulated in carcinomas compared to the adjacent normal tissue.26 This discrepancy 
may be due to the fact that we stained normal tissues from patients without any 
macroscopic or microscopic abnormalities in their colon and not normal looking mucosa 
adjacent to carcinomas of which we among others have demonstrated that it cannot be 
regarded as truly normal mucosa.23 
The frequent nuclear local ization of caspase-8 in both normal and neoplastic colorectal 
epithelium is remarkable, because caspase-8 is thought to be a cytoplasmic protein. This 
might be explained by post-translational modifications of caspase-8 such as sumoylation 
that is associated with nuclear localization of caspase-827 or co-localization of caspase-8 
with a known adaptor molecule that can be expressed in the nucleus such as FADD.28-30 
Additionally, paranuclear localization of caspase-8 was observed in a substantial number 
of colorectal tissues. This subcellular localization of caspase-8 has not been described 
before in colorectal tissue and has never been demonstrated by immunohistochemistry. 
There are several possible explanations for paranuclear localization of caspase-8. 
Paranuclear localization could reflect caspase-8 in the mitochondria, which is released 
upon apoptotic stimulation.31 More speculative, overexpressed procaspase-8 co-localizes 
with overexpressed FADD in the Golgi complex.32 Although caspase-8 expression was 
higher in colorectal adenomas and carcinomas compared to normal epithelium, further 
upregulation and/or a shift in cellular localization may be an effective way to potentiate 
rhTRAIL- and agonistic TRAIL receptor antibody-induced apoptosis. Caspase-8 expression 
has been shown to be induced by interferon-alpha, interferon-gamma and several 
chemotherapeutic drugs in colon cancer cell lines.33-35 Further research, however is 
necessary to obtain more insight in the mechanisms and consequences of the subcellular 
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localization of caspase-8 since it may influence the availability of caspase-8 for the 
assembling of the DISC, necessary for apoptosis induction via rhTRAIL or agonistic TRAIL 
receptor antibodies. 
lmmunohistochemical studies have indicated an upregulation of cFLIP in cancer tissue in 
comparison with normal tissue in several tumor types including sporadic colon cancer.18-
20·36'37 In the present study, both sporadic adenomas and carcinomas as well as HNPCC 
adenomas and carcinomas were included to investigate cFLIP expression in relation to 
colorectal carcinogenesis. We conclude that cFLIP is upregulated in both sporadic and 
HNPCC colorectal carcinomas in comparison to normal epithelium and adenomas. 
Previous studies in cel l line models have shown that cFLIP mediates resistance to 
chemotherapy and death receptor-induced apoptosis.18-20 In concordance, high cFLIP 
levels are associated with a poor prognosis. 38 In the present study, we found an 
association of high cFLIP expression with higher expression of DR4. High DR4 expression 
has been found to be associated with shorter overal l survival and disease-free survival in 
colon cancer.39 Whether the concomitant expression of cFLIP and DR4 has biological 
relevance with respect to survival in colon cancer needs to be established. 
Since we observed a strong upregulation of cFLIP in cancer tissue, cFLIP may be a 
potential target for anticancer therapy in combination with rhTRAIL or agonistic TRAIL 
receptor antibodies, especial ly in those colorectal cancer patients who have high cFLIP 
levels. NSAIDs can influence the expression of inhibitors of apoptosis such as cFLIP either 
directly or indirectly by inhibiting NF-KB.4° Furthermore, PPARy modulators41 and a 
variety of other substances17 have shown to reduce levels of cFLIP. 
This study shows a large variation in expression of caspase-8 and cFLIP in individual 
adenomas and carcinomas. Several studies imply that the caspase-8/cFLIP ratio is 
important in determining rhTRAIL sensitivity.21•22A2A3 Optimizing this ratio by 
upregulating caspase-8 and/or downregulating cFLIP seems a reasonable approach for 
optimal apoptosis induction via rhTRAIL. Contradictory to many studies mentioned 
before suggesting an anti-apoptotic function of cFLIP, some studies state that cFLIP is 
able to function as an activator of caspase-8.44,45 In these cases, downregulation of cFLIP 
would be unwanted. Future studies are needed to determine the functional relevance ,of 
the caspase-8/cFLIP ratio and the caspase-8 regulating functions of cFLIP. 
In conclusion, our study demonstrates that both cFLIP and caspase-8 are upregulated 
during colorectal carcinogenesis. In individual cases there is large variation in expression 
of caspase-8 and cFLIP. If future studies reveal that the caspase-8/cFLIP ratio is 
27 
I Chapter 2 
Caspase-8 and cFLIP expression during carcinogenesis 
functionally important, upregulation of caspase-8 and drug-induced downregulation of 
cFLIP may be important approaches in optimizing TRAIL- or agonistic TRAIL receptor 
antibody sensitivity in colorectal cancer. 
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ABSTRACT 
Background: TNF-Related Apoptosis Inducing Ligand (TRAIL) receptor agonistic agents 
and NSAIDs are interesting agents for chemoprevention and treatment of colorectal 
cancer. We investigated whether NSAIDs sensitize colon c�ncer and adenoma cell lines 
and ex vivo cultured human adenomas to recombinant human (rh)TRAIL. Involvement of 
the crucial Wnt signaling pathway in the sensitization of colon cancer cel ls was examined. 
Methods: Five colon cancer and two adenoma cell lines, human ex vivo adenomas and 
normal colonic epithelium were treated with aspirin or sulindac combined with rhTRAIL. 
Apoptosis levels, expression of intracellular proteins and TRAIL receptor membrane 
expression were assessed. Ls174T cel ls stably transfected with an inducible dominant 
negative TCF-4 (dnTCF-4) construct served to analyze the role of Wnt pathway activation. 
Results: Both rhTRAIL-sensitive and -resistant colon cancer cell lines were strongly 
sensitized to rhTRAIL by aspirin (maximum enhancement ratio 7.1). Remarkably, in 
adenoma cell lines sulindac enhanced rhTRAIL-induced apoptosis most effectively 
(maximum enhancement ratio 2.5). Although membrane TRAIL receptor expression was 
not affected by NSAIDs, caspase-8 activation was enhanced by combinational treatment. 
Several proteins from different biological pathways were affected by NSAIDs pointing at 
complex mechanisms of sensitization. Elimination of TCF-4 completely blocked the 
sensitizing effect in colon cancer cells. In ex vivo adenomas the combination of sulindac 
and rhTRAIL increased apoptosis from 18.4% (sulindac) and 17.8% (rhTRAIL) to 28.0%. (P 
= .003 and P = .005). 
Conclusion: NSAID-induced sensitization to rhTRAIL requires TCF-4 activity. Thus, the 
combination of TRAIL receptor agonistic agents and NSAIDs is a potential ly attractive 
treatment option for (pre)malignant tumors with constitutively active Wnt signaling such 
as colorectal tumors. 
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TNF-Related Apoptosis Inducing Ligand {TRAIL) receptor agonistic agents induce 
apoptosis in colon cancer cell lines and human colon tumor xenografts.1'2 These agents 
barely induce apoptosis in normal cel ls and phase 1/1 1 clinical trials currently show 
favorable toxicity profiles.3,4 Recently, it was shown that recombinant human {rh)TRAIL 
also induces apoptosis in colon adenoma cell lines and ex vivo in human colorectal 
adenomas.5'6 Therefore, these drugs are potential chemopreventive agents in patients at 
increased risk of developing colorectal cancer {CRC), such as patients with a hereditary 
predisposition {Familial Adenomatous Polyposis {FAP) or Lynch syndrome) and those with 
a history of colorectal adenomas or cancer.7 
RhTRAIL induces apoptosis by binding to its pro-apoptotic death receptors DR4 and DRS 
on the cell membrane. This leads to the formation of a Death-Inducing Signaling Complex 
{DISC) which results in activation of procaspase-8, initiating a cascade of events resulting 
in apoptosis.8 In colon cancer cell l ines, both intrinsic and acquired resistance to rhTRAIL 
occur which could limit its clinical use.9 
Non-Steroidal Anti-Inflammatory Drugs {NSAIDs) can prevent or delay CRC 
development.10 They exert their effect on tumor cel ls by cyclooxygenase {COX)­
dependent and -independent mechanisms.11 An important COX-independent mechanism 
is inhibition of the Wingless-int {Wnt) signaling pathway. Activation of this pathway is 
considered critical in the initiation of colorectal carcinogenesis. Inactivating mutations in 
the Adenomatous Polyposis Coli {APC) gene or activating mutations in the CTNNBl {P­
catenin) gene result in accumulation of �-catenin in the cytoplasm and subsequent 
nuclear translocation. In the nucleus, �-catenin activates the T-Cel l Factor-4 {TCF-4) 
transcription factor, which results in transcription of genes associated with 
carcinogenesis. NSAIDs are known to attenuate Wnt signaling through different 
mechanisms including reduction of �-catenin levels and interruption of the �­
catenin/TCF-4 interaction.12'13 Aspirin14 and the COX-2 selective NSAID celecoxib15 
reduced the occurrence of colorectal adenomas in patients with a history of colorectal 
adenomas. Lynch syndrome carriers appeared to benefit from aspirin on the long term, 
as the incidence of CRC was lower in previously treated individuals compared to non­
treated ones.16 Furthermore, the non-selective NSAID sulindac reduced the number and 
size of adenomas in patients with FAP.17 Although this chemopreventive action is 
promising, effects reported were incomplete and a significant proportion of patients 
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NSAIDs enhance the antitumor effect of rhTRAIL in colon cancer cell lines.18-20 Given the 
apoptosis inducing capacity of rhTRAIL and the effects of NSAIDs in colorectal adenomas, 
it is also of great interest to test the chemopreventive effects of the combination. The 
aim of this study was therefore to investigate whether aspirin and sulindac sensitize 
colon cancer cell lines, focusing on cell l ines with acquired or intrinsic resistance to TRAIL, 
and colon adenoma cell l ines to rhTRAIL-induced apoptosis. In addition, we investigated 
whether Wnt pathway activity plays a role in this sensitization. Final ly, in a clinically 
relevant ex vivo model, we determined whether NSAIDs specifical ly sensitized human 
colorectal adenomas to rhTRAIL without affecting normal colonic mucosa. 
METHODS 
Cell cultures 
Two human colon adenoma cell l ines, VACO-235 and VACO-330 (a kind gift from J.K. 
Wilson, Ireland Cancer Center, Cleveland, OH, USA), derived respectively from a villous 
and tubular adenoma, were used. A panel of colon cancer cell lines was tested. SW948 is 
sensitive to rhTRAIL, LOVO and Ls174T are intermediately sensitive, while CACO-2 and 
SW948-TR (sub line of the SW948)21 show intrinsic and acquired resistance to rhTRAIL, 
respectively. Ls174T-dnTCF-4 and Ls174T were kindly provided by H. Clevers (Hubrecht 
Laboratory, Utrecht, the Nederlands).22 The human bronchial epithelial cell line 16HBE 
and human lung fibroblast cell line IMR90 were used to examine possible toxicity of 
sulindac and rhTRAIL in non-dysplastic cells. For details on cell culture and cell line 
characteristics see the Supplementary Methods. 
Ex vivo human colorectal adenomas and normal colonic mucosa 
Individuals undergoing colonoscopy at the University Medical Center Groningen from 
May 2006 to August 2008 were approached prior to the procedure. The study protocol 
was approved by the medical ethical review committee of the University Medical Center 
Groningen. All patients gave written informed consent. Patient and adenoma 
characteristics are summarized in Table 1. In addition, biopsies from macroscopically and 
microscopical ly normal sigmoid mucosa were obtained at colonoscopy from patients 
without current evidence of adenomas. For details on ex vivo tissues see the 
Supplementary Methods. 
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Localization {%) 
Ascending/ transverse colon 
Descending/ sigmoid colon 
Rectum 
Low-grade d lasia LGD % 
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Culturing colorectal adenoma specimens and normal mucosa biopsies 
Directly after endoscopic resection, paired adenoma segments were treated for 24 hours 
with rhTRAIL, sulindac or the combination in adenoma culture medium in a 24-well 
plate.5 The incubator provided a humidified atmosphere (37 °C) with a constant carbogen 
flow to optimally oxygenize the tissue. Movement of the incubator facilitated the access 
of oxygen and nutrients to the tissue and the removal of waste products from the tissue. 
After incubation, adenoma segments were fixed in formalin and embedded in paraffin. 
From 12 adenomas, one adenoma segment was fixed directly after arriving in the 
laboratory, to evaluate differences in histologic properties between non-incubated and 
incubated untreated segments (i.e. culture artefacts). Normal mucosa biopsies were 
processed in the same manner. lmmunohistochemistry for Ki-67 was performed on all 
untreated incubated segments used as controls in the combination experiments (n = 22) 
by routine staining performed at the department of pathology in order to assess the 
proliferative capacity of colonic cel ls after 24 hours incubation. 
Drug exposure 
RhTRAIL was produced as described previously.23 Cancer cell lines were treated with a 
concentration of rhTRAIL dependent on their known sensitivity to rhTRAIL. The rhTRAIL­
sensitive cell line (SW948) was treated with 0.005 µg/ml, the intermediate sensitive cell 
l ine (LOVO) was treated with 0.01 µg/ml, the rhTRAIL-resistant cell l ines (SW948-TR and 
CACO-2) were treated with higher doses of 0.1 µg/ml. All cell lines were treated for 24 
hours. Intermediate rhTRAIL-sensitive Ls174T-dnTCF-4 and Ls174T cells were used in 
experiments to investigate the role of the TCF-4 transcription factor in sensitization to 
rhTRAIL. A shorter incubation period (S hours) with a higher rhTRAIL concentration (1 
µg/ml) showed optimal results. The concentrations used in adenoma cell lines (0.01 
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observations from our lab. 5 Due to optimization of the culture system, we were able to 
culture human samples for 24 hours instead of 5 hours as reported previously.5 The 
sensitive SW948 and resistant CACO-2 cel ls  were used as the positive and negative 
controls, respectively, for rhTRAIL treatment. Cell lines were treated with aspirin (0-10 
mM) or sulindac (0-100 µM) for 24 hours, except CACO-2 cel ls, which were treated for 48 
hours since sensitization did not occur after a shorter incubation period. Ex vivo 
adenomas and normal mucosa biopsies were treated with 100 µM of sulindac for 24 
hours. 
Quantification of apoptosis in cell lines 
In colon cancer cel ls and normal cel ls (16HBE and IMR90), apoptosis was identified by 
staining nuclear chromatin with acridine orange (10 µg/ml) and identifying the 
appearance of apoptotic bodies and/or chromatin condensation by fluorescence 
microscopy. To quantify apoptosis by other methods, M30 immunoreactivity and 
fluorometric caspase-3 activity assays were performed. In colon cancer and adenoma 
cells, M30 immunoreactivity (primary antibody, 1:50; Roche Diagnostics, Mannheim, 
Germany) was used on cytospins to quantify apoptosis.24 Relative caspase activity was 
obtained by comparing treated with untreated samples. Since VACO cel ls grow closely 
attached to each other, acridine orange assays are not applicable to these cultures. To 
quantitatively express efficacy of combination therapy {NSAID plus rhTRAIL) compared to 
both agents alone, we calculated enhancement ratios as fol lows: enhancement ratio = % 
apoptosis specifical ly induced by combination therapy / (% apoptosis specifical ly induced 
by NSAID alone + % apoptosis specifical ly induced by rhTRAIL). Specific apoptosis was 
defined as apoptosis after treatment minus apoptosis in untreated controls. 
Quantification of apoptosis in ex vivo exposed adenomas and normal mucosa 
H&E stained slides from paraffin embedded specimens were blinded and two 
investigators (DH, DO) independently evaluated apoptosis rates. At least three dysplastic 
crypts (normal crypts in case of normal mucosa biopsies) from three different areas were 
evaluated. Crypts lying at the explants outer rims were assessed for apoptosis since those 
crypts were most optimally oxygenized and most accessible to drug treatment by 
diffusion. At 400x magnification at least 1,000 epithelial cel ls  were counted. Apoptotic 
cel ls  were identified using morphological characteristics including cell shrinkage, nuclear 
condensation and formation of apoptotic bodies. Adenomas were classified as 
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responding to either treatment {rhTRAIL, sulindac or the combination) if specific 
treatment-induced apoptosis was > 5%. This level represents a relative increase of 
apoptosis of almost 50% from the mean basic level of apoptosis, which was considered 
relevant. In addition to quantification on H&E stained slides, immunohistochemistry for 
cleaved caspase-3 was performed as described previously25 in a subset of adenoma 
segments with low and high apoptosis rates {as determined in H&E stained slides). 
Analysis of membrane expression of TRAIL receptors using flow cytometry 
After treatment with aspirin or sulindac, analysis of TRAIL receptor membrane expression 
was performed as described previously.26 The following antibodies were used: 
huTRAILR1-M271 for DR4, huTRAILR2-M413 for DRS {gifts from Amgen, Seattle, WA, 
USA). A fluorescein isothiocyanate {FITC) labeled secondary antibody was used {Dako, 
Glostrup, Denmark). In VACO cells a phycoerythrin {PE) labeled secondary antibody 
{Southern Biotec, Birmingham, AL, USA) was used to clearly detect differences in 
receptor expression because FITC labeling produced a low signal. Membrane receptor 
expression was expressed as Mean Fluorescence Intensity {MFI) of al l analyzed cells. 
lmmunofluorescence 
SW948 colon cancer cel ls and VACO-235 colon adenoma cells were grown on glass plates 
coated with poly-L-lysin or collagen respectively. After treatment with aspirin (10 mM) or 
sulindac {100 µM), cel ls were incubated with mouse-anti-DR4 or mouse-anti-DRS 1:100 
{14-6644 and 14-9908, eBioscience, San Diego, CA, USA) for 45 minutes on ice. A fluor 
labeled secondary antibody was used {Alexa 488, San Diego, CA, USA). Cell s  were 
incubated with Hoechst {1:50,000) for 5 minutes. Staining was analyzed by fluorescence 
microscopy. 
Western blot analysis 
Preparation of protein lysates and Western blotting was carried out as described 
previously.26 The following primary antibodies were used: rabbit-anti-cleaved caspase-3 
{9661), mouse-anti-caspase-8 {9746), rabbit-anti-caspase-9 {9502), rabbit-anti-phospho­
Akt (9271), rabbit-anti-Akt (9272) {Cell Signaling Technology, Beverly, MA, USA), mouse­
anti-cFLIP {Alx-804-428, Alexis, Lausen, Switzerland), mouse-anti-c-Myc {sc-40), rabbit­
anti-IKB {sc-371) {Santa Cruz Biotechnology, CA, USA), mouse-anti-MCL-1 {AMS0, 
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Calbiochem, Gibbstown, NJ, USA) and mouse-anti-�-actin (ICN Biomedicals, Zoetermeer, 
the Netherlands). �-actin expression levels served as loading control. 
Statistical analysis 
SPSS for Windows software (SPSS Inc., Chicago, IL, USA) was used in al l statistical 
analyses. The Student's-t-test was used to determine differences between cell lines 
exposed to various conditions. For comparisons between treated and untreated tissue 
sections of ex vivo adenomas and normal mucosa biopsies the paired Wilcoxon signed 
rank test was used. P values of < .05 were considered significant. 
RESULTS 
Aspirin and sulindac sensitize colon cancer cell lines to rhTRAIL. 
Aspirin effectively sensitized al l colon cancer cell lines to rhTRAIL-induced apoptosis in a 
dose-dependent, synergistic manner (Figure lA-B, Supplementary Figure 1). The 
combination of aspirin and rhTRAIL gave enhancement ratios varying from 2.5 (in SW948-
TR) to 7 .1 (in CACO-2) as measured by M30 immunoreactivity. Cell lines with intrinsic 
(CACO-2) or acquired (SW948-TR) rhTRAIL resistance became responsive to rhTRAIL. 
Sulindac less markedly sensitized colon cancer cell lines to rhTRAIL-induced apoptosis 
(enhancement ratios 0.6 for CACO-2 up to 2.1 for Ls174T) (Figure lC). 
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Figure 1. Apoptosis induction in cancer cell lines after treatment with rhTRAIL (0.005-1.0 µg/ml) and aspirin (0-10 mM) 
or  sulindac (100 µM). Values are the mean ± SD of three independent experiments. * P < .05 for rhTRAIL compared to 
NSAID plus rhTRAIL. ** P < .05 for NSAID compared to NSAID plus rhTRAIL. (A) Apoptosis after aspirin plus rhTRAIL, 
measured using fluorescence microscopy. (B) Apoptosis after aspirin plus rhTRAIL, measured using M30 
immunoreactivity. (C) Apoptosis after sulindac plus rhTRAIL, measured using M30 immunoreactivity. 
Sulindac sensitizes adenoma cell lines to rhTRAIL. 
Monotherapy with aspirin, sulindac and rhTRAIL induced apoptosis in the adenoma cell 
lines VACO-330 and VACO-235 (Figure 2A-C). The combination of aspirin and rhTRAIL was 
more effective than the single agents but no clear potentiation occurred. Enhancement 
ratios were 1.4 for VACO-330 and 0.9 for VACO-235 (Figure 2A). Sulindac however 
effectively sensitized VACO-330 and VACO-235 to rhTRAIL-induced apoptosis in a 
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Figure 2. Apoptosis induction in adenoma cell lines after treatment with rhTRAIL (0.01 µg/ml) and aspirin (10 mM) or 
sulindac (100 µM) for 24 hours. Values are mean ± SD of three independent experiments. * P < .05 for rhTRAIL 
compared to NSAID plus rhTRAIL. ** P < .05 for NSAID compared to NSAID plus rhTRAIL. (A) Apoptosis after treatment 
with aspirin and rhTRAIL, measured using M30 immunoreactivity. (B) Apoptosis after treatment with sulindac and 
rhTRAIL, measured using M30 immunoreactivity. (C) Apoptosis, measured using Western blotting for cleaved caspase-3 
in VACO-330 following treatment with aspirin or sulindac combined with rhTRAIL. 
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NSAIDs do not enhance TRAIL receptor membrane expression and clustering, but affect 
multiple pathways. 
NSAID-induced upregulation of TRAIL receptor surface expression could theoretical ly 
explain the increase in rhTRAIL-induced apoptosis by aspirin and sulindac. However, in 
colon cancer cell lines no upregulation of DR4 and DRS membrane expression was 
observed following treatment with aspirin (Figure 3A) or sulindac (data not shown). 
Paradoxical ly, aspirin lowered expression levels of DR4. In adenoma cell lines, neither 
sulindac {Figure 3B) nor aspirin (data not shown) increased DR4 or DRS membrane 
expression. Furthermore, aspirin and sulindac did not induce large clustering of DR4 or 
DRS at the cell membrane as determined by immunofluorescence in VAC0-23S and 
SW948 cells {Supplementary Figure 2). 
In cancer cells, the combination of aspirin and rhTRAIL induced caspase-8 activation more 
effectively compared to the combination with sulindac. Moreover, enhanced cleavage of 
cFLIP, the most important inhibitor of caspase-8 activation, was observed upon aspirin 
plus rhTRAIL exposure, reflecting enhanced caspase-8 activation (shown for SW948-TR in 
Figure 3C). Caspase-8 cleavage was also induced in adenoma cells when rhTRAIL was 
combined with aspirin and especially with sulindac. cFLIP was not expressed in either 
adenoma cell line (Figure 3D). 
Several proteins belonging to different pathways that potential ly determine NSAID­
induced sensitization to rhTRAIL were investigated in LOVO and VACO adenoma cells. 
The results suggest an effect on the intrinsic apoptosis pathway (downregulation of the 
anti-apoptotic protein Mcl-1 and caspase-9 cleavage), on the Pl3K/Akt pathway 
(reduction in phospho-Akt and Akt) and on the NF-KB pathway (reduction in the 
expression of inhibitor IKB) {Supplementary Figure 3). In the VACO adenoma cell lines, 
sulindac had more effect on the proteins studied than aspirin and the reverse was 
observed in the colon cancer cell line LOVO. However, different proteins were affected in 
the two VACO adenoma cell lines, indicating the complex effects of NSAIDs. 
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Figure 3. TRAIL receptor membrane expression {determined using flow cytometry) after 24 hours incubation with 
aspirin {10 mM) or sulindac (100 µM). Values are expressed as the Mean Fluorescence Intensity (MFI) ± SD of three 
independent experiments; • P < .05 for sulindac or aspirin-treated cells compared to untreated cells. (A) Receptor 
expression after treatment with aspirin in cancer cell lines. (Bl Receptor expression after treatment with sulindac in 
adenoma cell lines. (C,D) Caspase-8 and cFLIP expression in cancer cell line SW948-TR (C) and adenoma cell line VACO-
330 (D) after 24 hours incubation with aspirin (10 mM) or sulindac (100 µM) and rhTRAIL. Positive controls for Western 
blotting of cFLIP: Ramos B-cell cell line, stably transfected with a cFLIPL construct. For caspase-8: SW948 treated with 
rhTRAIL. 
Increased rhTRAIL-induced apoptosis by aspirin and sulindac is mediated through TCF-
4. Aspirin and sulindac both sensitized Ls174T cel ls to rhTRAIL-induced apoptosis (Figure 
1B/C). Since NSAIDs are known to interfere with the Wnt pathway, we used a genetic 
approach to investigate the interaction between Wnt signaling inhibition and rhTRAIL 
sensitization. Doxycyclin-induced expression of dnTCF4 in Ls174T cells blocked 
transcriptional activity of TCF-4 as il lustrated by a time-dependent decrease in protein 
expression of the TCF-4 target c-Myc (Figure 4A). When dnTCF-4 expression was induced, 
aspirin no longer potentiated rhTRAIL-induced apoptosis as determined using 
fluorescence microscopy (Figure 4C) and M30 immunoreactivity (data not shown). 
Apoptosis levels in the doxycyclin treated control cell line were not affected indicating 
that the observed effect in dnTCF-4 expressing cells was not due to doxycyclin treatment 
(Figure 4B). Induction of dnTCF-4 also abrogated the sensitizing effect of sulindac on 
rhTRAIL-induced apoptosis (data not shown). These results demonstrate that effects of 
both aspirin and sulindac on rhTRAIL-induced apoptosis are mediated through TCF-4-
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Figure 4. Effects of induction of dnTCF-4 in Ls174T cells. Apoptosis after incubation with aspirin (10 mM) and rhTRAIL ( 1  
µg/ml) was measured using fluorescence microscopy. Values are the mean ± SD of  three independent experiments. * P 
< .05 in Ls174T-dnTCF-4 treated with aspirin and rhTRAIL: not induced vs. induced with doxycyclin. (A) TCF-4 
transcriptional target c-Myc is downregulated in a time-dependent manner after induction of dnTCF-4. (B) Apoptosis in 
Ls174T with and without doxycyclin induction. (C) Apoptosis in Ls174T-dnTCF-4 with and without doxycyclin induction. 
The combination of rhTRAIL and sulindac effectively induces apoptosis in human ex 
vivo treated adenomas. 
To define whether sulindac can sensitize adenomas to rhTRAIL-induced apoptosis, we 
cultured adenoma explants for 24 hours. There was no difference in the percentage of 
apoptotic cells between adenoma segments fixed directly in formalin after removal and 
paired pieces cultured untreated for 24 hours (n = 12, degree of apoptosis 14.4% and 
14.3% respectively, P = .754). The omnipresence of the short lived Ki-67 antigen reflects a 
high percentage of proliferating cells in al l segments after 24 hours of incubation, 
indicating that the culture environment was sufficient to maintain cells in cell cycle 
progression (Supplementary Figure 4). Both adenomas with low-grade dysplasia (n = 25) 
and with high-grade dysplasia (n = 23) were sensitive to 24 hours treatment with rhTRAIL 
(Table 2A/B, Figure SA). Not every adenoma responded to rhTRAIL treatment (25 
responders out of 48) which is similar to our previous findings following incubation with 
rhTRAIL for 5 hours (5). Both LGD adenomas and HGD adenomas were sensitive to 24 
hours treatment with sulindac (Table 2B). 
The combination of rhTRAIL and sulindac significantly induced more apoptosis than 
monotherapy in adenomas with either rhTRAIL (P = .005) or sulindac (P = .003) (n = 22) 
(Table 2B, figure SB/C). Apoptosis levels raised from 17.8% (rhTRAIL) and 18.4% 
(sulindac) to 28.0% (combination). Subgroup analyses showed that the enhancement was 
still significant in HGD adenomas and there was a trend towards significance in LGD 
adenomas. From 22 adenomas treated with rhTRAIL, sulindac and the combination, 
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12/22 adenomas responded to rhTRAIL, consistent with a response of 25/48 adenomas in 
the large group of rhTRAIL-treated adenomas, 10/22 adenomas responded to sulindac 
and 19/22 adenomas responded to the combination (Table 2C). A subgroup analysis of 
the adenomas not responding to rhTRAIL (10/22) demonstrated that 3/10 of these 
adenomas responded to sulindac, whereas 8/10 of these adenomas responded to the 
combination. This suggests that sulindac can circumvent resistance to rhTRAIL. 
In previous experiments treating adenoma samples with rhTRAIL for 5 hours, we showed 
that H&E staining and active caspase-3 staining gave similar apoptosis results.s Here, 
adenoma samples were co-incubated with rhTRAIL and sulindac for 24 hours. In several 
adenoma samples we could clearly identify and count active caspase-3 positive cells 
(Figure SD). However, in many samples staining of the early marker active caspase-3 was 
detectable but could not be related to individual cells. This is due to the fact that active 
caspase-3 is lost and/or shed in late apoptotic cel ls  in contrast to H&E, a late marker for 
apoptosis (and regarded as gold standard for apoptosis assessment).27 
Table ZA. Degree of apoptosis in untreated adenoma segments and segments treated with rhTRAIL (1 µg/ml) 
determined in H&E stained slides. 
Grou N Untreated % :I: SD P value 
All adenomas 48 11.5 ± 4.6 17.8 ± 7.0 < .001* 
LGD 25 9.4 ± 4.1 < .001* 
HGD 23 13.8 ± 4.2 19.0 ± 7.6 .001* 
1 paired Wilcoxon signed rank test 
* P <  .OS 
Table 2B. Degree of apoptosis in untreated adenoma segments and segments treated with rhTRAIL (1 µg/ml), sul indac 
(100 µM) or the combination determined in H&E stained slides. 
Group N Untreated rhTRAIL Sulinclac Combined P value P value 
{% :1: SD) (% :t sot {% :1: sot (" :I: SD) rhTRAIL vs  sulinclac vs 
combination 
All 11.9 ± 5.1 17.8 ± 5.8 18.4 ± 5.7 28.0 ± 14.3 .005* .003* 
LGD 9.7 ± 4.7 17.2 ± 6.2 20.3 ± 6.5 25.6 ± 11.5 .051 
HGD 12 13.7 ± 4.9 18.3 ± 5.7 16.9 ±4.6 29.9 ± 16.4 .034* .015* 
1 paired Wilcoxon signed rank test 
* P <  .OS 
• P value untreated vs rhTRAIL for all samples P = .001, for LGD P = .017, for HGD P = .012 
b P value untreated vs sulindac for all samples P = .001, for LGD P = .012, for HGD P = .034 
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Table 2C. Number of paired adenoma segments responding to rhTRAIL, sulindac or the combination* .  







* Response is defined as an increase of specific treatment-induced apoptosis of > 5% compared to the untreated adenoma sample. 
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Figure 5. Apoptosis induction in adenoma segments as determined in H&E stained slides after 24 hours treatment with 
rhTRAIL (1.0 µg/ml) and sulindac (100 µM). (A) Percentage of specific rhTRAIL-induced apoptosis in adenomas with 
LGD and HGD. (B) Apoptosis in adenoma segments {LGD + HGD) after treatment with rhTRAIL, sulindac and the 
combination. The distribution of adenoma segments and mean degree of apoptosis are displayed. * P < .05 for rhTRAIL 
compared to sulindac plus rhTRAIL. ** P < .05 for sulindac compared to NSAID plus sulindac. (C) Apoptosis induced by 
rhTRAIL (1.0 µg/ml), sulindac (100 µM) and the combination in adenoma segments from one adenoma with HGD as 
determined in H&E stained slides. Arrows indicate apoptotic cells. (D) lmmunohistochemistry for active caspase-3 in 
the same adenoma as in C. Magnification: 400x. This adenoma is sensitive for the combination. 
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RhTRAIL and sulindac do not induce apoptosis in non-dysplastic cell lines and normal 
colonic epithelium. 
To demonstrate tumor selectivity of our approach we treated non-dysplastic cell lines 
and normal colonic epithelium biopsies with sulindac, rhTRAIL or the combination. 
Neither normal bronchial epithelial cells nor normal lung fibroblasts were sensitive to 
therapy with sulindac and/or rhTRAIL (Figure GA). In addition, neither agent nor the 
combination induced apoptosis in biopsies from normal colonic mucosa (Table 2D, Figure 
6B) when cultured in the same manner as adenoma segments. These results indicate a 
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Figure 6. (A) Acridine orange apoptosis assay in 16HBE human bronchial epithelial cells, IMR90 human lung fibroblast 
cells and LOVO colon cancer cells after 24 hours treatment with the combination of sulindac (100 µM) and rhTRAIL 
(0.01 µg/m() showing no toxicity of the combination to normal cells while apoptosis is induced in LOVO cancer cells. 
Arrows indicate apoptotic cells. (B) H&E staining in an untreated normal epithelium biopsy and a biopsy from the same 
patient treated with the combination of sulindac (100 µM) and rhTRAIL (1 µg/ml) for 24 hours, showing no enhanced 
apoptosis induction after combined treatment. Magnification 400x. 
Table 2D. Degree of apoptosis in untreated normal mucosa biopsies and biopsies treated with rhTRAIL (1 µg/ml), 
sulindac (100 µM) or the combination determined in H&E stained slides. 
N Untreated 
(" ± SD) 
Normal colon 8 4.4 ± 1.2 
1 paired Wilcoxon signed rank test 
rhTRAIL 
(% ± SD) 
4.7 ± 1.0 
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DISCUSSION 
In this study, we demonstrate that in both TRAIL-sensitive and TRAIL-resistant colon 
cancer cell lines, sulindac and even to a larger extent aspirin enhanced rhTRAIL-induced 
apoptosis. In addition, we show that sulindac increases rhTRAIL-induced apoptosis in 
colon adenoma cell lines. The sensitizing effect of NSAIDs is completely blocked after 
induction of dnTCF-4, indicating that sensitization is mediated via the Wnt pathway 
transcription factor TCF-4. Final ly, we show enhanced induction of apoptosis in freshly 
removed human adenoma segments by the combination of sulindac and rhTRAIL, 
suggesting clinical relevance of our findings. 
Modulation of rhTRAIL-induced apoptosis by NSAIDs was not due to increased 
membranous expression of DR4 and DRS. Enhanced clustering of death receptors at the 
cell surface and redistribution into cholesterol-rich and ceramide-rich caveolae or lipid 
rafts has been shown to increase sensitivity to rhTRAIL19'28, but we did not observe 
increased receptor clustering after aspirin or sulindac in colon adenoma and carcinoma 
cells. The observed increase in caspase-8 activation by the combination of aspirin or 
sulindac and rhTRAIL does however implicate enhanced activation of the extrinsic 
apoptosis pathway. In our cancer cell lines, cFLIP cleavage was induced after aspirin plus 
rhTRAIL. Since caspase-8 activation was shown to correlate with cFLIP downregulation, 
enhanced cleavage of cFLIP by caspase-8 at the DISC may finally result in loss of 
inhibitory capacity of cFLIP.29•30 This mechanism cannot apply to adenoma cells since 
neither adenoma cell line expresses cFLIP. This is in agreement with our previous 
observation that cFLIP is generally overexpressed at later stages of colorectal 
carcinogenesis.31 It has been demonstrated previously that treatment with aspirin and 
sulindac resulted in very different expression profiles in colon cancer cell lines indicating 
that NSAIDs target multiple proteins/pathways.32 Our results suggest an effect on the 
intrinsic apoptosis pathway, the Pl3K/Akt pathway and on the NF-KB pathway. The effect 
on the investigated proteins differed between adenoma and cancer cells, between the 
two adenoma cell l ines and between treatment with sulindac and aspirin, indicating the 
complexity of the mechanisms involved, which needs further investigation. 
We have shown that the sensitizing effect of aspirin and sul indac on rhTRAIL-induced 
apoptosis is mediated through the Wnt pathway. Activation of this pathway is crucial for 
the development of CRC. Therefore, our findings indicate that the combination of these 
agents acts as targeted therapy, effective specifical ly in the pathological situation where 
the Wnt pathway is constitutively active. Accumulating evidence suggests that Wnt 
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pathway activation is indeed important for rhTRAIL sensitivity.33 Specifical ly c-Myc, which 
is transcriptionally  activated by TCF-4, is an important proto-oncogene required for 
rhTRAIL sensitivity.34'35 When we eliminated TCF-4 {and therefore downregulated its 
target c-Myc), a dramatic decrease in apoptosis induction by rhTRAIL in combination with 
an NSAID occurred. This shows that the combination of rhTRAIL and NSAIDs needs TCF-4 
activity to exert its apoptosis inducing effect. Since Wnt pathway activation is an early 
event in colon carcinogenesis36, it is of great interest to study the potential of NSAIDs and 
rhTRAIL as a combined chemopreventive strategy in individuals with a high risk of 
adenoma formation. At first sight, our results seem to be in conflict with several studies 
indicating that inhibition of TCF-4 activity is an important chemopreventive mechanism 
of NSAIDs.12'13 However, anti-carcinogenic effects of inhibiting TCF-4 activity through 
dominant negative TCF-4 overexpression have been attributed to induction of cell cycle 
arrest and differentiation and not to enhanced apoptosis induction.37 
Examining the enhancement ratios for aspirin and sulindac on rhTRAIL-induced 
apoptosis, we conclude that in adenoma cells the combination with sulindac was most 
effective, while in cancer cel ls this was the case for aspirin. The doses of aspirin and 
sulindac used to enhance rhTRAIL-induced apoptosis were relatively high al lowing short­
term incubation with high-dose NSAID to study the mechanism of sensitization for 
apoptosis. However, the aspirin and sulindac concentrations are in the same order of 
magnitude as clinical ly achievable.38•39 Also in mice, an aspirin dose of 400 mg/kg/day {an 
estimated serum concentration of > 5 mM40) sensitized breast cancer xenografts to 
TRAIL.41 
Finding effective strategies for chemoprevention is an important goal for management of 
individuals with a high risk to develop CRC. To verify effects seen in colon adenoma cell 
l ines with sulindac and rhTRAIL, we used the more clinical ly relevant model of ex vivo 
cultured human adenomas in which adenoma cells are kept in their original context 
preserving relatively normal cell-cell interactions. Basic apoptosis levels where higher in 
HGD adenomas compared to LGD adenomas. This is not surprising as apoptosis levels 
increase from normal mucosa, to adenoma, to carcinoma.42 We observed significant 
apoptosis induction by rhTRAIL in both LGD and HGD adenomas after 24 hours 
incubation. This effect was not observed in LGD adenomas after 5 hours incubation.5 This 
may be a consequence of a slower onset of apoptosis in LGD adenomas compared with 
HGD adenomas.43 The combination of sulindac and rhTRAIL was superior to treatment 
with either drug as single agent. Treatment-induced apoptosis raised from "'6% {TRAIL or 
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sulindac) to "'16% (combination) and was already observed after 24 hours of a single 
treatment, while in vivo treatment with rhTRAIL or sulindac is repeated frequently. As an 
example, repeated treatment with rhTRAIL and retinoic acid was recently reported to 
effectively reduce adenoma numbers in ApcMin mice.35 These results are thus 
encouraging when considering use of these agents in a chemopreventive setting. In 
addition, the lack of toxicity to normal cells when combining sulindac and rhTRAIL is an 
important finding in the context of chemoprevention. We are currently preparing a study 
in ApcMin mice in order to examine the in vivo efficacy of TRAIL receptor agonists in 
combination with sulindac against colorectal adenomas. 
In conclusion, the possibility to circumvent TRAIL resistance with NSAIDs may have 
important implications for the potential use of TRAIL receptor agonistic agents in cancer 
patients. Moreover, the enhancement of apoptosis in adenoma cells and ex vivo 
adenomas by combining sulindac and rhTRAIL, point at the importance of further 
exploration of this combination for chemoprevention of CRC. 
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SUPPLEMENTARY METHODS 
Cell cultures 
Two human colon adenoma cell lines, VACO-235 and VACO-330 (a kind gift from J.K. 
Wilson, Ireland Cancer Center, Cleveland, OH, USA), derived respectively from a villous 
and tubular adenoma, were used. VACO-235 has an APC mutation in both al leles and has 
a mutant K-ras allele. VACO-330 has wild type K-ras alleles.44 The Wnt pathway mutation 
status of VACO-330 cel ls has not been reported. �-catenin was however expressed 
equally between both VACO cel l lines, suggesting presence of a Wnt pathway mutation 
(unpublished data). Cells were cultured on rat tail collagen coated plates in Minimal 
Essential Medium (lnvitrogen Life Technologies, Breda, the Netherlands) supplemented 
with 2% fetal bovine serum, non-essential amino acids, l-glutamine, gentamicin, insulin, 
transferrin, selenium, epithelial growth factor and hydrocortisone. VACO cells were 
harvested by treatment with H2E dissociation medium for 5-10 min at 37 °C.5 A panel of 
colon cancer cell lines was tested. All colon cancer cel l lines bear a Wnt pathway 
mutation leading to TCF-4 transcriptional activity. LOVO, CACO-2, SW948 and SW948-TR 
cells are APC mutant cell l ines, while Ls174T cells bear a P-catenin mutation.45 LOVO, 
SW948, SW948-TR and Ls174T are K-ras mutant cell lines, CACO-2 has wild type K-ras 
al leles.46'47 SW948 is sensitive to rhTRAIL, LOVO and Ls174T are intermediately sensitive, 
while CACO-2 and SW948-TR (sub line of the SW948)6 show intrinsic and acquired 
resistance to rhTRAIL, respectively. Ls174T-dnTCF-4 and Ls174T were kindly provided by 
H. Clevers (Hubrecht Laboratory, Utrecht, the Nederlands).22 Ls174T-dnTCF-4 is stably 
transfected with a plasmid encoding an N-terminally truncated version of TCF-4 under 
control of a doxycyclin responsive promoter. Dominant-negative TCF-4 (dnTCF-4) does 
not bind P-catenin and its expression potently inhibits TCF-4 signaling. To induce dnTCF-4 
expression, doxycyclin (Sigma-Aldrich, Zwijndrecht, the Netherlands) was added at a final 
concentration of 1 µg/ml, 24 hours prior to the start of experiments. Ls174T is stably 
transfected with an empty vector containing the doxycyclin responsive promoter and 
was used as a control.37 The human bronchial epithelial cell line 16HBE and human lung 
fibroblast cell line IMR90 were used to examine possible toxicity of sulindac and rhTRAIL 
in non-dysplastic cells. All cell line experiments were performed in triplicate. 
Ex vivo human colorectal adenomas and normal colonic mucosa 
Individuals undergoing colonoscopy at the University Medical Center Groningen from 
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was approved by the medical ethical review committee of the University Medical Center 
Groningen. All patients gave written informed consent. Histological classification of 
adenomas was carried out on hematoxylin-eosin {H&E) stained slides by a pathologist. 
Growth type and degree of dysplasia of adenomas were defined according to the World 
Health Organization guidelines.48 For statistical purposes two groups were defined: 
adenomas with low-grade dysplasia {LGD), and adenomas with high-grade dysplasia 
{HGD, including adenomas that exhibit a mixture of LGD and HGD, HGD or focal 
intramucosal carcinoma). 
A total of 59 polyps was obtained. Two polyps were excluded from further analysis since 
they were classified as hyperplastic and inflammatory polyps, respectively. Two other 
polyps were excluded because crypts were not evaluable and apoptosis in the control 
sample was above the predefined level of 25%, respectively. Segments from 6 adenomas 
were incubated in adenoma culture medium only for time line control experiments. The 
remaining 48 colorectal adenomas were included for final drug treatment analysis. 
Patient and adenoma characteristics are summarized in Table 1. From each of eight 
individuals with a history of colorectal adenomas or with anemia of unknown origin, four 
biopsies from macroscopical ly and microscopical ly normal sigmoid mucosa were 
obtained at colonoscopy. At the time of biopsy, there was no evidence for the presence 
of adenomas. 
c:J aspirin (10 mM) 
14 rhTRAIL 
- aspirin + rhTRAIL 
CAC0-2 LOVO SW948 SW948-TR 
Supplementary Figure 1. Apoptosis induction in cancer cell lines after treatment with aspirin (10 mM) plus rhTRAIL 
(0.005-0.1 µg/ml), measured using a fluorometric caspase-3 assay. Values are the mean ± SD of three independent 
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Supplementary Figure 2. lmmunofluorescence for DR4 and DRS in SW948 colon cancer cells and VACO-235 colon 
adenoma cells after 24 hours treatment with aspirin (10 mM) or sulindac (100 µM) demonstrating the absence of 
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Supplementary Figure 3. Expression of MCL-1, caspase-9, phospho-Akt, Akt and the inhibitor of NF-KB (IKB) in colon 
adenoma cell lines VACO-235 and VACO-330 and colon cancer cell line LOVO after 24 hours treatment with aspirin (10 
mM) or sulindac (100 µM) demonstrating that the intrinsic apoptosis pathway, Pl3K/Akt pathway and NF-KB pathway 
are affected by NSAIDs to a variable extent depending on the cell line used. 
A =  aspirin, S = sulindac. 
Supplementary Figure 4. Ki-67 staining in an incubated (24 hours) untreated adenoma segment showing extensive 
proliferation of the epithelial crypt cells. 
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ABSTRACT 
Background: Ape mutant {ApcMin) mice develop multiple adenomas in their intestines and 
are widely used to study colorectal carcinogenesis and chemopreventive approaches. 
Molecular imaging of intestinal adenomas could potential ly  provide non-invasive 
longitudinal evaluation of these lesions in living mice. Therefore, the aim of this study 
was to investigate the role of 18F-FDG PET in the ApcMin mouse model . 
Methods: ApcMin mice (n = 8) fed a purified diet were imaged serial ly after injection of 
18F-FDG at age 9 and 12 weeks using a µPET rodent scanner. Abdominal uptake of the 
tracer was quantified. After dissection, intestines were imaged separately, and intestinal 
tracer uptake was quantified. Tracer distribution was compared with results from 
microscopic examination regarding adenoma number and size. Thereafter, findings were 
validated serial ly in 20 ApcMin mice aged 6, 8, 10 and 12 weeks that received standard 
chow to increase adenoma numbers. In vivo abdominal 18F-FDG uptake was correlated 
with microscopy results. 
Results: Microscopic examination showed that the mice developed 25-35 intestinal 
adenomas at age 12 weeks. Ex vivo 18F-FDG PET of the dissected intestines visualized all 
large adenomas and most small adenomas. Ex vivo total intestinal 18F-FDG uptake 
correlated with in vivo total abdominal uptake and with the number of large (2: 2 mm) 
adenomas at age 9 and 12 weeks. At 12 weeks, there was a clear correlation between in 
vivo abdominal tracer uptake and number of large adenomas but not the total number of 
lesions. 
Conclusion: Intestinal adenomas in ApcMin mice are metabolical ly  active lesions that take 
up 18F-FDG. Abdominal 18F-FDG uptake at age 12 weeks serves as a readout modality for 
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Colorectal cancer (CRC) develops from premalignant adenomas.1 Adenomas are common 
lesions with a prevalence at autopsy of around 35% in the Western world.2 Five percent 
of al l colorectal adenomas will become malignant over a period of 5-10 years; thus, 
prevention of CRC is of substantial importance. The relatively slow evolution from normal 
mucosa to adenoma to cancer provides a window of opportunity for intervention. 
Chemoprevention involves the long-term use of agents to prevent, delay, or even reverse 
the development of adenomas and cancer, thereby interfering with the process of 
carcinogenesis.3 The most prominent candidates for chemoprevention, Non-Steroidal 
Anti-Inflammatory Drugs (NSAIDs), are effective but only in a subset of individuals. 
Current research, therefore, focuses on new, preferential ly multi-targeted approaches 
for chemoprevention.4 
In chemoprevention research the Ape mutant (ApeMin) mouse model is of interest 
because it mimics both Familial Adenomatous Polyposis (FAP), a hereditary condition, 
and sporadic carcinogenesis. A truncating mutation in the murine Ape gene leads to 
multiple intestinal adenomas, especial ly located in the small intestine and to a lesser 
extent in the colon. These adenomas seldom progress toward malignancy, possibly 
because the mice die from anemia and cachexia before this transformation occurs. 5 
Despite the existing differences between colorectal carcinogenesis in human and mice, 
most histological and molecular features of adenomas in ApeMin mice are similar to those 
observed in human adenomas. 6 For this reason, and the fact that the heavy adenoma 
load facilitates the evaluation of chemopreventive effects, the ApeMin mouse model is 
widely used for studying colorectal carcinogenesis and chemopreventive approaches. 
Post-mortem microscopic examination is the gold standard for assessing adenomas in 
the mouse intestine. This method does not allow continuous non-invasive monitoring of 
chemopreventive effects in the same mice over time. Using an effective longitudinal 
method to non-invasively fol low intestinal adenoma development and growth in living 
mice could lead to better insight into treatment efficacy and could clearly lower the 
number of animals needed for those experiments. Non-invasive molecular imaging 
techniques, such as 18F-FDG PET, which visualizes glucose metabolism, can potential ly be 
of help in this respect. Malignant transformation is associated with increasing glucose 
consumption. 18F-FDG is actively taken up and accumulates in tumor cells.7 In humans, 
colorectal adenomas are detected by 18F-FDG PET to a variable extent depending on 
adenoma characteristics. s-19 18F-FDG PET in a mouse model of intestinal adenomas has 
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not been reported. The aim of this study was therefore to investigate the putative 
application of 18F-FDG PET for the detection of intestinal adenomas in the ApcMin mouse 
model, to evaluate its use for chemoprevention studies. 
METHODS 
Animals and experimental setup 
Experimental protocols were approved by the Institutional Animal Care Committee. 
Heterozygous male C57Bl/6J-ApcMin/J mice {age, 5 weeks) were obtained from Jackson 
Laboratories {Bar Harbor, ME, USA). Animals were housed in groups {4-5 mice) in a 
temperature-controlled room with a 12 hours l ight-dark cycle and ad libitum food and 
water. Mice were put on a purified diet {AIN-93G, Dyets, Inc, Bethlehem, PA, USA) or fed 
standard chow to increase adenoma numbers.20 Al l animals received fresh food weekly. 
The mice (n = 4 per group) in the purified diet group were scanned maximally twice at 
the ages of 9 and 12 weeks. The mice {n = 5 per group) fed standard chow were scanned 
at 1, 2, 3 or maximally 4 time points at the ages of 6, 8, 10 and 12 weeks. 
18F-FDG PET 
To improve 18F-FDG adenoma uptake before scanning, mice were fasted overnight and 
allowed free access to water. Animals were kept warm starting from 30 minutes before 
tracer injection by keeping the cage temperature at 30 °C using a heat lamp and a 
heating pad located beneath the cage.21 18F-FDG {15-20 MBq; pH 6.6 - 7.0; volume < 0.1 
ml) was injected into the penile vein while mice were anesthetized {isoflurane 
anesthesia, induction, 3% and maintenance, 1.5%). After tracer injection, mice were kept 
conscious, and warming continued during the uptake period of the tracer. PET was 
started at 60 minutes after 18F-FDG injection, again under isoflurane anesthesia. Animals 
were imaged using a microPET focus 220 rodent scanner {Siemens Preclinical Solutions, 
Inc.). Static images {20 minutes acquisition time) were obtained. Smal l-animal PET was 
performed in full 3-dimentional mode, that is including oblique lines of response. 
Sinograms were Fourier rebinned into 2-dimentional sinograms and consecutively 
reconstructed using an attenuation-weighted ordered-subset expectation maximization 
reconstruction. Data were corrected for randoms, scatter, attenuation, and dead-time. 
The reconstructed scanner resolution was tested in phantom experiments and was 1.5 
mm. After the last scan, animals were sacrificed directly by cervical dislocation and the 
intestines were removed. Longitudinally opened intestines pinned on a paraffin layer 
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were scanned after microscopic investigation, using the same scanning protocol. Decay 
correction was applied to enable comparison of ex vivo intestinal tracer uptake with 
whole-body data and with in vivo abdominal uptake in the l iving mice. 
Calculation of whole-body, abdominal and intestinal 18F-FDG uptake 
Smal l-animal PET images were analyzed using AMIDE (A Medical Image Data Examiner) 
software (version 0.9.1, Stanford University, Stanford, CA, USA). Whole-body activity (in 
MBq) was calculated by counting the total activity present within the image. For 
assessment of abdominal activity, a manually drawn Volume Of Interest (VOi) in the 
abdomen was created (Figure 1), and the total activity of this VOi was calculated. The VOi 
was constructed for each mouse separately, reaching from below the diaphragm. The 
bladder was left out of the VOi because 18F-FDG is excreted in the urine, and bladder 
activity was prominently visible at 60 minutes after injection. Intestinal activity (in MBq) 
was assessed by calculating the total activity present in the ex vivo-scanned intestines. In 
vivo abdominal and ex vivo intestinal uptake were expressed as a percentage of whole­
body uptake to correct for differences in injected tracer dose. Adenoma-to-background 
ratios were determined using the ex vivo images of the intestines of 9- and 12 weeks-old 
mice. VOis were constructed for adenoma regions and randomly chosen background 
regions of the small intestine. The maximum intensity of the adenoma and background 
VOis was assessed (defined on a pixel basis). Ratios were calculated by dividing the 
maximum intensity of adenomas by the maximum intensity of the background. 
Coronal plane Saglttal plane 
Figure 1. Whole-body 18F-FDG PET images of ApcMln mouse at age 12 weeks. VOi to calculate the abdominal uptake of 
tracer is shown in orange. 
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Examination by microscopy 
The entire intestine from the pylorus to the rectum was removed and placed in ice-cold 
Phosphate-Buffered Saline (PBS), pH 7.0. The intestine was divided into the following 4 
segments ("'4 cm each): proximal small intestine (duodenum), middle small intestine 
Uejunum), distal smal l intestine (ileum), and colon. Segments were opened 
longitudinally. Next, the intestines were rinsed with PBS and spread, using small pins on a 
paraffin layer in PBS, with the mucosal surface facing upward. Intestinal segments were 
examined under a dissecting microscope (Wild Heerbrugg, Gais, Switzerland) to record 
adenoma number, location, and diameter. Adenomas 2 mm or larger were classified as 
large adenomas in accordance with the literature.22 Schematic representations of the 
microscopic view were drawn to permit the comparison of microscopic results and 
results from ex vivo 18F-FDG PET of the intestine. 
lmmunohistochemistry was performed on paraffin slides of the small intestine and colon 
of the mice using the following antibodies: rat anti-Ki-67 (Dako, Glostrup, Denmark) and 
rabbit anti-GLUT-1 (Chemicon International, Temecula, CA, USA). 
Statistical analysis 
SPSS for Windows software (SPSS Inc., Chicago, IL, USA) was used in all statistical 
analyses. The Mann-Whitney U test was used to determine differences in radioactivity 
uptake between groups. Linear regression analysis was used to determine the correlation 
between differently measured 18F-FDG uptake values and between 18F-FDG uptake and 
adenoma numbers. P values < .OS were considered statistically significant. 
RESULTS 
Adenoma counts in ApcMin mice (age, 9 and 12 weeks). 
Both the total number of adenomas and the number of adenomas 2 mm or larger as 
counted by microscopy did not differ between 9- and 12 weeks-old mice (Table 1) . 
Table 1. Adenoma number in ApcMin mice (age, 9 and 12 weeks) fed purified diet 
Mean number of 
adenomas {range) ± SD 
1 Mean n1.1mber of 
adenomas :i!: 2 mm 
ra��J ± SD 
9 weeks 12 weeks 
26 (19-33) ± 6.2 21.25 {12-30) ± 8.2 
6.25 {4-11)± 2.2 5.75 ± 2.2 (3-8) 
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P value 9 vs l2 weeks) 
.39 
.81 
18F-FDG PET images in ApcMin mice (age, 9 and 12 weeks). 
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Visual analysis of the 18F-FDG PET images showed several abdominal hotspots in each 
mouse, likely reflecting intestinal adenomas (Figure 2A). It was unlikely that these hot 
spots represented physiological uptake because liver and kidney uptake (in vivo imaging 
results) and normal small intestinal uptake (ex vivo imaging results) were relatively low, 
in l ine with published data.23 The number of hot spots did not correlate with the total 
number of adenomas or the number of large adenomas as counted by microscopy. When 
the intestines of the 18F-FDG-injected mice were scanned ex vivo, al l adenomas larger 
than 2 mm could be detected by 18F-FDG PET in both 9- and 12-weeks-old mice. Smaller 
adenomas were detected by ex vivo imaging in 73% and 97% of cases in respectively 9-
and 12-weeks-old mice (Figure 28). In addition, extra hot spots were found with ex vivo 
imaging in the small intestine of 9-(9%) and 12-(27%) weeks old mice in areas in which no 
adenoma was found at examination with the dissecting microscope. Although 
background uptake was relatively low in the small intestinal segments, the colon showed 
more 18F-FDG uptake, and the degree of colonic background uptake strongly varied (1.3-
3. 7 times the background intensity of the small intestine). lmmunohistochemistry for 
proliferation (Ki-67) and the glucose transporter-1 revealed no differences in expression 
between small intestinal and colonic sections (data not shown). 
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Figure 2. (A) Whole-body 18F-FDG PET images of ApcMin mouse at age 12 weeks. Abdominal hot spots most likely 
reflecting intestinal adenomas are indicated by arrows. (B) 18F-FDG PET of intestines of ApcMin mouse at age 12 weeks. 
Large arrows indicate large adenoma�(2 mm), and small arrows indicate small adenomas (< 2 mm). Schematic 
representation of microscopic view of intestine with adenomas is shown below 18F-FDG PET image. 
Abdominal and intestinal uptake of 18F-FDG in ApcMin mice (age, 9 and 12 weeks). 
Although the number of microscopically detected adenomas did not increase with age of 
the mice, the total uptake of 18F-FDG in the ex vivo-scanned intestines did increase when 
expressed as a percentage of whole-body uptake (P = .03, Figure 3A). The adenoma-to­
background ratio was 1.4 for small and 2.1 for large (2: 2 mm) adenomas at age 9 weeks. 
At age 12 weeks, the adenoma-to-background increased to 2.4 for small and 4.8 for large 
(2: 2 mm) adenomas. These results demonstrate that 18F-FDG was well distributed 
throughout the intestine and that adenomas are metabolical ly  active lesions and take up 
18F-FDG to a higher extent than does normal small intestinal tissue. The uptake of 18F­
FDG in the total abdomen also increased with increasing age when expressed as a 
percentage of whole-body uptake (P = .03, n = 4 per group, Figure 3B). The ex vivo 
intestinal tracer uptake at both age 9 and, especial ly, age 12 weeks correlated with the in 
vivo abdominal uptake of the tracer (R2 = 0.51 and R2 = 0.82, respectively; P = .28 and P = 
.09, respectively; n = 4 per group) indicating that the calculation of abdominal uptake can 
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Figure 3. (A) Ex vivo intestinal 18F-FDG uptake expressed as percentage of whole-body 18F-FDG uptake in ApcMln m ice 
aged 9 (n = 4) and 12 (n = 4) weeks. Mean and SD are displayed. (B) In vivo abdominal 18F-FDG uptake expressed as 
percentage of whole-body 18F-FDG uptake in ApcMin mice aged 9 (n = 4) and 12 (n = 4) weeks. Mean and SD are 
displayed. (C) Correlation between ex vivo intestinal 18F-FDG uptake and in vivo abdominal 18F-FDG uptake in 4 ApcMin 
mice aged 9 weeks and 4 ApcMin mice aged 12 weeks. (D) Correlation between ex vivo intestinal 18F-FDG uptake and 
number of large intestinal adenomas based on microscopy in 4 ApcMln mice aged 9 weeks and 4 ApcMin m ice aged 12 
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Correlation between intestinal tracer uptake and microscopy. 
The ex vivo intestinal tracer uptake did not correlate with the total number of adenomas 
observed by microscopy (data not shown). However, ex vivo intestinal tracer uptake did 
correlate with the number of adenomas 2 mm or larger at age 9 and 12 weeks (R2 = 0.87 
and 0.84, respectively; P = .07 and P = .08, respectively; n = 4 per group, Figure 3D). 
Correlation between abdominal tracer uptake and microscopy. 
Because in vivo abdominal tracer uptake reflects ex vivo intestinal uptake of the tracer, 
we next assessed whether this abdominal uptake correlated with the number of 
adenomas 2 mm or larger. At the age of 12 weeks, there was a clear correlation (R2 = 1.0, 
P = .004, n = 4 per group, Figure 4A), which did not exist at 9 weeks of age (data not 
shown). 
In a second larger cohort, we scanned and sacrificed mice at age 6, 8, 10 and 12 weeks, 
to examine a larger time span and to validate our previous results. To maximize the 
number of adenomas, these mice were fed standard chow, not a purified diet, because 
adenoma numbers are reportedly higher in standard chow-fed mice.20 At age 6 and 8 
weeks, an insufficient number of large adenomas (� 2 mm) was present for analysis 
(Table 2). In this cohort, there was again a correlation between in vivo abdominal tracer 
uptake and number of adenomas 2 mm or larger at age 12 weeks (R2 = 0.84, P = .03, n = 5 
per group, Figure 4B) but not at 10 weeks (data not shown). 
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Figure 4. (A) Correlation between in vivo abdominal 18F-FDG uptake and number of large intestinal adenomas in 4 
ApcMin mice aged 12 weeks that were fed purified diet. (B) Correlation between in vivo abdominal 18F-FDG uptake and 
number of large intestinal adenomas in 5 ApcMin mice aged 12 weeks that were fed standard chow. 
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Table 2. Adenoma number in ApcMin mice (age, 6, 8, 10 and 12 weeks) fed standard chow 
Mean number 
of adenomas 
(range) ± SD 
Mean number 
ofadenomas 
� 2 mm 
(range) ± SD 
DISCUSSION 
& weeks 




32 {23-41) ± 9 
1.3 (1-2) ± 0.6 
10 weeks 12 weeks P value (10 vs 
12 weeks 
59.6 {�82) ± 34.8 (17-46) ± .02 
14.4 10.8 
14 (9-20) ± 5.0 14.2 {5-24) ± 7 .96 
This study shows that intestinal adenomas in ApcMin mice are metabolical ly active lesions 
that take up 18F-FDG and that abdominal 18F-FDG uptake at age 12 weeks can serve as a 
readout modality for large intestinal adenomas. 
In this study, adenomas could be visualized individually using ex vivo imaging of the 
intestines but not using in vivo imaging. Ex vivo stretching of the intestines minimizes 
fusion and overlay of hot spots due to close proximity of adenomas, thus al lowing 
visualization. In addition, less weakening and diversion occur in ex vivo imaging. 
Interestingly, when calculating the abdominal in vivo 18F-FDG uptake, the sum of the 
uptake of 18F-FDG in large adenomas detected adenoma-specific signals over background 
level. Therefore 18F-FDG PET seems especial ly suitable for fol low-up studies in mice older 
than 8 weeks because a sufficient number of large adenomas is present after this age. 
We observed a relationship between in vivo abdominal uptake and the number of large 
intestinal adenomas but not the total number of adenomas. This relationship may be 
first due to the fact that smaller aberrations are hard to detect in vivo because of partial­
volume effects with a reconstructed scanner resolution of 1.5 mm, leading to decreased 
contrast and localization. Secondly, the degree of dysplasia may influence the detection. 
There are indications that the degree of dysplasia does indeed increase with the age of 
ApcMin mice.24•25 The finding that the ex vivo intestinal 18F-FDG uptake increased at age 12 
weeks, compared with age 9 weeks, whereas the number of (both total and large) 
adenomas did not, strengthens the hypothesis that more advanced dysplastic lesions 
were well detected by the small-animal PET scanner at age 12 weeks. Possibly, adenoma 
numbers did not increase after age 9-10 weeks because angiogenesis could not keep up 
with the fast-growing adenomas as a result of the chaotic microvasculature observed in 
12 weeks old ApcMin mice26, leading to insufficient blood supply and stabilization or even 
regression of adenomas. 
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The relatively high background 18F-FDG uptake in the colon, compared with the normal 
small intestine, could reflect differences in physiological uptake between these 2 parts of 
the intestine in mice. 18F-FDG uptake in the colon of humans has been related to smooth 
muscle activity and constipation.27 In addition, the increased colonic uptake could reflect 
a relatively high metabolic state caused by the Ape mutation. In morphological ly normal 
colonic crypts of FAP patients with a proven APC germline mutation, aberrant expression 
of proteins involved in, for example, transcription and mitosis was found.28 Thus, 18F-FDG 
PET, compared with microscopic examination, could be even more sensitive because it 
provides information about glucose metabol ism of the mouse intestine as a whole. 
18F-FDG PET to detect colorectal adenomas in humans has yielded variable results. When 
18F-FDG PET is compared with colonoscopy in patients with a suspected adenoma, 
colonoscopy was more sensitive than 18F-FDG PET. The sensitivity of 18F-FDG PET 
depended on the size of adenomas. Adenomas smal ler than 0.5 cm were detected in 0-
33% of cases, whereas adenomas larger than 1 cm were detected in 59-100% of 
cases.8'1 1'12'17'18 The degree of dysplasia also strongly influenced the detection capability 
of 18F-FDG PET. Low-grade dysplastic adenomas were visualized in 13-33% of cases, 
whereas high-grade adenomas were detected in 67-76% of cases.11'18 In addition, one 
study reported that protruded adenomas were more easily detected than flat ones.19 In 
several studies, 18F-FDG PET scans were retrospectively reviewed for abnormal colonic 
foci. If scan results were positive, a dysplastic adenoma was found in 32-70 % of cases by 
subsequent diagnostic colonoscopy, indicating that abnormal colonic hot spots at the 18F­
FDG PET scan frequently reflect adenomas.10•15'16 In rats, only two small studies have 
been performed assessing the role of 18F-FDG PET in adenoma detection. In one study in 
4 rats with a total of 2 adenomas (7 and 9 mm), both lesions were found with 18F-FDG 
PET, although one of these lesions was found retrospectively.29 In a second study, the 
tumor-to-background ratio for 2 adenomas (< 2 mm) in 19 rats was < 1.0, indicating no 
higher tracer uptake in adenomas.30 Those experiments were, however, not conducted 
using an animal scanner, which might have strongly negatively influenced the results 
because of a suboptimal resolution of the human scan system when used for small 
animals. 
Besides 18F-FDG PET, other imaging techniques could improve the visualization of 
colorectal adenomas in ApcMin mice. CT isocontour analysis of 18F-FDG PET was shown to 
be a sensitive method to identify preclinical, mild and severe inflammation in models of 
immune colitis in mice and could also detect treatment-induced alterations in 
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inflammation.31 Micro-CT, compared with small-animal PET, provides a higher spatial 
resolution (0.3 mm). Combining micro-CT and small -animal PET might optimize 
visualization of colorectal adenomas. In addition, the precise effect of chemoprevention 
in a mouse model could be monitored via imaging of radiolabeled antibodies to a specific 
adenoma target - preferably already present in early stage colorectal carcinogenesis, for 
example COX-2, cyclin D1 or �-catenin. 
CONCLUSION 
Our study demonstrates the glucose metabolic activity of intestinal adenomas in ApcMin 
mice. Molecular imaging using 18F-FDG PET is suitable for visualizing the presence of 
adenomas in ApcMin mice because abdominal 18F-FDG uptake accurately reflects the 
number of large (� 2 mm) adenomas in the mouse intestine. 
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ABSTRACT 
Background: Agents targeting the TNF-Related Apoptosis Inducing Ligand (TRAIL) receptor 
are well tolerated in humans. We demonstrated that the NSAID sulindac enhances TRAIL­
induced apoptosis in vitro and ex vivo in human colorectal adenoma models. Therefore, this 
combination is of interest for chemoprevention of colorectal cancer. The aim of this study 
was to investigate in ApcMin mice a) the dose-response effect for sulindac and b) the 
tolerability of the species-specific agonistic mouse-TRAIL receptor antibody MD5-1. 
Methods: Sulindac was administered to ApcMin mice daily during a long period (7 weeks, 75 
and 150 ppm in food) or a short period (6 days, 0.3 and 0.6 mg/day via gavage) after which 
adenoma numbers and size were determined. ApcMin mice and wild type C57BL/6J mice 
were treated intraperitoneally with a low dose of 50 µg MD5-l, every 4 days. Mice were 
sacrificed after 7 weeks of treatment or earlier in case of > 15% weight loss or severe clinical 
symptoms. After death, macroscopic and histological examination was performed and serum 
liver enzymes were determined. 
Results: Sulindac treatment resulted in a dose-dependent decrease in the total number of 
adenomas (long period) and number of large (2: 2 mm) adenomas (long and short period). 
Already after 4 injections of MD5-l, ApcMin mice had to be sacrificed due to weight loss, 
behavioral changes and jaundice. Elevated serum liver enzymes were found. Tissue analyses 
showed l iver necrosis and disappearance of mouse-TRAIL death receptor positive cel ls of the 
bile ducts. Similar findings were observed in wild type C57BL/6J mice, indicating that the side 
effects are independent of an Ape gene mutation. 
Conclusion: Sulindac treatment for 6 days or 7 weeks effectively reduces the adenoma 
burden in ApcMin mice. Due to liver toxicity, low-dose MD5-1 is unsuitable for use in ApcMin 
mice nor in C57BL/6J wild type mice. 
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The development of colorectal cancer {CRC) is a relatively slow process, rendering this tumor 
type especial ly suitable for chemoprevention1. Chemoprevention involves the use of agents 
to prevent, delay or reverse the development of cancer. Different Non-Steroidal Anti­
Inflammatory Drugs {NSAIDs) demonstrated effects on adenoma formation and CRC 
prevention in both sporadic and hereditary contexts. 2-5 The effects reported are however 
incomplete, meaning that a proportion of individuals still develops cancer despite NSAID 
treatment. In a previous study we reported enhanced apoptosis induction by the 
combination of the NSAID sulindac and TNF-Related Apoptosis Inducing Ligand {TRAIL) in 
human adenoma cell lines and ex vivo cultured human adenoma samples.6 The death ligand 
TRAIL triggers apoptosis after binding to its proapoptotic death receptors DR4 and DRS on 
the cell membrane.7 It specifical ly targets dysplastic cel l s  without harming normal cells, 
which is an interesting property for use in a chemopreventive setting. In addition, 
recombinant human (rh)TRAIL and agonistic TRAIL receptor antibodies are non-toxic in 
humans.8 In colon cancer cells, NSAID-induced sensitization to rhTRAIL was dependent on T­
Cell Factor-4 transcriptional activity, indicating that this combination works specifical ly in 
cel ls with active Wnt signaling.6 For these reasons, it is of interest to explore the 
combination of sulindac and TRAIL receptor targeting for chemoprevention of colorectal 
cancer in vivo. 
The ApcMin model is the most frequently used mouse model to study colorectal 
carcinogenesis and evaluate effects of chemopreventive approaches. ApcMin mice develop 
multiple intestinal adenomas due to a truncating mutation in the murine Ape gene leading to 
Wnt pathway activation.9 Treatment with sulindac decreased the adenoma burden in ApcMin 
mice in several studies.10•11 Unlike humans, mice express only one death receptor for 
TRAIL.12 This receptor can be targeted using MDS-1, a mouse-TRAIL death receptor specific 
agonistic antibody.13 MDS-1 has the advantages of being species-specific and having a longer 
serum half-life compared to recombinant soluble TRAIL. For antibodies serum half-life is in 
the range of days, while for rhTRAIL serum half-life is 10 minutes in mice.14 MDS-1 was well 
tolerated in mice except for the C57BL/6J mouse strain.15 This mouse strain highly expresses 
the TRAIL death receptor on the cholangiocytes of the bile ducts. This is likely responsible for 
the observed cholestatic liver failure after 3 injections of 300 µg MDS-1. Since ApcMin mice 
are generated in a C57BL/6J background, toxicity may hamper the in vivo evaluation of 
TRAIL-based therapies for chemoprevention. 
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In this study we tested a) different treatment durations and concentrations of sulindac for 
their effects on the adenoma burden and b) the feasibility of low-dose MDS-1 in ApcMin mice 




Experimental protocols were approved by the Institutional Animal Care Committee. 5 weeks 
old and 8 weeks old heterozygous male C57BL/6J-ApcMin /J (ApcMin) mice and 5 weeks old 
male C57BL/6J wild type mice were obtained from Jackson Laboratories (Bar Harbor, ME, 
USA). Animals were housed in a temperature controlled room with a 12 hours l ight-dark 
cycle and ad libitum food and water. 
Treatment 
For long-term sulindac treatment, 6 weeks old C57BL/6J-ApcMin/J mice received sulindac 
{Sigma, St. Louis, MO, USA) administered in AIN-93G diet (Dyets, Inc, Bethlehem, PA, USA) at 
concentrations of 75 and 150 ppm for 7 weeks. Weight was assessed weekly. For short-term 
sulindac treatment, 12 weeks old C57BL/6J-ApcMin/J mice were treated with 0.3 or 0.6 mg 
sulindac in 200 ml Phosphate-Buffered Saline (PBS) daily via oral gavage for 6 days. Weight 
was assessed daily. Mice were sacrificed at the end of the treatment scheme. 
6 weeks old C57BL/6J-ApcMin /J and C57BL/6J mice were treated every 4 days with 50 µg of 
the agonistic hamster-anti-mouse-TRAIL receptor antibody MDS-1 (kindly provided by H. 
Yagita, Tokyo, Japan) administered as intraperitoneal injections. A dose of 50 µg was chosen 
since this was the lowest dose reported to have in vivo anti-tumor activity.16'17 Weight was 
assessed twice a week. Mice were sacrificed after completion of a 7 weeks treatment period 
or earlier in case of a > 15% decrease in weight or severe clinical symptoms (signs of 
dehydration, arched back, decreased reflexes, piloerection or biting). 
Histological tissue examination and immunohistochemistry 
Mice were sacrificed by cervical dislocation under isoflurane anesthesia. The entire intestine 
from the pylorus to the rectum was removed and placed in ice-cold PBS, pH 7.0. The 
intestine was divided in four segments of around 4 cm: proximal small intestine (duodenum), 
middle small intestine 0ejunum), distal small intestine (ileum) and colon. Segments were 
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surface facing upwards with small pins on a paraffin layer in PBS. Intestinal segments were 
examined under a dissecting microscope (Wild Heerbrugg, Gais, Switzerland) to record 
adenoma number, location and diameter. 
Livers and Swiss-rol led intestines were paraffin-embedded. Histological analysis was 
performed with hematoxylin and eosin staining. lmmunohistochemical analysis of tissues 
was executed using rat-anti-mouse-DRS (sc-73913, dilution 1:50, Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) and mouse-anti-�-catenin (610154, dilution 1:100, Becton Dickinson, 
Breda, the Netherlands). 
Serum determinations 
Directly after sacrificing, blood was collected via cardiac punction. Serum levels of ALP, AST, 
ALT, total bilirubin and direct bilirubin were measured using a Hitachi Modular automatic 
analyzer and compared to strain- and age-matched reference values.18 
RESULTS 
Sulindac efficiently decreases adenoma burden in ApcMin mice. 
In order to define a concentration causing a partial adenoma response to be able to 
demonstrate effect of sulindac in combination with an agent targeting the TRAIL receptor, 
ApcMin mice were treated with 75 ppm (n = 5) and 150 ppm (n = 5) sulindac in the food 
during 7 weeks. This resulted in a reduction in the total number of adenomas by 27% and 
71% as well as in the number of large (� 2 mm) adenomas by 76% and 90%, respectively 
(Figure lA). Sulindac treatment for 7 weeks using the highest concentration did not alter the 
mouse-TRAIL death receptor expression in normal or dysplastic intestinal epithelium {Figure 
lB). 
In order to investigate whether the adenoma burden already decreased after short-term 
treatment, ApcMin mice were treated with sulindac 0.3 mg/day/mouse (comparable with 100 
ppm sulindac administered in food, n = 3) and 0.6 mg/day/mouse (comparable with 200 ppm 
sulindac administered in food, n = 3) via gavage for 6 successive days; treatment resulted in 
a dose-dependent decrease in the number of large adenomas by 58% and 73%, respectively, 
but not in the total number of adenomas (Figure lC). 
No weight loss or cl inical changes were observed during sulindac treatment in either 
scheme. 
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Figure 1. (A) Total number of adenomas and number of adenomas � 2 mm in ApcMin mice treated with sulindac during 7 
weeks (mean ± SD, n = 5 per group) (B) Mouse-TRAIL death receptor expression in normal and dysplastic intestinal tissue 
from untreated and sulindac {150 ppm) treated ApcMin mice. (C) Total number of adenomas and number of adenomas � 2 
mm in ApcMin mice treated with sulindac during 6 days (mean ± SD, n = 3 per group). 
Intestinal adenomas in ApcMin mice show increased expression of 13-catenin and the 
mouse-TRAIL death receptor. 
lmmunohistochemical analysis on intestinal tissue from untreated ApcMin mice revealed 
cytoplasmic and nuclear expression of �-catenin in adenomas compared to membranous 
staining in the surrounding intestinal tissue (Figure 2A). This finding reflects activation of the 
Wnt pathway in these early lesions. In addition, expression of the mouse-TRAIL death 
receptor, the target for TRAIL-based therapy, was increased in intestinal adenomas 
compared to the surrounding intestinal tissue (Figure 2B). 
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Normal epithelium 
Figure 2. lmmunohistochemistry for (A) P-catenin and (B) the mouse-TRAIL death receptor in intestinal adenomas and 
surrounding intestinal tissue from an untreated Apc
Mln mouse. 
A low dose of the TRAIL receptor antibody MDS-1 causes toxicity in ApcMln mice. 
By using a six times lower dose of MD5-1 and less frequent administration {every 4 instead 
of 3 days) compared to the scheme reported to cause liver toxicity in wild type C57BL/6J 
mice15 , we anticipated to create a window in which adenomas could be effectively targeted 
while cholangiocytes would not be significantly harmed in ApcMin mice. Although a 7 weeks 
treatment period was planned, al l mice {n = 3) already had to be sacrificed 4 days after the 
fourth injection of 50 µg MD5-l, due to > 15% weight loss, behavioral changes and jaundice 
{Figure 3A). Serum levels of ALP, AST, ALT, total bilirubin and direct bilirubin were increased 
in MD5-1 treated mice {Figure 3B), reflecting severe cholestatic l iver failure. 
Histologic examination indeed demonstrated severe liver necrosis {Figure 3C). ApcMin mice 
expressed the mouse-TRAIL death receptor on the cholangiocytes in the l iver. After MD5-1 
treatment, mouse-TRAIL death receptor positive cel ls were lost in many bile ducts {Figure 
3D). We next examined the toxicity in C57BL/6J wild type mice to investigate if the ApcMin 
phenotype is enhancing toxicity. Therefore, wild type C57BL/6J mice {n = 4) were treated 
with the same regimen of 4 injections of 50 µg MD5-1 every 4 days. We observed jaundice in 
2 out of 4 mice, and l iver necrosis in 3 out of 4 mice, indicating that liver toxicity using this 
regimen also occurs in mice with intact Ape alleles. 
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Figure 3 .  Toxicity after 4 injections of 50 µg MDS·l in ApcMin mice. (A) Jaundice. (B)  H&E staining demonstrating liver 
necrosis. (C) Increased values of liver enzymes compared to age• and strain·matched reference values (mean ± SD, n = 3). 
AFP, AST, ALT: U/L. T·Bil, D·Bil : µmol/L. (D) Disappearance of mouse·TRAIL death receptor positive cholangiocytes of the 
bile ducts. Untreated mouse ( left) and treated mouse (right). 
DISCUSSION 
Short- and long-term sulindac treatment significantly reduced the adenoma burden in ApcMin 
mice. Treatment with sulindac was well tolerated. Treatment with the mouse-TRAIL receptor 
agonistic antibody MDS-1 induced severe liver toxicity already after 4 doses of 50 µg in 
ApcMin mice as well as C57BL/6J wild type mice. This shows that even low doses of MDS-1 
are sufficient to induce liver toxicity in the C57BL/6J mouse strain, possibly due to death 
receptor-mediated apoptosis of cholangiocytes. The presence of an Ape mutation was not 
conditional for this effect. 
Sulindac in the food during 7 weeks resulted in a reduction in the number and size of 
adenomas in ApcMin mice in a dose-dependent manner in line with previous studies. 10•11 
Sulindac via gavage during 6 days resulted in a reduction of the mean adenoma size. 
Previously, it was demonstrated that exactly the same regimen of sulindac administration in 
the same mouse model, resulted in an 81% overall reduction of adenomas. The size of 
adenomas, however, was not taken into account.19 We saw no reduction in the total number 
of adenomas. This can be the consequence of differences in the definition of adenomas or in 
the sulindac solution used for gavage, which may have affected intestinal uptake. In 
preclinical chemoprevention studies, sulindac is mostly administered in the food during 
several weeks. A few studies investigated the effects of short-term sulindac treatment either 
via gavage or in the food. A 67-81% reduction in adenoma numbers was observed already 
after 4-7 days treatment.19·21 It has even been suggested that the early induction of 
apoptosis, in the first days after administration, may be responsible for effective 
chemoprevention. 21 This suggests that a short period of sulindac treatment may be 
preferred in combination studies in order to adequately investigate mechanisms of 
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response. This and the observation that short-term treatment was effective and left room to 
improve the response by a second agent, forms the rationale for our next study. We will 
administer sulindac for a short period (200 ppm in food) in a study combining sulindac and 
TRAIL receptor targeting. 
Targeting of the mouse-TRAIL death receptor by MDS-1 effectively reduced the tumor load 
in mouse tumors when combined with various targeted agents.16'17'22-24 The toxicity 
observed in the C57BL/6J mouse strain, however, warrants a different approach in this 
strain. The death domain of the mouse-TRAIL receptor shows high homology with both the 
human TRAIL receptors DR4 (76%) and DRS (79%).12 Apart from murine TRAIL, also human 
TRAIL can bind to the mouse-TRAIL receptor.25 Recently, recombinant soluble human TRAIL 
was tested in ApcMin mice in combination with retinoid acid (RAc).26 The combination 
effectively reduced the adenoma burden, while these drugs as single agents did not. High 
levels of apoptosis were observed due to RAc-mediated upregulation of the TRAIL death 
receptors and downregulation of decoy receptors. This was measured at the protein and 
mRNA level in APC-knockdown normal colon cell l ines. This study clearly demonstrated the 
usefulness of combination therapy for chemoprevention. In contrast to MDS-1, human TRAIL 
did not induce side effects after repeated gifts.26 This may be due to the fact that TRAIL 
decoy receptors, two of which are present in mice27, protect cholangiocytes from TRAIL­
induced apoptosis. A difference in half-life and the route of drug clearance between MDS-1 
and rhTRAIL may also be related to the liver toxicity observed only fol lowing MDS-1.28 The 
authors moreover showed that short-term treatment with RAc and rhTRAIL (6 days, 4 TRAIL 
gifts) was as effective as long-term treatment with similar concentrations (6 weeks, 30 TRAIL 
gifts).26 
Previously, we showed enhanced apoptosis induction by the combination of rhTRAIL and 
sulindac in in vitro and ex vivo adenoma models.6 We and others demonstrated the 
effectiveness of short administration of sulindac in ApcMin mice while effective rhTRAIL doses 
can be safely administered to ApcMin mice. We are initiating a study with four treatment 
arms based on these encouraging in vitro and in vivo results. In this study ApcMin mice are to 
be treated with vehicle, sulindac (200 ppm in food), soluble rhTRAIL (10 mg/kg) or the 
combination of sulindac and rhTRAIL for 6 successive days in order to investigate the 
chemopreventive potential of this combination. 
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ABSTRACT 
Background: Comparing normal colorectal mucosa and adenomas focusing on 
deregulated pathways obtains insight into the biological processes of early colorectal 
carcinogenesis. 
Methods & results: Publicly available microarray expression data from 26 normal 
mucosa and 47 adenoma samples were analyzed. Biological pathways enriched in 
adenomas were identified with Gene Set Enrichment Analysis (GSEA). The analysis 
revealed 10, 11 and 16 gene sets distinguishing adenomas from normal mucosa 
according to Kyoto Encyclopedia of Genes and Genomes (KEGG), Gene Map Annotator 
and Pathway Profiler (GenMAPP) and Biocarta data bases, respectively. Biological 
pathways known to be involved in colon carcinogenesis such as cell cycle (P = .002) and 
Wnt signaling (P = .007) were enriched in adenomas. In addition, we found enrichment of 
novel pathways such as the Rb pathway (P = .002), Src pathway (P = .004), folate 
biosynthesis (P = .019), and Hedgehog signaling (P = .037) in adenomas. Microarray 
results for Rb and Src pathway genes were validated by qRT-PCR on mRNA isolated from 
an independent set of adenoma and normal colon samples. A high correlation between 
microarray data and qRT-PCR expression data was found. The relevance of targeting of 
identified pathways was demonstrated using the Rb pathway inhibitors roscovitine and 
PD-0332991 and the Src pathway inhibitor dasatinib. All inhibitors used induced cell 
growth reduction in adenoma cells. 
Conclusion: This study shows a bioinformatical and functional approach leading to 
potential new options for chemoprevention of colorectal cancer. 
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The development of colorectal cancer is a multistep process, often referred to as the 
adenoma-carcinoma sequence.1 In general, it takes 10-15 years to progress from normal 
colorectal epithelium, via the stage of an adenoma, to colorectal cancer. This time span 
provides a window of opportunity for chemoprevention, especial ly in high-risk patients 
with a history of an adenoma or cancer. In addition, chemoprevention is considered 
important for patients with Familial Adenomatous Polyposis (FAP) or Lynch syndrome, 
disorders that strongly predispose to the development of colorectal cancer.2 The urgent 
need for more effective chemoprevention warrants research on the biological 
background of colorectal adenoma formation in order to reveal possible targets. 
The development of the microarray technique has made it possible to perform whole 
genome expression profiling of different disease states. 3 Despite the high incidence of 
colorectal adenomas, surprisingly few microarray studies have been performed 
comparing normal mucosa and adenomas.4-7 Performing analysis on premalignant 
phenotypes is of special interest since these lesions represent a relatively homogeneous 
condition, providing information about the initial changes during colorectal 
carcinogenesis and about putative targets for chemoprevention. Integrating publicly 
available data of small studies profiling normal and adenoma tissue into one analysis wil l 
increase the power to detect biological relevant signals specific for adenoma formation. 
In the conventional method of analyzing microarray data, only the top few individual 
genes that are highly differential ly expressed between two phenotypes are reviewed.3 
Although such individual genes may prove to be relevant for adenoma formation, it is 
increasingly doubted whether large fold changes in individual genes will have more 
biological relevance than smal ler but coordinated fold changes in a set of genes encoding 
proteins lying along a single pathway.8 As in biological processes genes often cooperate 
in so-cal led biological pathways, analyzing microarray data at the level of pathways might 
provide us with more insight into biological mechanisms associated with the 
development of adenomas.9 In addition, integrating genes into functional sets enables us 
to consider al l genomic information available from a microarray platform rather than 
focusing on individual genes passing a certain significance threshold.8•10•11 Therefore the 
aim of this study was: 1) to analyze differences in pathway enrichment between normal 
mucosa and adenomas in a combined set of publicly available microarray expression 
data, 2) to validate these results in a newly generated data set of human normal colonic 
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epithelium and adenoma samples, and 3) to examine the functional relevance of 
targeting enriched pathways in adenoma cell l ines. 
METHODS 
Data acquisition 
We obtained microarray expression data from normal colorectal mucosa and adenomas 
from the Gene Expression Omnibus {GEO).12 Data sets were included if they met al l 
following criteria: 1) samples were hybridized to HG-U133 plus 2.0 {Affymetrix, Santa 
Clara, CA, USA), one of the most widely appl ied platforms providing a comprehensive 
coverage of the human genome. This array analyzes the expression level of over 47,000 
transcripts and variants, including 38,500 well -characterized human genes. 2) Raw data 
was available as an Affymetrix intensity file {CEL file) enabling us to pre-process the data 
in a uniform manner, and 3) normal mucosa samples were derived from healthy controls. 
Normal appearing mucosa from patients with an adenoma, cancer or inflammatory 
bowel disease was excluded since these entities can be accompanied by altered cellular 
properties of normal appearing epithelium.13 
Pre-processing and aggregation of CEL files was performed with Affymetrix Expression 
Console software. Expression summary was done using the Robust Multi-array Average 
{RMA) algorithm. For final inclusion, the data sets had to pass our quality control as 
described in the fol lowing section. 
Quality control and standardization 
Quality control was performed using Principal Component Analysis {PCA) on the sample 
correlation matrix. The PCA method condenses a multi-dimensional data set into a set of 
lower dimensions, in order to reveal the simplified l inear structure of the data that often 
underl ies them.14 Principal Components {PCs) are able to summarize expression 
information and are constructed in such a way that PCl explains the largest amount of 
variance in expression and each subsequent PC explains the largest amount of the 
remaining variance in expression while remaining uncorrelated with previous PCs. The 
most significant PC for a gene expression data matrix is frequently a constant pattern, 
which dominates the data.15 This pattern can be regarded as probe-specific variance, 
independent of biological samples hybridized to the array. The first PC can be used as a 
quality control and is named here PCqc.15'16 PCqc explaining the largest part of the 
variation, could be considered as variation that the arrays have in common.16•17 We 
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calculated correlations with PCqc (factor loadings) for each individual array. Factor 
loadings of PCqc can be seen as a quality index, as arrays of lesser quality would have 
lower or distinctly different correlations than arrays of good quality. By subtracting this 
common variation from the expression data, al l the gene-specific variation that does not 
contribute to differences between arrays was eliminated (i.e. the expression data were 
standardized by subtracting the first factor). 
Minimizing multiple study expression artifacts 
In our analysis we expected to find an expression effect due to the fact that samples 
were collected from multiple research groups, introducing systematic variation between 
the different data sets. By applying PCA on the standardized expression data, we aimed 
to identify the PC that could explain this systematic variation between the different data 
sets. For subsequent analysis, the variance explained by this PC was subtracted from all 
data to minimize this systematic variation between the data sets.16'18 
Cluster analysis 
Cluster analysis of samples was performed on the standardized and normalized data with 
average linkage hierarchical clustering according to the Euclidean distance measure 
(square root of the sum of the squared differences in each dimension) by using the 
Cluster 3.0 software.19 
Gene Set Enrichment Analysis (GSEA) 
GSEA was performed with GSEA 2.0 (Broad Institute, Cambridge, MA, USA).10•20 This 
method ranks genes according to their relative difference in expression (Student's t­
statistic) between two phenotypes (normal colorectal mucosa vs. adenomas). GSEA 
compares this l ist of ranked genes against a large collection of pathway data (gene sets) 
to determine if there is enrichment of one of these functional groupings. The list of 
ranked genes is processed from top to bottom. Whenever a gene belonging to the gene 
set of interest is found, a running enrichment score is increased by a certain amount 
according to the rank, otherwise the enrichment score is decreased. The Enrichment 
Statistic (ES) is the maximum deviation of the running enrichment score from zero. GSEA 
then reiteratively randomizes the sample labels a 1,000 times and retests for enrichment 
across the random classes. The gene sets that significantly outperform iterative random­
class permutations are considered significant. A significance threshold was set at a 
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nominal P value of .05 and a False Discovery Rate (FDR) of 0.30. FDR is the estimated 
probability that a gene set with a given ES represents a false-positive finding. A gene set 
with an FDR < 0.30 indicates that the result is likely to be valid 7 out of 10 times. These 
gene sets are considered most likely to generate interesting hypotheses and drive further 
research.10 In our analysis we assembled gene sets from well -accepted and widely used 
curated pathway data bases. A total of 169 functional gene sets as reported in the Kyoto 
Encyclopedia of Genes and Genomes data base (KEGG), 109 from the Gene Map 
Annotator and Pathway Profiler (GenMAPP), and 187 as reported in the Biocarta data 
base (http://www.biocarta.com/) were analyzed.21•22 
Patient material 
In order to validate our results generated on the integrated publicly available data, we 
obtained adenoma tissue from both low-grade dysplastic and high-grade dysplastic 
adenomas (n = 16) and normal colonic epithelium (n = 8) from individuals undergoing 
colonoscopy at the University Medical Center Groningen. Normal mucosa was obtained 
from individuals without a history of colorectal adenomas or cancer in which no 
aberrations were found at colonoscopy. The study protocol was approved by the medical 
ethical review committee of the University Medical Center Groningen. Al l patients gave 
written informed consent. Histological classification of adenomas was carried out on 
hematoxylin-eosin (H&E) stained slides by a pathologist. Samples were frozen in Tissue 
Teck and stored at -80 °C until analysis. 
Real-time qRT-PCR 
RNA was isolated from patient material by guanidinium thiocyanate-phenol-chloroform 
extraction23 after purification of the tissue by using a Micro-Dismembrator U (B.Braun 
Biotech International, Melsungen, Germany). After DNAse treatment (RNAse free DNAse, 
Amgen, Thousand Oaks, CA, USA) 1 µg of total RNA was reverse-transcribed using 
random primers (lnvitrogen, Breda, the Netherlands). 10 ng of cDNA was subjected to 
real-time quantitative PCR on an ABI PRISM® 7900 HT Sequence Detection System 
(Applied Biosystems, Milan, Italy) using Taqman Universal PCR Mastermix and Assays-on­
Demand (Applied Biosystems) specific for Rb pathway genes, Src pathway genes and 
ABCG2 following the manufacturer's instructions to detect corresponding mRNAs. The 
following assays were used: Rbl (Hs01078060_m1), CDK2 (Hs00608082_m1), CDC2 
(Hs00364293_m1), TP53 (Hs00153349_m1), CDK4 (Hs00364847 _ml), eye/in D1 
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{Hs00277039_ml), eye/in Bl {Hs00259126_ml), Src {Hs00178494_ml) and ABCG2 
{Hs00184979_ml). 185 rRNA was used as the reference gene for sample normalization 
and was amplified in separate wells within the same plate {Hs99999901_sl).4 All 
determinations were performed in triplicate. For data analysis SDS 2.3 software was 
used. Gene expression results were calculated using the delta Ct method. Student's t-test 
was performed to compare the expression between normal tissue and adenoma tissue. 
Cell lines, drug treatment and quantification of apoptosis 
Two human colon adenoma cell l ines, VACO-235 and VACO-330 {a kind gift from J.K. 
Wilson, Ireland Cancer Center, Cleveland, OH, USA), derived respectively  from a villous 
and tubular adenoma, were used. VACO cel ls were cultured on rat tail collagen coated 
plates as described previously.24 Human bronchial epithelial cell line 16HBE and human 
lung fibroblasts IMR90 served to detect possible toxicity in normal cells. Cel ls were 
treated with increasing concentrations {0-100 µM) of the Cyclin-Dependent Kinase {CDK) 
inhibitor roscovitine {LC Laboratories, Woburn, MA, USA) for 24 hours, with increasing 
concentrations {0-10 µM) of the specific CDK4/6 inhibitor PD-0332991 {a generous gift 
from Pfizer, Groton, CT, USA) for 5 days and with increasing concentrations {0-1000 nM) 
of the tyrosine kinase inhibitor dasatinib {LC Laboratories) for 48 hours. Cell growth was 
investigated by 3-{4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide {MTT) 
assays. Apoptosis was quantified using M30 immunoreactivity (primary antibody: Cell 
Signaling Technology, Leusden, the Netherlands) on cytospins {adenoma cells) or by 
staining nuclear chromatin with acridine orange {10 µg/ml) and identifying appearance of 
apoptotic bodies and/or chromatin condensation by fluorescence microscopy {normal 
cells). 
Western blot analysis 
Preparation of protein lysates and Western blotting was carried out as described 
previously.25 The following primary antibodies were used: rabbit-anti-PARP {Boehringer, 
Mannheim, Germany), mouse-anti-phospho Rb {sc-102), rabbit-anti-cyclin D1 {sc-718), 
goat-anti-CDK2 {sc-F1404), mouse-anti-p53 {sc-126) {all from Santa Cruz Biotechnology, 
Santa Cruz, CA, USA), mouse-anti-p21 {Merck, Darmstadt, Germany), rabbit-anti-cleaved 
caspase-3 {#9661), rabbit-anti-Src {#2109) and rabbit-anti-phospho Src family {Tyr416) 
{#2101) {all from Cell Signaling Technology, Beverly, MA, USA). �-actin {ICN Biomedicals, 
Zoetermeer, the Netherlands) expression levels served as loading control. 
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RESULTS 
Data acquisition, quality control and standardization 
Table 1 shows the data sets obtained from GEO that were initially included in the study. 
Quality control was performed with PCA. Figure 1 shows that the correlations (factor 
loadings) between the arrays and the first PC named PCqc were highly similar. However, 
the study with GSE accession number GSE9254 contains samples with distinctly lower 
correlations with the PCqc, indicating that this data set is of lower quality. We therefore 
excluded samples belonging to this data set from further analysis. 
We reanalyzed the data with PCA after al l arrays from GSE9254 had been excluded from 
the combined data set. The PCqc explained 94.8% of the total variance in expression. All 
arrays now showed highly similar correlations (factor loadings) with the PCqc (mean 
factor loading 0.97, range 0.93-0.99). Subsequently, we standardized our data by 
subtracting the variance explained by the PCqc as this represents probe-specific variation 
that does not contribute to differences between arrays. 
Table 1. In itial data sets included 






Profiling performed by 
Hong et al, 200760 Normal colon (n = 10) 
€arey et al, 200861 Normal colon (n = 8) 
LaPointe et al, 200862 Normal colon (n = 19) 
Galamb et al, 2008 Normal colon (n = 8) 
Adenoma {n =- 15..,.) _ __ ....., 
Sabates-Bellver et al, 20075 Adenoma (n = 32) 
Note: GSE accession numbers can be used to query the data set in the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) 
� 0 5  













Figure 1. Factor loadings of each individual array with the PCqc (from Principal Component Analysis). Factor loadings 
are highly similar, indicating comparable array quality. Arrays from GSE9254 were excluded from the final analysis 
because of their lower factor loadings with the PCqc. 
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Minimizing multiple study expression artifacts 
Performing PCA on the standardized data revealed two dominant PCs which explained a 
large amount of the total variance in expression in our standardized data set. PCl and 
PC2 explained 26.8% and 14.5%, respectively, of the total variance in expression {Figure 
2C). We expected that the variance in expression explained by the first two PCs would be 
driven primarily by tissue type {normal colorectal mucosa vs adenoma) and multiple 
study selection. Figures 2A and 2B show a scatter plot of the correlations {factor 
loadings) of individual arrays with PCl and PC2. In Figure 2A samples are labeled 
according to their tissue type and in Figure 2B according to study origin {GSE accession 
number). Figure 2A shows that there is a clear separation in factor loadings with PCl 
between normal colorectal mucosa and adenoma but no such clear separation in factor 
loadings with PC2. This indicates that PCl captures variance in expression that can be 
attributed to differences in tissue type. Figure 2B il lustrates that samples belonging to 
GSE4183 have highly similar factor loadings with PC2. Because GSE4183 contains both 
normal colorectal mucosa and adenoma samples the variance explained by PC2 cannot 
be attributed to tissue differences. Therefore we concluded that PC2 captures variance in 
expression caused by multiple study selection. To minimize the expression artifact 
caused by multiple study selection we subtracted the variance explained by PC2 from our 
standardized data. 
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Figure Z. (A) Scatter plot of factor loadings of individual arrays with PCl (from principal component analysis). (B) 
Scatter plot of factor loadings of individual arrays with PC2. The combined figures A and B indicate that the first PC 
captures variance in expression due to differences in tissue type (i.e. adenoma tissue vs. normal tissue). (C) Percentage 
of variance in expression explained by each subsequent PC. 
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Cluster array 
Hierarchical clustering analysis separated normal colorectal mucosa and adenoma 
samples into two distinct groups. This il lustrates that the variation in expression is mainly 
the consequence of differences in tissue types and not of experimental artifacts 
(Supplementary Figure 1). 
Differential individual gene expression in adenomas 
We found upregulation of several genes in adenomas that are known to be involved in 
colorectal carcinogenesis such as eye/in D126, MMP727 and CD4428 but also of many more 
genes with an unknown biological relevance. A heat map of the top-100 individual genes 
either up- or downregulated in adenomas vs normal mucosa is shown in Figure 3. 
Pathway enrichment in adenomas 
GSEA using pathway definitions from KEGG revealed 10 significant gene sets specific to 
adenomas at a nominal P value < .OS and FDR < 0.30. By using the KEGG data base as 
input for GSEA, several well-known causal pathways (cell cycle, Wnt signaling), resulting 
pathways (DNA base metabolism, transcription) and compensatory pathways (p53 
pathway) involved in carcinogenesis specifical ly distinguished adenomas from normal 
mucosa. In addition, the gene set for folate metabolism was upregulated in adenomas 
(Table 2A). GSEA using pathway definitions from GenMAPP revealed 11 gene sets 
significantly enriched at a nominal P value < .OS and FDR < 0.30 (Table 2B). GSEA using 
pathway definitions from Biocarta revealed 15 gene sets significantly upregulated in 
adenomas at a nominal P value < .05 and FDR < 0.30. The Rb pathway showed the 
highest Normalized Enrichment Score (NES) and P values (Table 2C). 
Using the KEGG, GenMAPP and Biocarta data bases, the pathways identified to 
distinguish adenomas from normal mucosa were often comparable, despite the 
differences in definitions of gene sets. These three well-accepted and widely used data 
bases not only differ in their pathway definitions, but also offer different analyzable gene 
sets. For example, the newly discovered Rb, Src and PTCl (Hedgehog) pathways enriched 
in adenomas are not present, as such, in the KEGG and GenMAPP data bases, while they 
were highly significantly upregulated in adenomas according to the Biocarta data base. 
Enrichment plots for Rb pathway, cell cycle and p53 pathway are shown in Figure 4. 
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Figure 3. Heat map of the top 100 individual genes up- or downregulated in adenomas compared to normal colorectal 
mucosa. Red indicates upregulation and blue downregulation. 
95 
I Chapter 6 
Pathway finding in colorectal adenomas 
Rb Pathway 
, � ----""""""·-· 
i :,-----3-,., 
! .  
i�  
,... 1UII t:l'JIII -- 11..- -­
ftn:lflo,,,ttdDDlft 
Cell Cycle p53 Signaling Pathway 
""-f4"-........ .  � 
, ... ....  S:.- tU,81 11..!lt --
A",M-t9 ..... 0,1b1ff 
Figure 4. Examples of GSEA enrichment plots for three biological pathways found enriched in adenomas: the Rb 
pathway, cell cycle and p53 signaling. 
Table 2A. KEGG gene sets enriched in adenomas 
Gene set 
Cell cycle 
p53 slSf!aling _P-athway 
Pyrimidine metabolism 
Basal transcription factors 








NES = Normalized Enrichment Score, NOM P value = nominal P value, FDR = False Discovery Rate 
Table 2B. GenMAPP gene sets enriched in adenomas 
Gene set NES 
Cell cycle 86 -2.07 
Gl to S cell cle reactome 68 -1.86 
RNA transcription reactome 37 -1.86 
DNA r:-eJ)lication reactome -1.79 
Pentose/phosphate pathway 23 -1.78 
Translation factors -1.78 
-1.74 
Nucleotide metabolism 12 
RNA J)otymerase 14 
Purine metabolism 114 -1.55 
NES = Normalized Enrichment Score, NOM P value = nominal P value, FDR = False Discovery Rate 
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Table 2C. Biocarta gene sets enriched in adenomas 
Gene set NES FDR 
Rb pathway 13 -1.81 0.257 
Arf thwa 16 -1.80 0.151 
22 .006 0.123 







PTCl pathway 10 -1.64 0.130 
16 -1.63 
Proteasome pathway 21 -1.55 0.202 
0.193 
26 -1.53 .039 0.206 
11 0.205 
NES = Normalized Enrichment Score, NOM P value = nominal P value, FDR = False Discovery Rate 
External validation of deregulation of the Rb and Src pathway by qRT-PCR 
In order to validate results obtained by our pathway analysis in a newly generated data 
set, we performed qRT-PCR for genes from two of the enriched pathways in the Biocarta 
data base, which are defined by relatively small gene sets. We chose the Rb pathway and 
Src pathway, because these routes were highly significantly differential ly  expressed 
between normal colonic epithelium and adenomas, while at the same time an inhibitor 
was available to test the functional relevance of these pathways. We compared 
expression of 6 different genes from the Rb pathway and 3 different genes from the Src 
pathway with qRT-PCR on mRNA isolated from an independent set of adenoma tissue (n 
= 16) and normal colonic epithelium (n = 8). For all 6 Rb pathway genes (Rbl, CDK2, 
CDC2, p53, CDK4, CCND1) and al l 3 Src pathway genes (Src, CDC2, CCNB1) mRNA 
expression was higher in adenoma tissue, in concordance with the microarray results. 
Notably, for most genes, the rank in the gene list corresponded with the relative change 
in expression as reflected by the ddCt value (Table 3 A/B). As a control for the reliability 
of the qRT-PCR experiments, the mRNA expression of ABCG2 was investigated since 
expression of this gene was most significantly downregulated in adenomas according to 
the microarray results. Indeed, in the independent set of samples there was much less 
expression of ABCG2 in adenoma tissue compared to normal colonic epithelium (ddCt 
+5,43). 
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Table 3A. RT-PCR validation results for 6 genes from the Rb pathway. 
Gene Rank in gene list"' Met"'* 
Rb1 18576 -1.85 
CDK2 19121 -1.87 
CDC2 20064 -1.87 
TP53 20245 -2.03 
CDK4 20535 -2.33 
Cy_clin D1 20583 















* Position in ranked gene list of according to differential expression between adenomas and normal tissue in the microarray data. 
Genes with a ranked position between 14568 and 20606 are upregulated in adenomas. A higher ranking indicates more significant 
differential gene expression between adenoma tissue and normal tissue in the microarray data. An increase in ranking is related to an 
increase in 66Ct. 
•• 66Ct = mean 6Ct adenoma - mean 6Ct normal colon 
Functional targeting of the Rb and Src pathway in colon adenoma cell lines 
In order to examine the functional relevance of performing pathway analysis as 
described above, we used functional inhibitors for two different pathways. The broad 
spectrum CDK inhibitor roscovitine was used to inhibit Rb pathway activation. Treatment 
of both adenoma cell lines VACO-23S and VACO-330 with roscovitine, led to a dose­
dependent induction of apoptosis (Figure SA/B/C) (growth reduction is demonstrated by 
an MTT assay in Supplementary Figure 2). Western blot analysis indeed revealed a clear 
dose-dependent reduction in expression of both total and phosphorylated Rb and cyclin 
D1. As expected, CDK2 levels were unchanged as roscovitine inhibits CDK2 activity and 
not protein expression.29 PS3, and subsequently p21, were strongly upregulated by 
roscovitine. In the highest concentration, p21 levels were reduced, likely due to caspase­
dependent cleavage (Figure SD). Normal fibroblasts and lung epithelial cel ls were not 
sensitive to roscovitine, yielding a therapeutic window for targeting this pathway {Figure 
SE). In order to examine the functional relevance of Rb pathway inhibition using a more 
specific inhibitor, VACO cells were also treated with the novel highly specific CDK4/6 
inhibitor PD-0332991. After S days of treatment significant growth reduction was 
observed along with a decrease in the level of phospho-Rb (Supplementary Figure 3). 
The tyrosine kinase inhibitor dasatinib was used to inhibit Src pathway activation. 
Treatment of VACO-23S and VACO-330 cel ls with relatively low concentrations of 
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dasatinib (S 100 nM) did not result in apoptosis (data not shown), but in dose-dependent 
growth inhibition (Figure GA). Western blot results showed a dose-dependent reduction 
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Figure S. Apoptosis induction after 24 hours treatment with the CDK inhibitor roscovitine (0-100 µM) in two colon 
adenoma cell lines, as determined by (A/B) M30 immunoreactivity and (C) Western blotting for cleaved caspase-3 and 
PARP. (D) Expression of Rb pathway proteins in two colon adenoma cell lines after treatment with increasing 
concentrations of roscovitine. (E) Apoptosis by roscovitine in normal fibroblasts ( IMR90) and normal bronchial 
epithelial cells (16HBE) as determined by acridine orange apoptosis assays. Values are the mean ± standard deviation 
of three independent experiments. 
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Figure 6. (A) Growth reduction after 48 hours treatment with increasing concentrations (0-1000 nM) of the the 
tyrosine kinase inhibitor dasatinib in two adenoma cell lines, as determined by an MTT assay. (B) Expression of Src and 
phospho-Src in two colon adenoma cell lines after treatment with increasing concentrations of dasatinib. 
DISCUSSION 
Until now, integrated analysis of available microarray data from multiple studies is not a 
common approach. However, such an approach is very interesting as combining 
expression data has the important advantage of having more power to detect biological 
relevant signals by increasing the available number of samples to be studied. To our 
knowledge, we have analyzed the largest set of microarray expression data from normal 
colorectal mucosa and adenoma samples to generate hypotheses on which biological 
pathways are implicated in early colorectal carcinogenesis. Moreover, we showed how to 
use Principal Component Analysis to screen for quality of microarray hybridization and 
how to minimize expression differences caused by multiple study selection. Finally, we 
validated expression of Rb pathway and Src pathway components that were enriched in 
adenomas with qRT-PCR, and blocked the functionality of these pathways in adenoma 
cell lines as a proof-of-concept for our pathway analysis approach. 
We identified individual significantly up- or downregulated genes in adenomas including 
several genes known to be involved in colon carcinogenesis. However, integrating all 
genomic information in a pathway analysis yielded even more interesting biological ly  
relevant information. To date, such analyses have not been performed on colorectal 
adenomas. A number of identified pathways is already known in the literature to play a 
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significant role in colon carcinogenesis, indicating the validity of our approach. However, 
we identified in addition interesting new pathways that have received l ittle attention in 
past research on adenomas of the colorectum. These pathways will provide potential 
new starting points for research on chemoprevention of colorectal cancer. 
The pathways that were specifical ly enriched in adenomas in our analysis are known to 
be activated in colorectal carcinogenesis {causal, resulting, or compensatory) such as the 
Wnt pathway3°, cell cycle routes31, DNA base metabolism, transcription, ATM-32'33, ARF-, 
p27-34 and p5335 signaling routes. In addition, we found novel pathways unique to 
adenomas among which are the Rb pathway, the Src pathway, folate biosynthesis and 
the PTCl pathway. Moreover we revealed potential ly new interesting pathways of which 
the biological relevance for colon adenomas remains to be elucidated. Although the 
importance of these routes is likely to be the case in colon carcinomas, there is not 
enough evidence to speculate about implications and targeting of these routes in 
adenomas {Table 2, for example the Skp2, the p27 and the Ets pathway).36"38 
We focused on two significantly enriched pathways in adenomas: the Rb pathway and 
the Src pathway. Rb is frequently inactivated or mutated in a wide variety of tumors 
thereby losing tumor suppressor function. In colon cancer paradoxical ly, the Rb protein is 
often overexpressed which has been related to anti-apoptotic responses and could be a 
critical step in colon carcinogenesis.39.4° In adenomas, several components of the Rb 
route show aberrant expression at protein level.41,42 Src family kinases are involved in 
many tumorigenic events including proliferation, survival, angiogenesis, adhesion, 
invasion and metastasis.43 Increased expression of Src was seen in colonic adenomas.44 
Relative differences in mRNA expression of Rb and Src pathway players between 
adenomas and normal mucosa were highly similar when comparing the microarray data 
and RT-PCR results. 
Cyclin-Dependent Kinase {CDK) inhibitors are effective agents to target the Rb pathway.45 
CDKs regulate progression of the cell cycle {mainly CDK2 and CDK4/6) and regulate 
transcription {mainly CDK7 and CDK9).46 The cell cycle regulating CDKs are part of the Rb 
pathway since they function - in complexes with cyclins - to stepwise phosphorylate Rb, 
resulting in activation of E2F-mediated transcription and cell cycle progression.47 As with 
al l second generation CDK inhibitors, the CDK inhibitor roscovitine shows preferable 
activity against one CDK {the Rb pathway component CDK2) but it also inhibits other 
CDKs {especial ly COK7 /9).48 We found that roscovitine induced changes in the expression 
of proteins involved in the Rb pathway. Several changes are likely to be the result of 
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CDK2 inhibition, including the loss of phospho-Rb and the upregulation of p53.49 
However, other observed changes in expression of Rb pathway proteins may be 
independent from CDK2 inhibition, but the result from CDK7 /9 inhibition, such as the loss 
of cyclin D1.50 In addition, CDK7 /9 inhibition can contribute to apoptosis induction by 
roscovitine and related compounds. 51 The CDK2/7 /9 inhibitor SNS-032 was shown to be 
effective for chemoprevention of intestinal tumorigenesis in lnk4a/Arf null ApcMin mice. 
The adenoma burden was reduced to 25% via lowering of the mitotic index and the 
induction of apoptosis.52 We additionally tested PD-0332991, a highly specific novel small 
molecule inhibitor of CDK4/6, the other CDKs involved in the Rb pathway. The antitumor 
effect of PD-0332991 is total ly dependent on the presence of Rb since this agent showed 
no activity against Rb-negative cel ls and RNAi depletion of Rb resulted in resistance in 
previously sensitive cell lines.53'54 Treatment of VACO adenoma cells with PD-0332991 
resulted in growth reduction together with a reduction in phospho-Rb levels. 
Importantly, a recent study demonstrated the functional importance of targeting the Rb 
pathway with this drug for colorectal cancer chemoprevention in vivo. In the ApcMin 
mouse model, treatment with PD-0332991 for 5 days resulted in a strong reduction of 
proliferation in intestinal adenomas without effects on normal intestinal enterocyte 
prol iferation. This indicates a therapeutic window as supposed by our pathway analysis 
showing enrichment of the Rb pathway in adenomas.55 The fact that CDK4/6 complexes 
and phospho-Rb levels are upregulated following APC loss (in nearly al l cases the first hit 
in colorectal carcinogenesis), highlights that activation of the Rb pathway is truly an early 
event during colorectal carcinogenesis, which makes it sensible to target this route for 
chemoprevention.55 Whether Rb pathway inhibition by second generation broad 
spectrum CDK inhibitors such as roscovitine, or more selective inhibitors such as PD-
0332991 are more suitable for colorectal chemoprevention is an interesting subject for 
future research. The simultaneous inhibition of cell cycle, activation of p53 and induction 
of apoptosis by roscovitine might be of advantage since it offers the possibility to hit 
adenoma cells via multiple ways. On the other hand, more selective compounds may 
exert less side effects, which is an important aspect of treatment in a chemopreventive 
setting. 
Src activation is blocked by the tyrosine kinase inhibitor dasatinib which dually inhibits 
Src family kinases and Bcr-Abl, with the latter not being present in adenoma cells. 
Dasatinib is well tolerated and the drug has entered the clinic for patients with 
leukemia.56 Dasatinib has shown activity against colon cancer cells in preclinical 
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models.57•58 The potential of dasatinib in adenomas has not been investigated yet. We 
demonstrate a growth reduction in colon adenoma cells at relatively low concentrations 
of dasatinib, indicating that the observed effects are Src specific.59 Our experiments are a 
proof-of-concept, showing that pathway analysis results in the identification of pathways 
related to carcinogenesis, which can finally lead to effective targeting of those pathways. 
In conclusion, we have shown a bioinformatical and functional approach leading to 
potential new therapeutic options for chemoprevention of colorectal cancer. 
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Supplementary Figure 1. Cluster diagram resulting from hierarchical clustering analysis illustrating that the largest part 
of the variation in expression is caused by d ifferences in tissue type. 














Supplementary Figure 2. Growth reduction in two colon adenoma cell l ines after 24 hours treatment with the CDK 
inhibitor roscovitine as determined by an MTT assay. 
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Supplementary Figure 3. (A) Growth reduction in two adenoma cell lines after 5 days treatment with the specific 
CDK4/6 inhibitor PD-0332991 (0-10 µM) as determined by an MTT assay. (B) Expression of Rb and phospho-Rb in two 
adenoma cell lines after treatment with increasing concentrations of PD-0332991. 
108 
CHAPTER 7 
Perspectives for tailored chemoprevention and treatment of 
colorectal cancer in Lynch syndrome 
Dianne M. Heijink1•2, Elisabeth G.E. de Vries1, Jan J. Koornstra2, Geke A.P. Hospers1, 
Robert M.W. Hofstra3, Marcel A.T.M. van Vugt1, Steven de Jong1, Jan H. Kleibeuker2 
1Department of Medical Oncology, 2Department of Gastroenterology and Hepatology, 
3Department of Genetics, University Medical Center Groningen, University of Groningen, 
the Netherlands. 
Critical Reviews in Oncology/Hematology 2011; in press 
I Chapter 7 
Perspectives for chemoprevention and treatment in Lynch syndrome 
ABSTRACT 
Lynch syndrome (LS) is caused by a germline mutation in one of the mismatch repair 
(MMR) genes. The resulting loss of MMR gene function induces a strong mutator 
phenotype and predisposition to colorectal cancer (CRC). LS mutation carriers undergo 
regular colonoscopic surveillance and have extensive colonic resection in case of cancer 
because of the chance of metachronous tumors. Given the high risk and early onset of 
CRC, LS mutation carriers are good candidates for chemoprevention. Furthermore, 
evidence increases indicating that the response of MMR-deficient tumors to standard 
chemotherapy and radiotherapy differs from that of MMR-proficient tumors. Efforts 
should thus be directed at designing tailored strategies concerning both 
chemoprevention and medical cancer treatment for LS individuals. This review provides 
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Lynch syndrome (LS), formerly called Hereditary Non-Polyposis Colorectal Cancer 
(HNPCC), strongly predisposes to the development of colorectal cancer (CRC) and other 
malignancies at a relatively young age. 3-5% of al l CRCs are associated with this 
syndrome.1 LS is the consequence of a germ line mutation in one of the mismatch repair 
(MMR) genes with the subsequent somatic loss-of-function of the second allele. A defect 
in the MMR system is characterized by increased mutagenesis, which contributes to 
stepwise carcinogenesis, involving mutations in genes including P-catenin, APC, TGFPRII, 
K-Ras and Bax (Figure 1).2'3 A hallmark of the syndrome is microsatel l ite instability (MSI) 
but it has to be noted that also 15% of sporadic CRC cases show MSI due to 
hypermethylation of an MMR gene promoter region, mostly affecting the MLHl 
promoter.1 Tumor characteristics of both entities are very similar. There are, however, 
also clear differences: LS mutation carriers develop CRC at a younger age and also have 
an increased risk of extracolonic malignancies due to the MMR gene germline mutation. 
LS-associated and sporadic MSI tumors may exhibit somewhat different mutation 
patterns - as for example BRAF mutations were recently reported in sporadic MSI but 
not LS-associated CRCs.4'5 In this review, we focus on LS-associated tumors and LS 
preclinical models. In case of l imited data, we have included data from generic MSI 
tumors. Clearly, results valid for generic MSI tumors, ultimately have to be validated in 
LS-associated tumors in order to draw conclusions for this specific patient population. 
In this review, we discuss the current state of art for chemoprevention and treatment of 
LS-associated CRC, followed by recent clinical evidence for improvements. An important 
part focuses on insights obtained from preclinical research. Therapeutic responses and 
the underlying mechanisms can be carefully examined preclinical ly and these results 













Figure 1. In Lynch syndrome, a defective mismatch repair system causes a mutator phenotype, resulting in a strong 
predisposition for colorectal cancer. 
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1. The Lynch syndrome 
Genetics and diagnosis 
The autosomal dominantly inherited LS is caused by a germline mutation in one of the 
MMR genes MSH2, MLHl, MSH6 or PMS2. Of the mutations identified in clinical ly 
suspected families, the majority is found in either MSH2 or MLHl. A mutation in MLHl is 
present in 50% of cases, in MSH2 in 39% of cases.6 MMR proteins (homologues of the 
bacterial MutS and MutL proteins) function in complexes, that recognize and repair 
replication errors.7 The MMR system plays an important role in maintaining the fidelity of 
replication. Inactivation of MMR confers a strong mutator phenotype with a high rate of 
spontaneous mutations. Microsatel l ites, repetitive DNA sequences of mostly one or two 
nucleic acids, are particularly susceptible to DNA replication errors when the MMR 
system is less functional. Variability in number of repeats due to expansion or to 
shortening of DNA sequences in microsatel lite regions of tumor DNA as compared with 
the length of those sequences in matched normal tissue, is cal led MSI. MSI of a tumor is 
defined as high (MSI-H) when more than 30% of a set of minimally five tested markers 
displays instability, and as low (MSI-L) when less than 30% of the markers shows 
instability. If none of the markers is instable, the tumor is classified as microsatel lite 
stable (MSS).8 
Age at CRC diagnosis, tumor multiplicity and family history have been the primary 
parameters for identifying individuals with LS.9-11 When LS is suspected on the basis of 
these parameters, additional molecular studies are performed. Studies include MSI 
analysis and immunohistochemical analysis of MMR proteins. If loss of MLHl is found, it 
is useful to examine somatic hypermethylation of the promoter region of this gene. Loss 
of MMR function as suggested by MSI analysis and immunohistochemistry and the 
absence of somatic hypermethylation, warrants germline mutation analysis of MMR 
genes in order to confirm the diagnosis of LS.12'13 A germline mutation is found in about 
80% of the cases in which MSI is present, immunohistochemistry shows the absence of a 
MMR protein, and MLHl promoter hypermethylation is not detected.14 Since LS cannot 
be excluded if no germline mutation is found, there is obviously room for improvement 
on genetic testing for LS. 
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2. Preclinical models for Lynch syndrome 
2.1 Cell line models 
MMR-deficient cell lines are the most adequate models to study LS-associated CRC in 
vitro. All MMR-deficient human CRC cell lines reported in the literature are summarized 
in Table 1. In addition, several MMR-deficient cell lines originating from other organs 
(endometrium, ovary, prostate) are available.15 In accordance with the clinical 
prevalence, the majority of MMR-deficient CRC cell lines has a defect in MLHl. The 
defects seen in MLHl-deficient cell l ines are either a mutation (comparable with LS) or 
epigenetic silencing of expression due to hypermethylation of the MLHl promoter 
region.16 In contrast with the clinic, there are only few CRC cell lines available with a 
defect in MSH2. 








HCT15/ DLD1 MSH6 
Defect 
Base substitution resulting in a 
termination signal at exon 9 codon 252 
Base substitution in exon 4 codon 117 
Base substitution in exon 8 codon 226 
+ methylation 
Base substitution in exon 5 codon 129 
Nonsense mutation 
2 b substitution in exon 16 codon 618 
Promoter methylation 




Deletion of exon 3-8 
1 bp deletion at codon 222 resulting in 
a nonsense mutation and frameshift 
mutation at codon 1103 which causes 
Colon (p) 
Colon (p) 
Cecum (p), poorly differentiated 
Colon (p) 
? 
Colon (p), Dukes C 
Colon (p), poorly differentiated 
Colon (p), well differentiated 
? 
Colon 
Colon (metastasis in left 
supraclavicular region), stage D 
Colon (p) Dukes C 
HCT-8/ HRT-18144 MSH6 Truncating mutations in the 2 alleles of Cecum (p) 
MSH6 
(p) = primary tumor 
? = unknown 
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2.2 Mouse models 
Mouse models defective in one of the MutS and MutL homologues have been used to 
functionally study MMR genes and the consequences of functional loss of these genes. 
Unlike the human situation, mice with a heterozygous mutation in an MMR gene are not 
cancer prone.17 The shorter life span of mice makes somatic loss of the wild type al lele in 
heterozygous mice less likely. In order to study LS in mice, both alleles of an MMR gene 
therefore need to be inactivated. Such mice primarily develop lymphomas and skin 
tumors, but also display gastrointestinal tract tumors, primarily located in the small 
intestine.17 Interestingly, patients with bial lelic germline mutations in an MMR gene 
develop mal ignancies similar to their counterpart MMR homozygous knockout mice.18 
Of all mouse models with a defect in a MutS homologue (MSH2, MSH3, MSH6), the 
phenotype of MSH2-deficient mice is most aggressive. In wild type mice, more than 50% 
of the animals exceeds a 2-years life span, whereas MSH2-deficient mice display a short 
survival: al l animals die within one year due to the strong tumor (lymphoma) 
predisposition.17 Recently, a conditional MSH2 mouse model (VC-Msh2-/LoxP) was 
generated in which MSH2 was specifical ly knocked out in the intestinal mucosa by Cre­
LoxP-mediated inactivation of MSH2. These mice develop intestinal adenomas and 
adenocarcinomas but no lymphomas, making this model suitable for studying 
therapeutic effects on colonic carcinogenesis in MMR-deficient mice.19 MSH6-deficient 
mice are phenotypically similar to the conventional MSH2-deficient mice20, but the onset 
of tumor development and mortality is delayed probably due to the absence of 
frameshift mutations since the MSH2/MSH3 complex repairing larger insertion/deletion 
mismatches is still intact.18 Thus far, MSH3 mutations have not been implicated in LS. In 
accordance with the evidence in humans, MSH3-deficient mice have a normal survival 
and only a slight increase in gastrointestinal tumors at advanced age.21 
Concerning deletion of MutL homologues (MLH1, PMS1, PMS2, MLH3) in mice, only 
MLH1 and PMS2 knockouts lead to tumor development - consistent with the human 
situation. MLHi-1- mice have a strong cancer predisposition (lymphomas, skin tumors and 
gastrointestinal tumors) and reduced survival, similar to MSH2-I- mice. Inactivation of 
PMS2 results in a less aggressive phenotype with lymphomas and sarcomas but without 
intestinal tumors.17'22 
Loss of APC gene function seems critical for cancer development in a MMR-deficient 
genetic background. Combining mutant MMR genes with a mutant murine Ape allele 
(Apc
Min/+ or Apc1638N/+ mice) thus provides an opportunity to study Ape driven 
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carcinogenesis in an MMR-deficient context. The combined mutation of these genes 
results in accelerated tumorigenesis and limits tumor development almost exclusively to 
the intestinal tract.18 Because of the genetic similarity between Apc/MMR-deficient 
mouse tumors and human LS tumors, these mouse strains provide an excellent tool for 
studying novel treatment options. 
3. Current and future practice in the management of Lynch syndrome patients 
3.1 Chemoprevention 
3.1.1 Current status and clinical evidence for future chemopreventive strategies 
At this moment, chemoprevention is not part of the management of LS. Cl inical 
chemoprevention trials performed in LS individuals are summarized in Table 2. Aspirin 
seems of real interest. In preclinical work, aspirin suppressed the mutator phenotype and 
increased MMR protein expression in MMR-deficient cell lines.23'24 In patients with 
sporadic colorectal adenomas, aspirin prevented new adenomas.25-27 The randomized 
CAPP2 study analyzed the use of aspirin versus placebo for up to 4 years in 693 LS 
individuals and did initial ly not show a beneficial effect. 28 However, 5 years after 
randomization, the incidence of new colon cancers started to diverge between the 
placebo and aspirin group. Although most participants discontinued aspirin use after the 
trial, by 9 years after randomization, there were about 50% fewer cancers in the previous 
aspirin group. The effect was most obvious in those who received aspirin for over 2 
years. A dose inferiority study is now being planned to evaluate the effects of a lower 
dose of aspirin on LS cancer prevention. 29 This course shows that a long duration of 
fol low-up is important in chemoprevention studies in order not to miss significant long­
term effects. 
Although results from a chemoprevention trial with celecoxib in LS gene carriers are to 
be awaited, the results from a study focusing on alterations in gene expression in normal 
colonic mucosa after celecoxib treatment using samples from patients included in this 
trial have already been published.30 It was discovered that celecoxib may suppress the 
immune response and cell adhesion and may stimulate TGF-� signaling. Since the 
magnitude of the changes in gene expression was in general relatively small, it is unclear 
whether the effects observed are clinical ly relevant. 
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The relatively late protective effect of aspirin holds promise for the use of NSAIDs for 
chemoprevention.29 In view of this, it is interesting that nitric oxide (NO)-donating aspirin 
derivatives recently appeared to be more effective than aspirin in suppressing MSI in 
MMR-deficient LS CRC cell lines. Suppression of MSI was detected after 8 weeks of 
treatment and gradually  increased from O out of 6 to 4 out of 6 microsatel lite markers 
being stable after 20 weeks of treatment.31 NO-NSAIDs are supposed to exert lower 
toxicity, since NO is an important mediator of gastric mucosa! defense.32 Long-term 
effects of NO-aspirin use are still unknown but l imited laboratory and clinical data 
demonstrate reduced gastrointestinal toxicity33 and the preliminary preclinical evidence 
from NO-aspirin use for chemoprevention in LS is promising. 
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In a recent report, the non-specific NSAID sulindac induced unwanted proliferative 
effects in an MMR-deficient mouse model .34 Sulindac inhibited tumor formation in the 
small intestine of Ape mutant mice, but increased tumor formation in the small intestine 
of MLH1 mutant mice after 6 months treatment. Inflammation of the small intestine was 
observed in MLH1 mutant but not Ape mutant mice. In a second study using an Ape+I­
MSH2-I- mouse model, the number of small bowel adenomas was lower in mice treated 
with the specific COX-2 inhibitor MF-tricyclic compared with controls and mice treated 
with sulindac.35 This indicated that specific COX-2 inhibition might be superior to non­
specific COX-inhibition for chemoprevention in LS. Surprisingly, there was a lack of effect 
of COX-2 inhibition on the number of large bowel adenomas, despite the fact that small 
and large bowel adenomas showed similar expression levels of COX-2. In Ape+1-MSH2-I· 
mice, adenomas primarily develop in the small bowel, but the mechanism for the 
selective effect of COX-2 inhibition was not clarified. The results from both studies 
underscore the need for research into the differential response to NSAIDs of MMR­
deficient versus MMR-proficient cells. Furthermore, these studies encourage using 
different agents in the same model to investigate which agent is superior. Lastly, 
cautiousness is needed when translating these results to the clinic since NSAID-induced 
proliferative effects have been observed in a precl inical model. 
In addition to NSAIDs, other compounds have attracted attention for chemopreventive 
purposes in LS. Mesalazine (5-ASA, the active compound of sulfasalazine), which is used 
for the treatment of inflammatory bowel disease, was shown to improve replication 
fidelity in both MLH1-proficient and -deficient cel ls  as judged by lower frameshift 
mutation rates in the investigated microsatel lite region.36 Surprisingly, aspirin, which is 
structurally related to mesalazine and reported to decrease MSI, did not show this effect 
in the same study.36 In addition, a second study reported that mesalazine activated a 
replication checkpoint, thereby slowing down DNA replication and improving replication 
fidelity in several MMR-deficient cell l ines.37 Since the speed of tumor progression 
correlates with the overall mutation rate, mesalazine might significantly delay the 
manifestation of an MMR deficiency-driven tumor. 
A new field of research is the development of prophylactic vaccines. Frameshift 
mutations characteristic for MSI and LS only occur in tumor cel ls and malignant 
progenitor cells. It was discovered that mutation-driven amino-acid changes in frequently 
mutated genes like TGFPRII, Bax and CDX2-2 can lead to the generation of immunogenic 
neopeptides that may serve as tumor-specific antigens. These Frameshift Derived 
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Peptides {FSPs) carry cytotoxic lymphocyte epitopes that can be used to stimulate T-cells 
from LS individuals. FSP-specific T-cell responses can already be detected in peripheral 
blood of healthy LS mutation carriers, indicating that a vaccine may serve as a preventive 
application.38-40 By combining several frameshift peptides, a multivalent vaccine for MSI­
H cancers can be developed, which may result in immune-mediated specific targeting of 
(pre)malignant cells in the majority of LS mutation carriers.39,41 The amino acid sequence 
of several antigens is now known and vaccines are being developed for study purposes. 
Summarizing, preclinical research reveals promising results of NO-aspirin and specific 
COX-2 inhibitors. Concerns were raised about the proliferative effects of sulindac in 
MMR-deficient mice. Preclinical research furthermore showed encouraging effects of 
mesalazine and vaccines containing FSPs. 
3.3 Adjuvant chemotherapy 
3.2.1 Current status and clinical evidence for future chemotherapeutic strategies 
The gold standard for adjuvant chemotherapy of high-risk stage 2 and stage 3 CRC 
patients is a 5-fluorouracil {5-FU)-based regimen. Currently, FOLFOX {5-FU/leucovorin 
{LV), oxaliplatin) is considered the optimal chemotherapy regimen in this setting.42 No 
distinction is made between sporadic cancer and cancer in LS individuals for the choice of 
chemotherapeutical agents. 
Retrospectively collected data address the role of 5-FU in patients with MSI-H tumors. 
Some early {small and non-randomized) cl inical studies showed beneficial effects of 5-FU 
in MSI-H tumors in the adjuvant setting in stage 3 colon cancer.43-47 However, these 
studies did not prospectively stratify for MSI-H tumors and did not compare 
chemotherapy with no treatment in the MSI-H group. More recent retrospective 
analyses of data from randomized trials al l demonstrated, with one exception48, that 5-
FU based chemotherapy does not improve prognosis in patients with MSI-H tumors.49-57 
For the combination 5-FU/LV with oxaliplatin, so far, only one study retrospectively 
determined the value of MSI for the prediction of benefit.58 MSI phenotype was 
determined using immunohistochemistry for MLHl, MSH2 or MSHG. The study did not 
differentiate between LS tumors or sporadic MSI tumors. In this study FOLFOX 
significantly improved 3-year Disease Free Survival {DFS) from 57.9% {5-FU plus LV, n = 
20) to 100% {FOLFOX, n = 12) in stage 3 CRC patients with MSI-H tumors. The effect of 
MSI status on response to FOLFOX is currently being assessed in a large phase Il l trial 
{ECOG E5202). 
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Adding irinotecan to 5-FU/LV (FOLFIRI) in the adjuvant setting did not increase the 
response compared to 5-FU/LV alone for stage 2 and 3 CRC.59•61 However, it was 
beneficial for the subgroup of patients with MSI-H tumors. A recent prospective study 
investigated 5-FU/LV with or without irinotecan in patients with stage 3 CRC.62 Patients 
were randomized to receive 5-FU plus LV with or without irinotecan. Patients with a MSI­
H tumor (n = 96) had a better 5-year DFS than patients with a MSS tumor (n = 606) after 
5-FU plus irinotecan (probability 0.76 versus 0.59). A trend toward improved 5-year DFS 
was observed in MSI-H patients treated with 5-FU/LV plus irinotecan compared to MSI-H 
patients treated with 5-FU/LV alone (probability 0.76 versus 0.57). In preliminary results 
from a second study, the same trend was observed.63 
MMR-deficient tumors display often near diploid stable chromosomes. Chromosomal 
instability refers resistance to mitotic inhibitors, near diploid cel ls are however sensitive 
to mitotic inhibitors such as taxanes. Therefore, the response to a new taxane 
(patupilone) is investigated in a current trial in local ly advanced or metastatic MSI colon 
cancer.64 In addition, a phase II trial is currently investigating the efficacy of 
methotrexate in MSH2-deficient advanced CRC patients, based on preclinical evidence as 
described hereafter. 
Summarizing, in contrast to 5-FU in the adjuvant setting which does not improve 
prognosis in MSI-H tumors, the addition of oxaliplatin or irinotecan seems to improve the 
response to therapy in this subset of tumors. Trials investigating the taxane patupilone 
and methotrexate are recruiting patients. 
3.2.2 Preclinical evidence for future chemotherapeutic strategies 
Cells with defects in a DNA repair system are likely to display differential sensitivity for 
genotoxic agents. Several chemotherapeutic agents have been thoroughly tested in 
MMR-deficient cell lines and the results show that MMR-deficient cel l s  are 
chemoresistant to a variety of monotherapies including several platinum-based drugs, 
methylating agents, alkylating agents and topoisomerase II inhibitors.65•67 In vitro, MMR­
deficient cel ls were also less sensitive to 5-FU, due to less efficient recognition of 5-FU 
incorporation into DNA and subsequent damage tolerance.68"71 
The topoisomerase I inhibitor irinotecan seems effective in preclinical MMR-deficient 
models. l rinotecan induces DNA damage by creating single-strand breaks which can 
become double-strand breaks during replication. In a panel of CRC cell lines either 
proficient or deficient for MMR, it was shown that MMR-deficient cel ls were much more 
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sensitive to irinotecan than MMR-proficient cells, independent of the p53 status.72-75 
Cells with additional mutations in the double-strand break repair genes MREll or RADS0 
were most sensitive to this compound. When combined with thymidine, irinotecan­
induced cytotoxicity was even higher, which was again pronounced in the presence of an 
MREll mutation.74'75 Patient-derived MSI-H tumor specimens in mice (tumor xenografts) 
were more sensitive to irinotecan than MSS tumor specimens, further strengthening the 
idea that irinothecan specifically benefits in this subset of MSI tumors. The presence of a 
p53 mutation hampered this sensitivity in vivo. 76 As p53 mutations are observed at a 
much lower frequency in LS-associated tumors than in MSS tumors77, this observation 
has no negative impl ications for most LS patients. Final ly, in a retrospective study in 
patients with metastatic CRC, MSl-driven inactivation of target genes such as Bax 
positively modified the response of MSI-H tumors to irinotecan. 78 From all 
chemotherapeutic agents, irinotecan is most extensively investigated for use in MSI 
tumors, showing promising responses in a preclinical setting. 
Preclinical data on the efficacy of oxaliplatin do not exist, however it is known that 
oxaliplatin, unlike cisplatin, works independently of the MMR system which makes it 
favorable for use in MMR-deficient tumors.79•80 
Preclinical data in MMR-deficient cel ls further indicated the use of bulky rhodium {Il l )  
intercalators, which specifically target DNA base mismatches.81'82 These agents bind 
single base mismatches in DNA by intercalation and promote strand breaks at the 
mismatched site upon photoexcitation. Inhibition of proliferation was preferential ly seen 
in MMR-deficient cel ls compared to MMR-proficient cel ls, indicating a selective response 
of MMR-deficient cells. Another compound, brostall icin, a DNA minor groove binder, 
showed cytotoxicity in MMR-deficient cells.83 The drug is entering the clinic and is 
currently being tested in phase 1/1 1 trials in sarcoma and myeloma patients. 
In preclinical in vitro and in vivo models, MMR-deficiency was found to be associated 
with hypersensitivity to the DNA cross-linking agents CCNU and mitomycin C.84•85 
However, since 2000 no publications investigated the role of these agents in MSI cancer. 
Using a l ibrary screening of commonly used drugs, Martin et al recently identified the 
folate antagonist methotrexate as a therapeutic agent to selectively kill endometrial and 
colon cancer cells lacking functional MSH2. Methotrexate treatment caused 
accumulation of potentially lethal oxidative {8-OHdG) DNA lesions, which were rapidly 
cleared in M5H2-proficient cells, but persisted in M5H2-deficient cells. As expected, 
addition of folic acid could rescue the methotrexate-induced lethality in M5H2-deficient 
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cells.86 No methotrexate sensitivity was observed in MLHl-deficient CRC cells, in 
concordance with previous results.87 Intriguingly, results from another group showed the 
presence of more methotrexate-resistant colonies of MMR-deficient (including MSH2-
deficient) CRC cells when compared to MMR-proficient CRC cel ls.88 These apparently 
contradicting observations may be caused by the fact that colony numbers were 
investigated after 1 month continuous methotrexate treatment in the latter study, 
compared to 14 days treatment in the first study. Methotrexate is an old 
chemotherapeutic which was initial ly not beneficial for CRC patients in most trials 
performed in the past.89 However, at that time MSI testing was not performed. Possibly, 
the preclinical results of the selective effect of methotrexate in M5H2-deficient tumors, 
can be translated to the clinic. 
Combining chemotherapeutics with new agents in order to circumvent resistance is 
another potential attractive approach to improve treatment of CRC in LS. An example is 
the use of the Poly (ADP-Ribose) Polymerase-1 (PARP-1) inhibitor AG14361, which 
restores sensitivity to temozolamide in MMR-deficient CRC cells.90 By using this PARP-1 
inhibitor, the primary cytotoxic locus of temozolamide is probably shifted from 06-
methylguanine (MMR-deficient cells are tolerant to 06-adducts) to N3-methyladenine 
and N7-methylguanine adducts which are normally repaired by the base excision repair 
pathway. After inhibition of PARP-1, which is critical ly required for base excision repair, 
methyladenine and methylguanine adducts accumulate, resulting in increased levels of 
cytotoxicity. In a similar manner, methoxyamine was shown to block base excision repair 
and restore sensitivity to alkylating agents.91 The pyrimidine nucleoside analogue BVDU 
(brivudin) was shown to restore sensitivity to bleomycin in MMR-deficient tumor cel ls. 
The proposed effect of BVDU resulted from inhibition of homologous recombination, 
which is normally inhibited by the MMR system but is still intact in MMR-deficient cells 
due to which bleomycin-induced double-strand breaks could be repaired in these cel ls.92 
Summarizing, despite the resistance of MMR-deficient cells to a wide variety of clinical ly 
used chemotherapeutic drugs, there are indications for effective agents from clinical and 
preclinical work. In this respect, the topoisomerase I inhibitor irinotecan seems 
promising. Oxaliplatin was effective in one trial investigating its use in MSI-H CRC, but is 
not yet extensively investigated. Other options mentioned are methotrexate, patupilone, 
new intercalating agents like bulky rhodium (Il l )  intercalators and DNA minor groove 
binders and combinations of inhibitors of the base excision repair or homologous 
recombination pathways and chemotherapy. 
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3.3 Radiotherapy 
3.3.1 Current radiotherapeutic strategies 
The rectum is the second tumor predilection site in LS. Rectal cancer comprises 8% of 
MlHl-deficient LS associated CRCs and 28% of MSH2-deficient LS associated CRCs.93 
Radiotherapy is part of the neoadjuvant treatment for T2/T3 rectal cancer prior to 
surgical resection of the tumor and for locally advanced T3/T4 rectal cancers in 
combination with 5-FU. Currently, no data are available evaluating differential effects of 
neoadjuvant radiotherapy or chemoradiation in patient with MMR-deficient rectal 
tumors compared to patients with MMR-proficient rectal tumors. 
3.3.2 Preclinical evidence for future radiotherapeutic strategies 
Precl inical studies evaluating the effects of irradiation of MMR-deficient cells have 
yielded conflicting results. Some studies indicate there is no response to irradiation94'95, 
while others do report almost similar96'97 or even increased sensitivity compared to 
MMR-proficient cells.98 Several studies show requirement of the MMR system for the 




suggesting that cells deficient in MMR may respond differently to radiotherapy. 
Moreover, several reports recommended cautiousness when irradiating MMR-deficient 
tumors. Accelerated growth of intestinal tumors after irradiation was reported in MlHl­
knockout mice suggesting an increased risk of secondary cancers after radiotherapy for 
LS patients.100 In addition, increased sensitivity of primary biallelic MSH2-deficient human 
neonatal cells to irradiation was shown. Reduced viability and increased chromosomal 
damage of these non-tumor cells also indicated some reserve regarding radiotherapy.101 
So-called radiosensitizers can make tumor cells more sensitive to radiotherapy. In 
preclinical models, MMR-deficient cells are hypersensitive for the combination of 
radiosensitizers and radiotherapy. MlHl-deficient HCT-116 cells were less sensitive to 5-
fluoro-2'-deoxyuridine (FdUrd) alone, consistent with the decreased sensitivity to 5-FU 
chemotherapy. When FdUrd treatment was fol lowed by irradiation however, these 
MlHl-deficient cel ls exhibited greater radiosensitization when compared with MMR­
proficient cells. Likewise, siRNA-mediated depletion of MLHl resulted in 
radiosensitization, indicating that MLHl deficiency is a favorable factor for 
radiosensitization with FdUrd. Mechanistically, it appears that DNA misincorporations 
induced by dTTP depletion (FdUrd inhibits thymidylate synthase resulting in dTTP 
depletion) were not corrected before irradiation, resulting in radiosensitization.102 In the 
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same way, the radiosensitizer gemcitabine {2',2'-difluoro-2'-deoxycytidine, dFdCyd) 
sensitized MLHl-deficient, but not -proficient cel ls to irradiation, this time via increased 
DNA misincorporations due to dATP depletion.103•104 The halogenated thymidine 
analogues ldUrd and BrdUrd also selectively targeted MLHl- and M5H2-deficient drug­
resistant cel ls for radiosensitization.105 Moreover, using an in vivo model of MLHl­
deficient and -proficient colon cancer xenografts, the orally  administered radiosensitizer 
5-iodo-2-pyrimidinone-2'-deoxyribose (IPdR) was shown to differential ly sensitize the 
MMR-deficient tumors to radiotherapy, again suggesting that MMR-deficiency 
potentiates radiosensitization.106 Clinical phase 1/11 trials with IUdR-mediated 
radiosensitization in MMR-deficient gastrointestinal tumors are now being planned. 123I­
or 124I-IUdR PET/CT-scanning will be performed to monitor IUdR/-DNA levels in the tumor 
versus normal tissues in order to determine the therapeutic window.107 One small 
patient study relating MSI testing to response to therapy found that MSI-H rectal tumors 
showed a complete response to neoadjuvant FOLFIRI plus radiotherapy in 3 out of 5 
cases (60%), while a complete response was only obtained in 7 out of 36 cases (20%) of 
MSS tumors.108 As neoadjuvant (chemo)radiation comprises the standard therapy of 
rectal cancer, we strongly encourage retrospective analysis of tumor specimens to clarify 
whether chemo(radiation) is indeed effective in MSI-H rectal tumors and less effective in 
MSS rectal tumors. If this is truly the case, the indications for chemoradiation in LS­
associated rectal cancer should possibly be extended. 
3.4 Molecular targeted therapies 
Calcium channel blockers deserve attention for the treatment of LS tumors. Fourteen 
MMR-deficient cancer cell lines including CRC cell l ines, showed increased selective 
sensitivity to both nifedipine and carboxyamidotriazole as compared to MMR-proficient 
cell l ines.109 In vitro, calcium channel blockers selectively inhibited invasiveness, induced 
apoptosis, and inhibited proliferation of MMR-deficient cells. Importantly, restoration of 
MMR by selective chromosomal transfer reversed the observed sensitivity to calcium 
channel blockers. In 2001 a LS patient with metastatic CRC experienced a complete 
tumor response after treatment with a high dose of nifedipine alone.109•110 However, 
thereafter no new responses have been reported. Nevertheless, calcium channel 
blockers seem to be attractive agents for trials in the future. Furthermore, it would be 
interesting to study the chemopreventive capability of calcium channel blockers. 
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Increased sensitivity to curcumin, a dietary pigment which is currently evaluated clinical ly 
for the treatment of CRC, was observed in MMR-deficient cells.111 MMR-deficient cells 
displayed reduced double-strand breaks and G2-M checkpoint activation, due to which 
cel ls failed to undergo cell cycle arrest and died through mitotic catastrophe. Curcumin 
treatment may therefore be especial ly useful in the treatment of MSI-H cancers. 
Antibodies against the Epidermal Growth Factor Receptor {EGFR), cetuximab and 
panitumumab, and against the Vascular Endothelial Growth Factor {VEGF), bevacizumab, 
have obtained a place in the treatment of patients with metastatic CRC. No data are yet 
available about sensitivity of MSI-H tumors to those agents. However, ongoing studies 
address the role of MSI in response to FOLFOX with or without cetuximab or 
bevacizumab.112 
Mutations occurring in MMR-deficient tumors are often inactivating mutations resulting 
in a loss-of-function of tumor suppressor genes and the affected pathways may therefore 
not directly be suitable for targeted therapies. However, also activating mutations in 
several oncogenes in MMR-deficient CRC have been reported. For example, a BRAF 
mutation occurs in up to 40% of MMR-deficient CRCs, compared with 5-15% in MMR­
proficient tumors.113-116 Surprisingly, this BRAF mutation was only found in cel ls 
exhibiting MMR-deficiency due to MLHl promoter hypermethylation in sporadic CRC, 
while this mutation is not present in tumors of LS patients.5'117 Resistance to cetuximab 
or panitumumab was reported in tumors with a BRAF mutation118, in line with results for 
K-Ras mutated cel ls.119 Targeting BRAF and its downstream effectors may be effective in 
patients with an activating BRAF mutation. Novel RAF and MEK inhibitors are under 
clinical evaluation and show promising results.120•121 Given the existing data, these 
inhibitors may prove to be useful only in non-LS MMR-deficient tumors. 
P/3K mutations also show a high prevalence {11-37%) in the MSI-H subgroup of CRCs 
compared to MSS tumors.122-124 A mutation in the P/3K catalytic subunit {P/3KCA) gene 
leads to increased Pl3K pathway activity and activation of survival signaling mainly via 
Akt.125 In the presence of wild type K-Ras, Pl3KCA mutations are associated with a poor 
prognosis126 and P/3K mutated cells, like cells with a K-Ras or BRAF mutation, do not 
respond to EGFR targeted antibodies. 127 Inhibitors of Pl3K and Akt, have demonstrated 
anti-tumor activity especially in P/3K mutated colon cancer cells. This makes these 
agents, which are now tested in the clinic, of potential interest for CRC patients with a 
P/3K mutation.128'129 In a recent study investigating the response of a panel of MMR­
deficient cell lines to low molecular weight compounds, these cel ls were found 
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specifically sensitive to inhibition of the Pl3K-Akt-mTOR pathway.130 These results again 
underline the importance of studying the effects of inhibition of this pathway in MSI 
tumors. 
The concept of synthetic lethality is emerging in the treatment of cancer. 131 Synthetic 
lethality exists if loss of function of two genes or proteins is lethal, while loss of function 
of one of those genes or proteins is not. This concept can be used in cancer treatment by 
inhibiting the second gene or protein if the first gene or protein is silenced by the disease 
(i.e. a mutated tumor suppressor gene). An example is the use of PARP-1 inhibitors 
blocking the base excision repair pathway, in cel ls depending on this pathway due to a 
mutation in the homologous recombination pathway genes BRCAl/2.132 Inhibiting PARP-
1 was not found synthetically lethal with MMR deficiency133, although a recent trial is 
investigating the PARP-1 inhibitor olaparib in patients with stage IV CRC. However, a 
recent report demonstrated that deficiency of MSH2 is synthetically lethal with loss of 
the DNA polymerase POLB, while deficiency of MLHl is synthetical ly lethal with loss of 
DNA polymerase POLG.134 After silencing of DNA polymerase POLB and POLG in MSH2-
deficient and MLHl-deficient cells respectively, 8-OXdG oxidative DNA lesions 
accumulated leading to the induction of lethal DNA breaks. Specific DNA polymerase 
inhibitors are not available yet, but effort should be directed at developing these 
pharmacologic inhibitors in order to clinical ly assess its value. 
Summarizing, several molecular targeted therapies attracted attention in preclinical work 
on MMR-deficient cells. Calcium channel blockers, curcumin, inhibitors of EGFR and 
VEGF, Pl3K/Akt inhibitors and DNA polymerase inhibitors all deserve to be further 
evaluated. Drugs targeting BRAF only seem beneficial in non-LS MSI tumors. 
4. Conclusion 
LS-associated CRC differs from sporadic CRC in its genetic background and development. 
LS mutation carriers therefore receive tailored therapy including regular surveil lance 
colonoscopy and more extensive colonic resection after a tumor has established. The 
high risk and early onset of CRC in LS mutation carriers reveals an important role for 
chemoprevention, which is currently not available for these patients. A recent update on 
a large chemoprevention trial performed in LS individuals using aspirin demonstrated a 
late-onset post-medication protective effect of aspirin. Other chemoprevention trials did 
not show a beneficial effect of the drug tested (sulindac, calcium, resistant starch). In 
preclinical research, however, NO-donating aspirin, selective COX-2 inhibitors, 
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mesalazine and prophylactic vaccines seem promising novel candidates. A long-term 
follow-up is probably needed to evaluate the chemopreventive effects of therapy. 
Chemoprevention is ideally accomplished by long-term low-dose treatment, due to 
which responses may be missed in a relatively short follow-up. Patients with MSI-H 
tumors are currently treated with the same chemotherapy and radiotherapy regimens as 
CRC patients with MSS tumors. It becomes, however, increasingly clear that the response 
of MMR-deficient tumors to standard therapy differs from that of MMR-proficient 
tumors. Adjuvant chemotherapy consisting of 5-FU alone is not effective in LS patients. 
Preclinical and clinical studies indicate efficacy of 5-FU plus irinotecan or oxaliplatin as 
well as of new agents specifically targeting the MMR-deficient cells. Resistance to 
chemotherapy can be circumvented using inhibitors of the base excision repair or 
homologous recombination pathways. Targeted therapies with calcium channel blockers 
or Pl3K inhibitors are attractive. Extensive research is required even within the subgroup 
of MMR-deficient tumors, since response differences may exist depending on the gene 
mutated and the mode of MMR gene inactivation. For example, the decision to target 
BRAF or not depends on whether MLHl is mutated or whether its promoter is 
hypermethylated. The concept of synthetic lethality can be exploited by developing 
inhibitors of DNA polymerases for its use in MMR deficient cells. Interestingly, MMR­
deficient tumor cel ls seem to be extremely sensitive to radiosensitization. 
Little more than 20 years after the LS became a worldwide recognized syndrome, we 
know a lot more about the presentation and genetic background, and screening 
programs were developed. Clinical and especially preclinical research revealed options 
for specific treatment of LS individuals as described in this review (Figure 2). However, 
this new field in LS research is not receiving enough attention yet. For the coming years it 
is a major challenge to further investigate and/or identify promising agents for tailored 
management of LS individuals. 
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Figure 2. Options for chemoprevention and treatment of LS-associated CRC/MSI-H CRC based on clinical and preclinical 
evidence. 
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Summary 
Colorectal cancer {CRC) is a major cause of cancer-related mortality worldwide. There are 
two complementary strategies to reduce this. The first is to put more effort in the 
development of new treatment strategies, the second is to focus on prevention and early 
detection. CRC is potential ly preventable given its relatively slow development. During 
this process, the accumulation of oncogenic mutations leads to progression from normal 
colorectal epithelium to the premalignant stage of an adenoma, and eventually to 
cancer. Prevention is especial ly worthwhile in individuals at increased risk of developing 
CRC such as those with a hereditary predisposition like Lynch syndrome (germline 
mismatch repair gene (MMR) mutation) or Familial Adenomatous Polyposis (FAP, 
germline APC gene mutation). Prevention consists of regular surveil lance colonoscopy, 
which is currently offered to high-risk individuals. In addition, it would be valuable to 
prevent the development or progression of colorectal neoplasms by drug-based 
therapies. In randomized trials, several Non-Steroidal Anti-Inflammatory Drugs {NSAIDs) 
demonstrated chemopreventive effects and the NSAID celecoxib is registered for 
chemoprevention in FAP patients. However, the protection by NSAIDs is not complete, 
pointing to the need for more effective strategies. Both CRC treatment and 
chemoprevention can potential ly benefit from molecular targeted therapies. TNF-Related 
Apoptosis Inducing Ligand (TRAIL) is an interesting new agent in this respect. TRAIL can 
induce apoptosis by binding to the TRAIL death receptors, DR4 and DRS. The selectivity of 
this agent, which induces apoptosis in transformed cells but not in normal cells, makes it 
interesting for cancer treatment as well as chemoprevention. TRAIL induces apoptosis in 
CRC cell s  and adenoma cells. In cancer cells, optimal levels of apoptosis are often 
reached after combination treatment including an agent which sensitizes cel ls to TRAIL. 
In this thesis novel targeted drug therapies for treatment and especial ly 
chemoprevention of CRC were explored, with a focus on the combination of TRAIL and 
NSAIDs using in vitro, ex vivo and in vivo models. 
After a an introduction and description of the contents of the thesis in Chapter 1, in 
Chapter 2 the results from a study investigating the basal expression levels of two 
important players in the extrinsic TRAIL apoptosis pathway, caspase-8 and cFLIP, are 
described. Caspase-8 functions as a pro-apoptotic protein. cFLIP however, is an anti­
apoptotic protein due to its ability to replace caspase-8 in the Death Inducing Signaling 
Complex {DISC) which is formed after binding of TRAIL to its receptors. Using 
immunohistochemistry expression levels of both proteins were examined in normal 
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colorectal epithel ium (n = 20), adenomas (n = 66) and carcinomas (n = 44). Expression of 
the two proteins did not differ between sporadic or Lynch syndrome-associated 
adenomas and carcinomas. Expression of caspase-8 was increased in adenomas and 
carcinomas compared to normal colorectal epithelium. cFLIP expression was highest in 
carcinomas. This indicates that caspase-8 and cFLIP protein levels increase during 
carcinogenesis. There was in addition an extensive heterogeneity in expression (ratio) of 
the two proteins in the tissues analyzed. 
In Chapter 3 a study was described in which human CRC cell l ines, adenoma cell l ines and 
ex vivo cultured human adenoma samples were treated with aspirin or sul indac in 
combination with recombinant human (rh)TRAIL. Both TRAIL-sensitive and -resistant 
cancer cell l ines were strongly sensitized to rhTRAIL by aspirin. In adenoma cells, sulindac 
enhanced TRAIL-induced apoptosis most effectively. This sensitization by sulindac was 
also observed in ex vivo cultured human adenomas. After 24 hours single dose 
treatment, apoptosis levels increased from 18.4% (sulindac) and 17.8% (rhTRAIL) to 
28.0% (combination). Thereafter, the mechanism of sensitization was examined. TRAIL 
death receptor membrane expression did not increase after aspirin or sulindac treatment 
and there was no enhanced clustering of the death receptors. Combined treatment did 
enhance caspase-8 activation in both adenoma and CRC cell l ines. cFLIP could not be 
detected in adenoma cell l ines, in l ine with the results presented in Chapter 2. In CRC cell 
l ines, however, cFLIP cleavage was observed. Caspase-8 can cleave cFLIP, thus increased 
caspase-8 activation wil l result in enhanced cFLIP cleavage and ultimately an increase in 
TRAIL sensitivity. Measurements of marker proteins representing several intracellular 
pathways demonstrated involvement of the intrinsic apoptosis pathway, Akt pathway 
and NF-KB pathway. This indicates that the sensitization is multifactorial ly determined by 
complex mechanisms. The Wnt pathway is crucial for colorectal carcinogenesis. Its role in 
the NSAID-induced sensitization to TRAIL was investigated in a cancer cell l ine stably 
transfected with inducible dominant-negative TCF-4 (dnTCF-4). El imination of TCF-4 
completely blocked the sensitizing effect, i l lustrating that the combination of aspirin or 
sulindac plus rhTRAIL works as targeted therapy, only in the presence of pathological 
Wnt signaling. 
ApcMin mice are widely used to study colorectal carcinogenesis and chemopreventive 
approaches. These mice harbor a truncating mutation in the murine Ape gene leading to 
the development of multiple intestinal adenomas. A non-invasive method for the 
longitudinal evaluation of intestinal adenomas in these mice would be an important 
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improvement for the use of this model. Therefore, the use of fluorodeoxyglucose (FDG) 
PET imaging was investigated as described in Chapter 4. To this end, 18F-FDG uptake was 
compared with results from microscopic examination regarding adenoma number and 
size. In vivo imaging revealed a few 'hot spots' per mouse probably reflecting adenomas. 
Ex vivo imaging of the dissected intestines however, allowed visual ization of all large 
adenomas (2: 2 mm) and most smaller adenomas. Ex vivo total intestinal 18F-FDG uptake 
correlated with in vivo total abdominal uptake and with the number of large adenomas 
at age 9 and 12 weeks. At 12 weeks of age, there was a clear correlation between in vivo 
abdominal tracer uptake and the number of large adenomas but not the total number of 
lesions. The results indicate that intestinal adenomas in ApeMin mice are metabol ically 
active lesions that take up 18F-FDG and that abdominal 18F-FDG uptake at age 12 weeks 
can serve as a qualitative readout for large intestinal adenomas. 
Based on the interesting results of the combination of sulindac and rhTRAIL in human 
adenoma cell l ines and ex vivo cultured human adenoma samples (Chapter 3), this 
combination is of importance to be tested in vivo. In the study described in Chapter 5 
different concentrations and treatment durations of sulindac were tested in order to find 
a suitable regimen for a combination study. Sulindac administered in the food during 7 
weeks resulted in a clear dose-dependent reduction in the total number of adenomas 
{71% reduction using the highest concentration) and number of lar� i mm) 
adenomas {90% reduction using the highest concentration) .  Recently, short-term 
sulindac treatment for 1 week was shown to be as effective in these mice as long term 
treatment.1'2 In our hands, sulindac treatment via gavage for 6 days, resulted in a 
reduction of the number of large adenomas {73% reduction using the highest 
concentration), but not in the total number of adenomas. It was previously reported that 
targeting of the mouse-TRAIL death receptor in C57BL/6J mice using the mouse-TRAIL 
receptor specific agonistic antibody MDS-1 resulted in liver toxicity. The toxicity was 
observed after 3 injections of 300 µg MDS-1, administered every 3 days. Toxicity was due 
to TRAIL receptor-mediated apoptosis of cholangiocytes, which highly express the 
mouse-TRAIL death receptor.3 We aimed to find a therapeutic window using a low 
concentration of MDS-1, but experienced similar side effects in ApeMin mice (with a 
C57BL/6J background) after only 4 injections of 50 µg of MDS-1 every 4 days. The same 
liver toxicity was observed in C57BL/6J mice without an Ape mutation after the same 
treatment regimen indicating that the toxicity was independent of the Ape mutation. It 
was recently demonstrated that repeated treatment with rhTRAIL was non-toxic in 
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ApcMin mice4. This may be due to the fact that TRAIL decoy receptors protect 
cholangiocytes from TRAIL-induced apoptosis. A difference in half-life and the route of 
drug clearance between MDS-1 and rhTRAIL may also be related to the liver toxicity 
observed only following MDS-1. Based on the results described in Chapter 5, a study is 
currently performed in which ApcMin mice are treated with vehicle intraperitoneally, 
sulindac in food, rhTRAIL intraperitoneally  and the combination of sulindac and rhTRAIL 
daily for 6 consecutive days. 
In Chapter 6 a search for novel targets for chemoprevention by making use of the 
microarray technique for whole genome expression profiling was described. Differences 
in pathway enrichment were analyzed between normal mucosa (n = 26) and adenomas 
(n = 47) in a combined set of publicly available microarray expression data. By using Gene 
Set Enrichment Analysis (GSEA), 10, 11 and 16 gene sets distinguished adenomas from 
normal mucosa according to KEGG, GenMAPP and Biocarta data bases, respectively. 
Biological pathways known to be involved in colon carcinogenesis such as cell cycle and 
Wnt signaling were enriched in adenomas. In addition, we found an enrichment of 
pathways not currently known to be involved in adenoma formation such as the Rb 
pathway, Src pathway, folate biosynthesis, and Hedgehog signaling. Microarray results 
for Rb and Src pathway genes were validated by qRT-PCR on mRNA isolated from an 
independent set of adenoma and normal colon tissue samples. There was a high 
correlation between microarray data and qRT-PCR expression data. The relevance of 
targeting identified pathways was proven for the Rb pathway with its inhibitors 
roscovitine and PD-0332991 and for the Src pathway with the inhibitor dasatinib. Al l 
these drugs inhibited growth in colon adenoma cells. 
Tumors arising in Lynch syndrome individuals differ from sporadic tumors regarding their 
genetic background and phenotypic characteristics. Given the high risk and early onset of 
CRC in Lynch syndrome mutation carriers, these individuals are good candidates for 
chemoprevention. Currently, no proven chemoprevention strategy is available for this 
population. Furthermore, evidence increases that the response of MMR-deficient tumors 
(including Lynch syndrome-associated tumors) to standard chemotherapy and 
radiotherapy differs from that of MMR-proficient tumors. In Chapter 7 a l iterature study 
is described in which results from clinical and preclinical studies regarding 
chemoprevention and medical treatment of CRC in Lynch syndrome were reviewed. 
Aspirin exhibited a late-onset protective effect in Lynch syndrome carriers. Other 
chemoprevention trials did not show a beneficial effect of the compound tested 
143 
I Chapter 8 
Summary, general discussion & future perspectives 
(sul indac, calcium, resistant starch). In preclinical research, however, NO-donating 
aspirin, selective COX-2 inhibitors, mesalazine and prophylactic vaccines seem interesting 
candidates. Adjuvant chemotherapy consisting of 5-fluorouracil alone does not improve 
disease-free or overall survival in Lynch syndrome patients. Preclinical studies and clinical 
studies in stage 3 CRC patients indicate efficacy of 5-fluorouracil plus irinotecan or 
oxaliplatin in MMR-deficient tumors as well as of new chemotherapeutic agents 
specifical ly targeting the MMR-deficient cells. Furthermore, preclinical research indicated 
that calcium channel blockers, Pl3K inhibitors and inhibitors of DNA polymerases are 
attractive compounds for further research. Interestingly, MMR-deficient tumor cel ls 
seem to be extremely sensitive to radiosensitization via chemotherapy. It is a major 
challenge to further investigate and/or identify interesting agents for tailored 
management of Lynch syndrome individuals. 
General discussion and future perspectives 
TRAIL and NSAIDs for chemoprevention of CRC: promises and hurdles 
Agents targeting the TRAIL receptor are well tolerated in humans5• Virtually  all colorectal 
adenomas - from sporadic, FAP-associated as well as Lynch syndrome-associated origin -
express the pro-apoptotic TRAIL receptors DR4 and DRS indicating that the target for 
TRAIL is present.6 The Groningen group previously demonstrated that TRAIL induces 
apoptosis in colon adenoma cel l l ines and ex vivo cultured human adenomas while not 
harming normal colonic epithelium.7 Recently, it was shown that the combination of 
retinoic acid and TRAIL effectively reduces the adenoma load in ApcMin mice, suggesting 
potential for a TRAIL-based combination for chemoprevention.4 The observation that 
both agents as single agent were not effective while the combination was, underscores 
the usefulness of combination therapy for CRC chemoprevention. Using adenoma cell 
l ines and ex vivo cultured adenomas, it was demonstrated in this thesis (Chapter 3) that 
NSAIDs also significantly enhance TRAIL-induced apoptosis in premalignant cells. 
Interestingly, the optimal NSAID to sensitize adenoma cel ls to TRAIL was sulindac, while 
the combination of TRAIL and aspirin resulted in the highest effect in cancer cells. 
Therefore, it is important to realize that different NSAIDs exert different effects 
depending on the cel l type. 
There are several reasons why NSAIDs are attractive agents to be combined with TRAIL 
for chemoprevention. Firstly, NSAIDs have already proven to be preventive agents for 
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sporadic colorectal carcinogenesis as well as carcinogenesis in FAP and Lynch syndrome.8-
11 Moreover, NSAIDs are widely used, cheap and general ly well tolerated. Thirdly, it was 
observed that the combination of TRAIL and NSAIDs is working only in cells with active 
Wnt signaling. Since Wnt pathway activation is crucial to colorectal carcinogenesis, this 
indicates that the combination works as targeted therapy. Lastly, it was recently 
demonstrated in the ApcMin mouse model that sulindac eliminates stem cel ls  with 
aberrant Wnt signaling.1 Increasingly, only a small proportion of tumor cells, the so-called 
cancer stem cells or tumor initiating cells, is considered to be especially capable of 
initiating tumor growth.12 In this respect, the stem cells must be targeted in order for 
therapeutic strategies to be effective - and sulindac seems capable to (partially) do so. 
A favorable toxicity profile is extremely important for chemoprevention given the long­
term treatment intention in healthy individuals. In order to minimize toxicity of 
chemopreventive treatments, novel administration strategies are worth exploring. 
Although still far from clinical use, nanoparticle-mediated drug delivery or local drug 
release systems making use of pH and transit time control led release are examples of 
strategies that may facilitate save chemoprevention.13•14 
Preclinical research of CRC chemoprevention 
Preclinical research forms the basis of progress in the understanding of colorectal 
carcinogenesis and the discovery of novel strategies for chemoprevention. In vitro 
chemoprevention research requires adenoma cell lines. Early passage adenoma cel ls 
represent a good model for adenomas.15 The VACO-235 and VACO-330 adenoma cell s  
used in our research, are like most available adenoma cell lines derived from sporadic 
adenomas. In addition, a few cell lines exist, which are generated from FAP-associated 
adenomas.16 Lynch syndrome adenoma cell l ines are still lacking. Availability of these cell 
lines is of interest since Lynch syndrome-associated neoplasms harbor a distinct genetic 
background. Furthermore, preclinical and clinical research has indicated that Lynch 
syndrome-associated carcinomas respond differently to various therapies, which may be 
true for adenomas as well .17 
In addition to cell line work, it is of interest to examine the effects of drugs on freshly 
removed patient material. We demonstrate in this thesis that effects on apoptosis could 
be assessed in ex vivo cultured adenoma samples after 24 hours treatment with sulindac 
and rhTRAIL. This model is suitable to test the apoptosis inducing effects of agents, but 
for example cellular proliferation and expression of proteins can be examined in these 
145 
I Chapter 8 
Summary, general discussion & future perspectives 
samples as well. Besides using this model for preclinical research, this ex vivo culturing 
system may ultimately also be used in clinical decision making, by testing patient samples 
and directing therapy on the basis of ex vivo observed sensitivity. 
Novel options for chemoprevention have to be tested in mouse models. The ApcMin 
mouse model is the most frequently used model to study colorectal carcinogenesis in a 
sporadic or FAP-associated context (both characterized by an APC gene mutation). This 
model differs from the human situation as ApcMin mice get adenomas predominantly in 
the smal l intestine instead of in the colon and they do not progress into invasive lesions. 
Recently, a ApcMin mouse model with an additional mutation in the Cdx2 gene was 
developed in which adenomas are localized in the colon. Moreover, it was discovered 
that introduction of a SMAD4 mutation in ApcMin mice resulted in invasive tumors. 18 
Mouse models for Lynch syndrome are widely available. These mice are carrying a 
mutation in one of the MMR genes. They develop next to intestinal adenomas, 
lymphomas. It is therefore of interest that recently, a cre-LoxP-mediated MSH2 
conditional knockout model was generated, in which MSH2 is inactivated in a tissue­
specific manner. These mice only develop intestinal adenomas.19 The generation of such 
models is important since it facil itates preclinical research in models that are closely 
mimicking the human situation. 
Non-invasive imaging modalities to visualize adenomas in these mouse models would 
greatly help monitoring the effects of chemopreventive strategies. As we demonstrate 
(Chapter 4), abdominal 18F-FDG uptake correlates with the number of large intestinal 
adenomas. Since large adenomas are not present in young mice and since FOG PET 
scanning does not al low direct visualization of the adenomas, improvements are 
certainly needed. CT isocontour analysis of FOG PET images is an appropriate method to 
identify the degree of inflammation in a mouse immune colitis model.20 Therefore, such 
an approach might be applicable in adenoma models as well. In addition, imaging 
techniques using tracers visualizing molecular characteristics specific for adenomas 
should be tested since accuracy of this approach has been demonstrated in cancer 
models using tracers directed against a wide variety of molecular markers.21'22 
A limitedly explored area in chemoprevention research involves the use of microarray 
expression data. Depositing microarray data on publicly accessible platforms permits 
combining multiple data sets in order to increase the sample size and stimulates optimal 
use of the data for different purposes and analyses. Combining data sets from different 
research groups requires a robust analysis in order to standardize the data and correct 
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for batch differences. We demonstrated {Chapter 6) that this can be done using Principal 
Component Analysis. Microarray data can be analyzed both at the conventional single 
gene level as well as at the level of biological pathways. Since smaller but coordinated 
changes in sets of genes belonging to one pathway may contribute more to adenoma 
formation than large changes in single genes, pathway analysis may lead to biological ly 
relevant discoveries as demonstrated by our analysis {Chapter 6). Our results justify 
expanding the research at targeting of the Rb and Src pathways. Inhibition of the Rb 
pathway using the specific CDK4/6 inhibitor PD-0331991 already demonstrated reduced 
proliferation in adenomas from ApcMin mice.23 Other interesting starting points revealed 
by our analysis, which include the folate pathway and Hedgehog signaling, can be 
explored for chemoprevention as well .  
Chemoprevention should be tested by combination of different agents in order to 
maximize therapeutic effects and minimize toxicity. The combination of NSAIDs and 
TRAIL is of interest and deserves further exploration for chemoprevention of CRC. 
Apoptosis induction by these agents seems an elegant approach to selectively kill 
dysplastic cel ls. Additional research in specific preclinical models of sporadic and 
hereditary tumors is needed, given the existing differences in genetic background and 
tumor biology. Acknowledging the importance of these models is a first step getting 
closer to real 'personalized targeted therapy' based on the molecular characteristics of 
colorectal adenomas and cancer. 
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SAMENVATTING 
Dikkedarmkanker (darmkanker, colorectaal carcinoom) is wereldwijd een belangrijke 
sterfteoorzaak. Deze sterfte kan warden teruggedrongen door betere 
behandelingsmethoden te ontwikkelen, maar ook door meer te focussen op vroege 
detectie en preventie. Darmkanker ontstaat vrijwel altijd uit een premaligne afwijking, 
een poliep oftewel adenoom. De transformatie van normaal epitheel naar darmkanker 
via het adenoomstadium neemt meerdere jaren in beslag, wat mogelijkheden biedt voor 
preventie van darmkanker. 
Preventiestrategieen zijn in het bijzonder interessant voor mensen met een verhoogd 
risico op het ontwikkelen van darmkanker. Het gaat dan om mensen met een erfelijke 
predispositie zoals mensen met het Lynch syndroom (veroorzaakt door een 
kiembaanmutatie in een mismatch repair (MMR) gen) of Familiaire Adenomateuze 
Polyposis (FAP, veroorzaakt door een kiembaanmutatie in het Adenomateuze Polyposis 
Coli (APC) gen). Preventie bestaat momenteel uit regelmatige colonoscopische controle 
en het vervolgens verwijderen van eventuele afwijkingen in de darm of een deel van de 
darm. Het gebruik van chemopreventieve middelen zou de ontwikkeling van adenomen 
en darmkanker in hoogrisicogroepen kunnen vertragen of zelfs voorkomen. Non­
stero'idale anti-inflammatoire middelen (NSAID's) bleken in verschillende 
gerandomiseerde chemopreventiestudies het aantal nieuw ontwikkelde adenomen en 
carcinomen in de darm te verminderen. NSAID's bieden echter geen volledige 
bescherming. Dit betekent dat het nodig is om betere chemopreventiestrategieen te 
ontwikkelen. 
Het gebruik van een nieuw soort middelen, de zogenaamde 'targeted drugs' die gericht 
zijn tegen specifieke componenten in de eel die belangrijk zijn voor carcinogenese, biedt 
nieuwe perspectieven voor zowel de behandeling als chemopreventie van darmkanker. 
Tumor Necrosis Factor (TNF)-Related Apoptosis Inducing Ligand (TRAIL) is zo'n specifiek 
middel. Binding van TRAIL aan haar pro-apoptotische receptoren DR4 en DRS op de 
celmembraan resulteert in apoptose (geprogrammeerde celdood). Resultaten uit eerder 
onderzoek demonstreren dat TRAIL apoptose induceert in darmkanker- en 
adenoomcellijnen, maar niet in normale cellen. In kankercell ijnen is aangetoond dat de 
mate van apoptose-inductie sterk kan warden verhoogd door TRAIL te gebruiken in 
combinatie met diverse andere middelen. In dit proefschrift zijn middels onderzoek in in 
vitro1 ex vivo en in vivo modellen nieuwe targeted therapies voor de behandeling en 
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vooral voor chemopreventie van darmkanker onderzocht, met een focus op de 
combinatie van TRAIL en NSAID's. 
Na een korte introductie en beschrijving van de inhoud van het proefschrift in Hoofdstuk 
1, zijn in Hoofdstuk 2 de resultaten beschreven van onderzoek naar de basale 
expressieniveaus van twee belangrijke spelers in de extrinsieke TRAIL-apoptoseroute, de 
eiwitten caspase-8 en cFLIP. Caspase-8 is een pro-apoptotisch eiwit. cFLIP is een anti­
apoptotisch eiwit omdat het in staat is caspase-8 te vervangen in het Death-Inducing 
Signaling Complex (DISC), het complex dat gevormd wordt na binding van TRAIL aan haar 
receptoren. Met behulp van immunohistochemie is gekeken naar de expressie van beide 
eiwitten in normaal darmepitheel (n = 20), adenomen (n = 66) en carcinomen (n = 44). De 
expressie van caspase-8 en cFLIP was vergelijkbaar in sporadische adenomen en 
carcinomen en Lynch syndroom-geassocieerde adenomen en carcinomen. Caspase-8 
kwam hoger tot expressie in adenomen en carcinomen in vergelijking tot normaal 
epitheel. De expressie van cFLIP was het hoogst in carcinomen. Dit betekent dat de 
expressie van caspase-8 en cFLIP toeneemt gedurende de carcinogenese. De expressie 
van de twee eiwitten en hun expressieratio varieerde echter sterk in de verschillende 
weefsels. 
In Hoofdstuk 3 zijn de resultaten beschreven van een studie waarin darmkankercell ijnen, 
adenoomcellijnen en ex vivo gekweekte humane adenomen behandeld werden met 
aspirine of sulindac (NSAID's) in combinatie met recombinant humaan (rh)TRAIL. De 
combinatie met aspirine zorgde voor een sterke sensibilisatie van zowel TRAIL-gevoelige 
als TRAIL-resistente kankercellen voor TRAIL. Adenoomcellen waren met name gevoelig 
voor de combinatie van sulindac en TRAIL. Ook in de ex vivo gekweekte adenomen werd 
gezien dat de cellen gevoelig waren voor deze combinatie: na 24 uur behandeling steeg 
het percentage apoptotische cel len van 18,4% door sulindac en 17,8% door rhTRAIL naar 
28,0% door de combinatie. Vervolgens werd gezocht naar de oorzaak van dit 
sensibiliserende effect. De expressie van de TRAIL receptoren op de membraan 
veranderde niet onder invloed van aspirine of sulindac en er werd geen toegenomen 
clustering van de receptoren gezien. Combinatiebehandeling resulteerde in een 
versterkte activatie van caspase-8 in de adenoom- en kankercellijnen. cFLIP werd niet 
gedetecteerd in adenoomcellen, hetgeen in overeenstemming is met de resultaten 
beschreven in Hoofdstuk 2. In de kankercellijnen was cFLIP na combinatiebehandeling 
geknipt in kleinere fragmenten. Caspase-8 kan cFLIP knippen, zodat meer caspase-8 
activatie zal leiden tot meer geknipt cFLIP. Uiteindelijk kan dit bijdragen aan een 
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verhoogde TRAIL-gevoeligheid. De expressie van een aantal eiwitten die deel uitmaken 
van verschillende intracellulaire signaaltransductieroutes werd eveneens bestudeerd. Er 
waren aanwijzingen dat zowel de intrinsieke apoptoseroute als de Akt-route en NF-KB­
route betrokken zijn bij sensibilisatie voor TRAIL in de adenoom- en kankercell ijnen. Deze 
resultaten impliceren dat de verhoogde gevoeligheid voor de combinatie van een NSAID 
en TRAIL wordt gemedieerd via multifactorieel bepaalde complexe mechanismen. 
Activatie van de Wnt-route is cruciaal is voor de carcinogenese in het darmepitheel. In 
een kankercellijn die stabiel getransfecteerd was met een induceerbaar TCF-4 construct 
(dnTCF-4), leidde uitschakeling van TCF-4 (Wnt-route transcriptiefactor) tot een compleet 
verlies van gevoeligheid van de cellen voor de combinatie. Dit betekent dat de 
combinatie van aspirine of sulindac en TRAIL een vorm is van 'targeted therapy' en alleen 
werkt als er pathologische activatie van de Wnt-route is. 
ApcMin muizen worden veel gebruikt in onderzoek naar de carcinogenese van de darm en 
de effectiviteit van chemopreventieve strategieen. Deze muizen hebben een mutatie in 
het Ape gen waardoor zij tientallen adenomen in de darm ontwikkelen. Onderzoek in dit 
model zou erg geholpen zijn bij een non-invasieve methode om de adenomen in de darm 
longitudinaal te kunnen evalueren. Daarom onderzochten we de mogelijkheid om 
fluorodeoxyglucose (FDG) PET beeldvorming te gebruiken in het ApcMin model zoals 
beschreven in Hoofdstuk 4. 18F-FDG uptake werd daartoe vergeleken met het aantal en 
de grootte van adenomen die met een dissectiemicroscoop werden gedetecteerd. In vivo 
beeldvorming liet enkele 'hot spots' per muis zien die waarschijnlijk adenomen 
reflecteerden. Ex vivo beeldvorming van de darmen toonde echter alle grote (� 2 mm) 
adenomen en de meeste kleinere adenomen. De ex vivo gemeten opname van 18F-FDG in 
de darm correleerde met de in vivo gemeten totale opname in het abdomen en met het 
aantal grote adenomen op het moment dat de muizen 9 en 12 weken oud waren. Op de 
leeftijd van 12 weken was er zelfs een sterke correlatie tussen de in vivo gemeten 
opname in het abdomen en het aantal grote adenomen. Deze studie toont aan dat 
darmpoliepen in ApcMin muizen metabool actieve laesies zijn die 18F-FDG opnemen. De in 
vivo gemeten 18F-FDG opname in muizen met een leeftijd van 12 weken is bovendien een 
kwalitatieve maat voor het aantal grote adenomen. 
Gezien het gunstige effect van combinatiebehandeling met sulindac en rhTRAIL in 
adenoomcel lijnen en ex vivo gekweekte adenomen (Hoofdstuk 3), is het van belang deze 
combinatie in vivo te testen. In de studie beschreven in Hoofdstuk 5 werden ApcMin 
muizen behandeld met sulindac in verschil lende concentraties gedurende een variabele 
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behandelperiode om een geschikte strategie te kiezen voor de combinatiestudie. Zeven 
weken behandeling met sulindac in het dieet resulteerde in een dosisafhankelijke 
reductie van het totale aantal adenomen van 71% bij gebruik van de hoogste 
concentratie en een reductie van het aantal adenomen grater dan 2 mm van zelfs 90% bij 
gebruik van de hoogste concentratie. Recent werd aangetoond, eveneens in het ApeMin 
model, dat kortdurend gebruik van sulindac gedurende een week even effectief is als 
langdurig gebruik. In onze studie resulteerde 6 dagen behandeling met sulindac in een 
daling van het aantal grate adenomen (73% bij gebruik van de hoogste concentratie), 
maar niet van het totale aantal adenomen. Behandeling van C57BL/6J muizen met MDS-
1, een agonistisch antilichaam specifiek gericht tegen de muizen-TRAIL receptor, leidde in 
eerder onderzoek tot levertoxiciteit. Deze toxiciteit zag men na 3 intraperitoneale 
injecties met 300 µg MDS-1 elke 3 dagen. De toxiciteit werd toegeschreven aan TRAIL 
receptor-gemedieerde apoptose van cholangiocyten, die de TRAIL receptor in hoge mate 
tot expressie brengen. In Hoofdstuk 5 is tevens een studie beschreven waarin werd 
onderzocht of het mogelijk is een lage concentratie MDS-1 te gebruiken en daarmee een 
therapeutisch 'window' te creeren. Dit zou moeten leiden tot effecten op 
adenoomvorming zonder toxiciteit voor de cholangiocyten. Na slechts 4 injecties met 50 
µg MDS-1 elke 4 dagen, trad echter in ApeMin muizen (C57BL/6J achtergrond) en C57BL/6J 
muizen zonder Ape mutatie dezelfde levertoxiciteit op. Dit geeft aan dat ook een lagere 
dosering MDS-1 leidt tot toxiciteit en dat de geobserveerde toxiciteit onafhankelijk is van 
een Ape mutatie. Recent werd aangetoond dat het herhaald injecteren van rhTRAIL niet 
toxisch is in ApeMin muizen. Dit komt mogelijk door de expressie van TRAIL 
decoyreceptoren die cholangiocyten beschermen tegen TRAIL-ge"induceerde apoptose. 
Ook verschil len in de halfwaardetijd en de wijze van klaring van MDS-1 en rhTRAIL 
kunnen een oorzaak zijn van het feit dat de levertoxiciteit alleen gezien werd na 
behandeling met MDS-1. Gebaseerd op de resultaten beschreven in Hoofdstuk 5, wordt 
er momenteel een studie opgezet waarin ApeMin muizen gedurende 6 dagen behandeld 
warden met placebo intraperitoneaal, sulindac in het dieet, rhTRAIL intraperitoneaal of 
de combinatie van sulindac en rhTRAIL. Deze studie levert hopelijk een strategie op die 
uiteindelijk nuttig kan zijn voor mensen met een verhoogd risico op het ontwikkelen van 
darmkanker. 
In Hoofdstuk 6 is beschreven hoe werd gezocht naar nieuwe targets voor 
chemopreventie door gebruik te maken van de micraarray-techniek waarmee een 
expressieprafiel van het gehele genoom kan warden verkregen. Deregulatie van 
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biologische routes werd geanalyseerd door gebruik te maken van voor iedereen 
toegankelijke microarray-expressiedata, waarbij normaal weefsel {n = 26) werd 
vergeleken met adenomen {n = 47). Met Gene Set Enrichment Analysis {GSEA) werden 
10, 11 and 16 genensets {een set bestaat uit genen die behoren tot een biologische 
route) ge'identificeerd die adenomen van normaal darmweefsel onderscheidden volgens 
respectievelijk de KEGG, GenMAPP en Biocarta database. Biologische routes die bekend 
zijn vanwege hun rol in de carcinogenese van de darm, zoals de celcyclus en de Wnt­
route, waren inderdaad verrijkt in adenomen. Bovendien werden er gedereguleerde 
routes gevonden waarvan tot op heden niet bekend was dat ze betrokken zijn bij 
adenoomvorming, zoals de Rb-route, Src-route, folaat biosynthese en de Hedgehog­
route. De microarray-resultaten voor de Rb- en Src-route werden gevalideerd door 
middel van qRT-PCR op mRNA dat ge"isoleerd werd uit een onafhankelijke set monsters 
van adenomen en normaal darmweefsel. Er was een sterke correlatie tussen de 
microarray-data en qRT-PCR-data. Door gebruik te maken van de Rb-route-remmers 
roscovitine en PD-0332991 en de Src-route-remmer dasatinib werd de relevantie van het 
therapeutisch interfereren met de ge'identificeerde routes bewezen. Deze medicamenten 
zorgden voor remming van celgroei in adenoomcellijnen. 
Tumoren die ontstaan in de context van het Lynch syndroom verschillen van sporadische 
tumoren wat betreft hun genetische achtergrond en fenotypische kenmerken. Vanwege 
het hoge risico op en vroege ontstaan van darmkanker zijn Lynch syndroom 
mutatiedragers geschikte kandidaten voor chemopreventie. Op dit moment is er geen 
bewezen effectieve chemopreventiestrategie voor deze populatie. Er is steeds meer 
bewijs dat de respons van MMR-deficiente tumoren {waaronder Lynch syndroom­
geassocieerde tumoren) op de standaard chemotherapie en radiotherapie verschilt van 
MMR-proficiente tumoren. In Hoofdstuk 7 is een literatuurstudie beschreven waarin de 
resultaten van klinische en preklinische studies op het gebied van chemopreventie en 
kankerbehandeling in het kader van het Lynch syndroom zijn samengevat. Aspirine 
toonde op de lange termijn een beschermend effect in Lynch syndroom mutatiedragers. 
Andere klinische chemopreventiestudies lieten geen effect zien van sulindac, calcium of 
resistent zetmeel . In preklinisch onderzoek werd echter aangetoond dat 
stikstofmonoxide-donerende aspirine, selectieve COX-2 remmers, mesalazine en 
profylactische vaccins bestaande uit frameshift afgeleide peptides interessante middelen 
voor chemopreventie zijn. Adjuvante chemotherapie bestaande uit 5-fluorouracil 
monotherapie lijkt de ziektevrije overleving en totale overleving in Lynch syndroom 
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patienten met darmkanker niet te verbeteren. Preklinische studies en klinische studies in 
patienten met stadium Il l tumoren lieten zien dat 5-fluorouracil in combinatie met 
irinotecan of oxaliplatin mogelijk wel effectief is bij patienten met MMR-deficiente 
tumoren. Hetzelfde bleek in preklinisch onderzoek het geval te zijn voor nieuwe 
chemotherapeutica die specifiek gericht zijn tegen MMR-deficiente cellen. Preklinisch 
onderzoek toonde verder aan dat calciumantagonisten, Pl3K-remmers en DNA 
polymerase-remmers interessante middelen zijn voor verder onderzoek. Bovendien 
l ijken MMR-deficiente tumorcellen extreem gevoelig te zijn voor radiosensibilisatie met 
chemotherapie. Het identificeren en testen van nieuwe middelen voor een persoonlijke 
(preventie)behandeling van Lynch syndroom mutatiedragers, is een grate uitdaging voor 
de toekomst. 
157 
I Chapter 9 





De onderzoekswereld is heerlijk. De combinatie van Geneeskunde en onderzoek was niet 
altijd makkelijk, maar het plezier van het onderzoek heeft het meer dan waard gemaakt. 
De momenten van intens geluk door een gelukt experiment, een nieuw bedachte 
hypothese of een geaccepteerd artikel - ook al duren ze maar even - doen de dagen van 
'gewoon hard werken' en mislukte proeven verbleken. lk kan me een leven zonder 
onderzoek niet voorstellen. Tijdens de periode van mijn promotieonderzoek heb ik 
samen mogen werken met veel fijne mensen die belangrijk zijn geweest bi j de 
totstandkoming van dit proefschrift. Een aantal van deze personen wil ik hier graag 
noemen. 
Veel dank ben ik verschuldigd aan mijn promotores Prof. dr. E.G.E. de Vries en Prof. dr. 
J.H. Kleibeuker en mijn copromotores Dr. S. de Jong en Dr. J. J. Koornstra. 
Beste Liesbeth, gedurende de afgelopen jaren heb ik me steeds meer gerealiseerd hoe 
bijzonder ji j bent. Altijd keek ik uit naar jouw commentaar op mijn manuscripten, omdat 
ik zoveel vertrouwen heb in jouw visie. Altijd legde je de vinger op de zere plek en droeg 
je oplossingen aan die de stukken beter maakten. Je scherpte is bewonderenswaardig. 
Jouw denken over grenzen heen en positieve en 'sexy' manier van schrijven zijn 
inspirerend voor mij geweest. Je enthousiasme heeft me erg gestimuleerd en heeft me 
veel plezier gegeven. lk ben er trots op jouw promovendus te zijn. 
Beste Jan, jij was de eerste persoon met wie ik in aanraking kwam toen ik plannen had 
om onderzoek te doen naast mijn studie Geneeskunde. Vanaf het eerste moment heb ik 
je betrokkenheid gevoeld. lk waardeer het enorm dat je altijd uitgebreid de tijd nam om 
gecorrigeerde manuscripten van A tot Z met mij door te lopen. Je nauwkeurige 
aanpassingen maakten al le manuscripten beter. Jouw klinische blik heeft er voor gezorgd 
dat ik de plaats van mijn onderzoek in de klinische praktijk beter kon duiden. Je 
bemoediging en plezierige manier van samenwerken zijn heel belangrijk voor me 
geweest. 
Beste Steven, met jou heb ik gedurende mijn promotieonderzoek het meest intensief 
samengewerkt. Jij bent degene die ik het best heb leren kennen en die mij het best kent. 
Je bent voor mij het voorbeeld van de echte wetenschapper. Je denkt snel en 'out of the 
box'. De stroom aan ideeen en hypotheses raakte nooit op. Voor jou is een laatste punt 
160 
Dankwoord I 
nooit gezet. lk waardeer het enorm dat je me hebt meegenomen in jouw enthousiasme 
over onderzoeksresultaten. Regelmatig dacht ik - jouw redenaties over celbiologische 
mechanismen aanhorende - dat ik ook heel gelukkig zou kunnen zijn als bioloog. Het was 
fijn dat je deur altijd openstond voor overleg. De discussies die ik met jou had, waren het 
leukste en meest waardevolle aspect van mijn promotieonderzoek. 
Beste Jan Jacob, jij was met jouw onderzoek een grondlegger voor dit proefschrift. 
Talloze keren heb ik jouw artikelen geciteerd. Je was heel toegankelijk voor mij als 
beginnend onderzoeker. Als jij scopieprogramma had, brandde de pieper in mijn zak en 
wachtte ik op jouw 'lk heb er weer een !' Heel fijn vond ik het dat je er onophoudelijk 
voor in was om n6g meer biopten en adenomen voor weer nieuwe experimenten te 
verzamelen. 
De leden van de leescommissie, Prof. dr. J.A. Gietema, Prof. dr. A.J. Moshage en Prof. dr. 
S.T. Pals wil ik hartelijk danken voor de beoordeling van mijn proefschrift. 
Mijn dank gaat verder uit naar andere personen die nauw betrokken zijn geweest bij mijn 
onderzoek. 
Beste Hilde (Hilde Jalving), wat was ik blij dat jij er was toen ik begon met mijn werk op 
het lab. Hoewel jij bijna promoveerde toen ik begon, kon je je goed verplaatsen in mij als 
beginneling in het onderzoek. Je maakte me wegwijs op het lab, stelde me gerust als ik 
de dingen door elkaar haalde en vertelde me dat ik niet moest schrikken als ik n iets van 
een research meeting begreep. Het was geweldig dat je zoveel geduld had en zo 
gemakkelijk tijd vrij maakte. De vele apoptose assays die jij hebt uitgevoerd, vormden de 
basis van Hoofdstuk 3 van dit proefschrift. lk vind het leuk dat ik je ook nu weer achterna 
ga, als ik begin met de opleiding lnterne Geneeskunde. 
Beste Dorenda (Dorenda Oosterhuis), toen ik startte met het KWF-project, was jij 
inmiddels enorm bedreven in het kweken van onze VACO-vriendjes. Het in leven houden 
van deze cellen kon jij als geen ander en vormde de rode draad gedurende de hele 
onderzoeksperiode. Je hebt vele honderden cytospins gemaakt, veel geblot, M30 
kleuringen gedaan en geworsteld met de carbogeenstoof. Je bleef altijd vrolijk, ook als er 
weer een proef herhaald moest worden. Je nauwkeurigheid en geduld met het 
opspelden van de muizendarmen en het tellen van de poliepen is ongeevenaard. We 
kunnen heel tevreden zijn over de uitkomsten van de proeven ! 
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Beste Wytske (Wytske Boersma), van jou heb ik al l e  mogelijkheden van de 
immunohistochemie geleerd. De kookpan van de pathologie zal ik niet snel vergeten. Als 
er stress was, was jij er altijd om een proef in te zetten of een extra kleuring te doen. Je 
hebt me enorm en op een heel plezierige manier geholpen. 
Beste co-auteurs, jullie bijdragen aan de verschillende hoofdstukken van dit proefschrift 
zijn heel belangrijk geweest. lk heb het als zeer waardevol en leerzaam ervaren om 
samen te werken met mensen van buiten het lab. Een aantal personen wil ik in het 
bijzonder noemen. Dr. J. Wesseling, beste Jelle, jij leerde me niet al leen te kijken door de 
microscoop maar ook te zien. Prof. dr. H. Hollema, beste Harry, van jou kreeg ik 
uitgebreid uitleg over apoptose en dysplasie in de darm van mens en muis. Beste Wouter 
(Wouter Nagengast), door jou raakte ik thuis in de wereld van PET-reconstructies, VOi's 
en decay corrections. Jouw idee om de muizendarmen ex vivo te scannen was geniaal. 
Beste Rudolf (Rudolf Fehrmann), hoewel jouw computertrucs voor mij niet te begrijpen 
zijn, heb ik het heel leuk gevonden meer te weten te komen over de bio-informatica. 
Alie patienten die deelnamen aan de studie beschreven in Hoofdstuk 3 wil ik hartelijk 
bedanken voor het afstaan van een deel van endoscopisch verwijderd weefsel voor 
onderzoeksdoeleinden. De MDL-artsen van het UMCG wil ik bedanken voor het 
verzamelen van deze weefsels. 
Collega's en oud-col lega's van het Multidisciplinair Oncologisch Laboratorium, ik wil jul l ie 
hartelijk bedanken voor heel veel fijne jaren op het lab. Het lab is de afgelopen jaren mijn 
tweede thuis geweest. ledereen heeft zijn eigen expertise waardoor het nooit moeilijk 
was iemand te vinden om mee te overleggen of om mij iets nieuws te leren. lk heb het 
heel leerzaam gevonden om naar ieders verhaal te luisteren tijdens de apoptose 
meetingen, journal clubs en research meetingen. Annemieke (Annemieke Meijer), 
Dorenda (Dorenda Oosterhuis), Haukeline (Haukeline Volders), Janet (Janet Stegehuis) en 
Pauline (Pauline de Graeff), hoewel 'het lab' inmiddels niet meer is wat ons bijeen 
brengt, hoop ik op een voortzetting van onze laboverstijgende activiteiten. 
Beste Hetty (Hetty Timmer) en Coby {Coby Meijer), dank voor jullie hulp de afgelopen 
jaren. Er is geen probleem waar jul l ie geen oplossing voor weten. lk heb me enorm 
gesteund gevoeld door jullie betrokkenheid. Beste Gretha (Gretha Beuker) en Bianca 
(Bianca Smit), dank voor de nodige secretariele ondersteuning. 
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Medewerkers van de Centrale Dienst Proefdieren, hartelijk dank voor de hulp bij mijn 
dierexperimenten. Jullie flexibiliteit en persoonlijke benadering zijn geweldig. lk 
waardeer het erg dat jullie altijd bereid waren mee te den ken. 
Jurgen Sijbesma, Johan de Jong en Aren van Waarde van de afdeling Nucleaire 
Geneeskunde, dank voor jul l ie hulp bij het uitvoeren en plannen van mijn PET-proeven 
en de bereidheid te zoeken naar oplossingen als ik tegen een probleem aanliep tijdens 
het scannen van mijn muizen. 
Mijn dank gaat eveneens uit naar de programmagroep van de Junior Scientific 
Masterclass, voor de mogelijkheid een MD/PhD traject te doorlopen. De cursusweek op 
Schiermonnikoog in mijn tweede jaar Geneeskunde was een grote bron van inspiratie. lk 
had direct zin in onderzoek en het MD/PhD traject was mij op het lijf geschreven. Prof. 
dr. H.J. Verkade, beste Henkjan, ik had mij geen betere mentor kunnen wensen. Je 
adviezen zijn heel waardevol geweest. 
Lieve vriendinnen en vrienden, dank voor veel fijne momenten waar ik erg van kon 
genieten. In het bijzonder wil ik mijn paranimfen noemen. Lieve Linda, jij snapt mij en ik 
snap jou. Onze vriendschap was l iefde op het eerste gezicht. lk verwonder me steeds 
opnieuw over jouw drang naar 'nieuw', je vrolijkheid en je diepgang. Jouw kracht is van 
een andere planeet. Lieve Renee, met jou kon ik als geen ander bomen over de 
enterohepatische kringloop, granulomateuze afwijkingen, nierfunctiestoornissen en 
tegenwoordig over chemopreventie en prolapsen. Onze vriendschap is vanzelfsprekend. 
Zo makkelijk, zo logisch, voor altijd ! 
Lieve Jan, Renata, Laurie en Jonathan, jullie waren fijne gesprekspartners in de vele 
gesprekken over studeren en onderzoek. lk kijk uit naar al le gesprekken en momenten 
van samenzijn in de toekomst. Jullie hebben een bijzonder plekje in mijn hart. 
Lieve oma, je bent een voorbeeld voor mij. Jouw liefde en manier waarop je kunt 
genieten van de kleine dingen in het leven zijn heel bijzonder. Je was er op al le 
belangrijke momenten in mijn leven, ik ben zo gelukkig dat je er ook nu bent. 
Lieve broer, Daan, paranimf, hoe ver je ook weg bent, we zijn altijd bij elkaar. lk 
bewonder je ondernemende karakter en levenslust. Je journalistieke kwaliteiten zijn voor 
mij een zekerheid. lk ben trots op je. Voor nu, voor altijd, onvoorwaardelijk. 
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Lieve mam en pap, de weg van mijn leven hebben we samen - zij aan zij - bewandeld. 
Een wereld zonder jullie bestaat niet. Jullie zijn de liefste ouders van de wereld, mijn 
al les. 
Tot slot, lieve Arne, onze liefde is het belangrijkste in mijn leven. Jouw 'Het komt wel 
goed' geeft me keer op keer vertrouwen. Je verfrissende kijk op dingen, je 
nieuwsgierigheid, je humor en je serieuze kant maken je enorm bijzonder. l k  hou van je. 
You mean the world to me. 
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